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Background: Despite a wide range of contraceptive options available in the United 
Kingdom, the unplanned pregnancy rate remains high. Contraceptive services are 
currently delivered by general practitioners, sexual health clinics and pharmacies, but 
there may be scope to expand the places that these are offered, and increase the 
options available within each service.  Doing so could increase the uptake of 
contraceptive methods, particularly the most effective methods, and therefore reduce 
the unplanned pregnancy rate.  
Aim and objectives: Research in this thesis aimed to investigate novel delivery 
models of contraception. The research had two main areas of focus. Firstly the 
capacity of the pharmacy to deliver regular contraception was examined, in the 
context of existing literature, and then through a pilot study. After that the expansion 
of contraception care to maternity services was investigated, first in the literature and 
then using an observational study.  
Methods: In undertaking this thesis I used a variety of methods. Two patient surveys 
were employed to investigate patients’ perspectives on proposed novel methods of 
contraceptive delivery. A pilot study investigated the feasibility and acceptability of 
delivery of the contraceptive injection at the pharmacy. Quantitative results about the 
numbers of injections given were collected, as were patient questionnaires. 
Qualitative one-to-one interviews were conducted with participating pharmacists, 
these were recorded, transcribed and analysed.  
An observational study was also undertaken to assess routine delivery of insertion of 
intra-uterine contraception at the time of caesarean section. Patients were seen at six 
weeks following insertion, and contacted by telephone at three, six and 12 months 
about satisfaction and continuation of the method. 
Results: 220 women completed a questionnaire about attending the community 
pharmacy to receive a contraception injection. 33% of current non-users indicated 
that they would consider using this method if it was available at the pharmacy.  
50 established users of the contraceptive injection participated in a pilot project 
receiving up to three injections from the community pharmacy. Only 48 injections of 
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a possible 150 were delivered at the community pharmacy. Only 7 participants 
received all three injections at the pharmacy, and participants reported mixed 
experiences accessing the pharmacy. The practical obstacles around pharmacy 
engagement and the challenges of retaining participants were significant, and more 
research is necessary before proceeding with a randomised controlled trial.  
250 women on a postnatal ward completed questionnaires about their pregnancy 
intentions. 96.7% were not planning a baby in the next year, but only 23.6% were 
planning on using the most effective methods of contraception. One in three 
respondents described themselves as likely to use either an implant or intra-uterine 
contraception if it could be inserted before they left the hospital.  
In an observational study, 120/877 women opted to have intra-uterine contraception 
inserted at the time of caesarean section. Continuation rates at 12 months were 84.8% 
of those contacted, and 92.6% were either ‘very’ or ‘fairly’ happy with their 
contraception.  
Conclusion:  Although patients are receptive to contraception being delivered using 
novel service models, alternatives to current practice need careful investigation. 
Contraceptive injections at the community pharmacy are not necessarily more 
convenient for patients, and therefore may not increase uptake of this method. 
However, offering intrauterine contraception to patients at the time of caesarean 
section is highly acceptable to patients, and results in a substantial majority 
continuing this highly effective method. 
Robust and careful research using a range of methods can help to identify which 





Despite many contraceptive options being available in the United Kingdom, a high 
number of pregnancies are still unplanned, meaning that they occur before they were 
wanted, or when they were not wanted at all. Mothers with unplanned pregnancies 
present later for maternity care and are more likely to have a premature and a low 
birth-weight baby. Both mother and child are at greater risk of violence and abuse 
when the pregnancy is unplanned. Contraception in Scotland is currently available 
from GPs, sexual health clinics and pharmacies, but lots of women still don't use it, 
or don’t use the most effective methods. The research in this study looks at different 
ways to offer contraception from those that are currently available.  
In our first study we looked at increasing the places where women could receive 
contraception to include the community pharmacy, where currently just emergency 
contraceptive pills and condoms are available. Women who were already using the 
contraceptive injection could receive up to three injections from one of eleven 
trained community pharmacists, instead of from their doctor or at a clinic. This might 
make this method more attractive to women, and as this method is more effective 
than either condoms or contraceptive pills, the two most popular methods, this might 
reduce unplanned pregnancy rates. Unfortunately there were lots of problems with 
this study. Staff at the pharmacy sometimes gave women wrong information, and 
women were not able to attend the pharmacy when they wanted to, so actually a lot 
of women participating received their injection at the clinic after all. In 
questionnaires afterwards some women were enthusiastic about getting their 
injection at the pharmacy but some pointed out the problems that they had 
experienced. The pharmacists were interviewed and they were generally positive 
about the idea, but they did not always appreciate the difficulties the women 
experienced.  
This thesis also investigated offering women contraceptive methods in the time just 
after they have had a baby. When this research was started, women in Scotland were 
rarely offered contraceptive options at this time. One contraceptive method that is 
very effective is intrauterine contraception, a contraceptive device that is fitted inside 
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the womb. We offered all women who were having an elective (not an emergency) 
caesarean section the option of having intrauterine contraception inserted at their 
operation, after their baby was delivered. We then followed all these women up with 
a visit at six weeks, and a telephone call at three, six and twelve months. Very few 
devices came out, and a year later a very high number of women who we contacted 
were still using their device for contraception, and were very happy with it. Offering 
this effective contraceptive method at this time therefore seems to be convenient for 
women and straightforward.  
We concluded that not all ways to expand contraceptive delivery work for women, 
but some do, and it is a good idea to conduct careful research to make sure new ideas 










My research fellowship was made possible due to an unrestricted grant from HRA 
Pharma. I am very appreciative of their support, and of my supervisors’ support in 
securing the funding.  
I am incredibly grateful to all of the participants who so generously gave up their 
time to participate in research both contained in this thesis and conducted throughout 
the course of my fellowship. The generosity of research participants in contributing 
towards the advancement of medical knowledge is always humbling to me.  
Thank you to the staff at Chalmers Centre, Edinburgh, St. John’s Hospital, 
Livingston and the Simpson Centre for Reproductive Health in Edinburgh for your 
support, enthusiasm and flexibility which are so necessary when conducting medical 
research.  
I am extremely grateful to both of my supervisors, Professors Sharon Cameron and 
Anna Glasier, for the fantastic opportunity to complete this PhD, their constant 
encouragement of me, and for all of the unique and wonderful opportunities that 
completing this research fellowship has given me access to.  
I would like to thank my amazing family, lovely friends and treasured quartet for 
their unending support and love throughout completion of this PhD. A final and 
special thank you must go to my Dad, Professor Simon Heller, for assistance both 
practical and emotional, and for passing on his passionate belief in medical research 




List of abbreviations used in this thesis 
COC   Combined oral contraceptives  
Cu-IUD  Copper intrauterine device 
DMPA-IM  Depot medroxyprogesterone acetate: intramuscular 
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DNA   Did not attend 
EHC   Emergency hormonal contraception 
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Chapter 1 Introduction 
This chapter details the background and rationale for undertaking the research 
described in this thesis. I examine the problem of unplanned pregnancy in a global, 
national and Scottish context, and review the contraceptive options for women in use 
in the United Kingdom.  Current national service for contraceptive provision is then 
outlined, and novel options for contraceptive access are identified. The aims, 
rationale and justification for the research are then presented. 
A note on the timing of the research explored in this introduction 
Contraception delivery in Scotland and the UK in the field of maternity and 
postpartum care has changed considerably since this thesis was commenced. 
International literature shows an increasing focus on starting the most effective 
methods immediately postpartum from 2011 (Celen et al., 2011; Bhutta et al., 2011; 
Glazer et al., 2011; Levi et al., 2012; Curry et al., 2012; Tocce et al., 2012b; Tocce et 
al., 2012a). However immediate postpartum contraception did not gain attention in 
the United Kingdom until 2015. This was due in part to research to which I 
contributed (Heller et al., 2016; Cameron et al., 2017; The Scottish Government, 
2015), and guidelines produced at the beginning of 2017, which cite research 
described in this thesis (Faculty of Sexual and Reproductive Healthcare, 2017).  This 
introduction will therefore concentrate on contraception services when the research 
commenced, in the summer of 2013. The concluding chapter of the thesis will reflect 
the changed landscape, and examine the most recent evidence for contraceptive 
delivery. 
1.1 Background and statement of problem 
1.1.1 Unintended pregnancy in a national and global context 
Unintended pregnancy remains an ongoing problem in the United Kingdom, despite 
a variety of contraceptive options available to women. The idea of an unintended or 
unplanned pregnancy generally describes pregnancies that are either unwanted 
(occurring when no pregnancy was desired), or mistimed (occurring earlier than a 
desired pregnancy) (Santelli et al., 2003). However, the dichotomous concept of 
unintended versus intended pregnancy may be inadequate, as women’s relationship 
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to the ‘wantedness’ of their pregnancy may alter with pregnancy course and outcome 
(Trussell et al., 1999). This variability complicates answers to interviews and surveys 
about pregnancy intentions by suggesting that such research may only capture a 
snapshot of mutable feelings.  
The London Measure of Unplanned Pregnancy was developed in response to 
demands for a reconceptualising of unplanned pregnancy. It used interviews over 
time with women who had a variety of pregnancy outcomes to build a valid measure 
of unplanned pregnancy. The measure was then rigorously tested for reliability, and 
enabled women to express mixed feelings about their pregnancy irrespective of 
outcome (Barrett et al., 2004). The most recent National Survey of Sexual Attitudes 
and Lifestyles (Natsal-3), one of the largest and most scientific studies of sexual 
behaviour, used the London Measure of Unplanned Pregnancy (LMUP) to examine 
pregnancy intentions of 591 women who had a pregnancy with a known outcome in 
the year preceding their interview. 16.2% of pregnancies were unplanned, 29% were 
classed as ambivalent, and 54.8% were planned (Wellings et al., 2013). Similar data 
from Edinburgh, Scotland in 2006 showed that 65.6% of total pregnancies (ending in 
abortion, miscarriage or a continuing pregnancy) are intended, 25.8% were 
ambivalent and 8.6% were unintended (Lakha and Glasier, 2006). Whether or not to 
classify ambivalent pregnancies as unintended is complex. The developers of the 
LMUP emphasise that the scale represents a spectrum rather than definitive 
categories (Barrett et al., 2004). Other surveys where women are offered only the 
option of intended pregnancy (the respondent wanted to have a baby at the time the 
pregnancy occurred) or unintended pregnancy have put an unplanned pregnancy rate 
as high as 49% (Finer and Henshaw, 2006), suggesting that when presented with 
only two choices women classify a larger proportion of pregnancies as unintended. 
Despite the inherent complexities as described above, the dichotomy of 
intended/unintended pregnancy has been essential to researchers and public health 




The impact of unintended pregnancy on society is substantial. Mothers with 
unintended pregnancies present later for antenatal care, are more likely to have a low 
birth weight infant and to deliver prematurely (Shah et al., 2011) and are less likely 
to breastfeed, or breastfeed for a shorter duration (Gipson et al., 2008). Evidence 
suggests a positive association between unintended pregnancy and child abuse, and 
between unintended pregnancy and child mortality (Mohllajee et al., 2007). One 
population-based study from the United Kingdom found that children registered with 
the child protection agency by the age of six were nearly three times likely to be a 
result of a pregnancy their mother considered unintended (Sidebotham et al., 2003). 
Unintended pregnancy is also likely to have a substantial impact on maternal well-
being; unintended childbearing carries a significantly increased risk of maternal 
depression, anxiety and psychological ill health (Gipson et al., 2008). Women with 
unwanted or mistimed pregnancies are also more likely to be a victim of physical 
violence than women with intended pregnancies, regardless of other characteristics 
(Gazmararian et al., 1995). In addition, women with unintended pregnancies are far 
more likely to live in poverty, and to be made poorer by raising children or paying 
for abortions (Forrest, 1994).  
Termination of pregnancy is also an important outcome of unplanned pregnancy. 
Although not all pregnancies ending in termination are unplanned, evidence suggests 
that only about 5% of pregnancies that result in a termination were initially an 
intended pregnancy (Finer and Henshaw, 2006), and figures from Edinburgh, 
Scotland put this figure at less than 1% (Lakha and Glasier, 2006; Schünmann and 
Glasier, 2006). Unintended pregnancies therefore account for the vast majority of 
abortions. In Scotland there were 12,082 abortions performed in 2015. 98.3% of 
these were carried out because “continuance of the pregnancy would involve risk, 
greater than if the pregnancy were terminated, of injury to the physical or mental 
health of the pregnancy woman” (NHS Scotland Information Services Division, 
2016a). These abortions were carried out under ‘Ground C’ of the 1967 abortion act 
(1967). Abortions for fetal anomaly (and perhaps therefore more likely to have been 
originally a planned or wanted pregnancy) therefore accounted for less than 2% of 
abortions in Scotland. Although a termination of pregnancy in the United Kingdom is 
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an extremely safe and straightforward procedure, whether medical or surgical (Kulier 
et al., 2001; Kulier et al., 2011; Say et al., 2002), any reduction in unplanned 
pregnancy would reduce the termination of pregnancy rate.  
Abortion and its status in many countries makes the global burden of unplanned 
pregnancy extensive. Estimates are that each year in 2010-2014 there were 35 
abortions per 1000 women aged 15-44 worldwide. Globally 25% of pregnancies end 
in abortion. Extensive data from 2010-2014 were published in 2016, obtained from 
official statistics and published or unpublished national studies. Abortion legality 
does not affect abortion rates, this research showed a rate of 37 abortions per 1000 
women in countries where abortion is prohibited completely or allowed only to save 
a woman’s life, and 34 where it is available on request (Sedgh et al., 2016). In 
countries where abortion is illegal and therefore unsafe, unintended pregnancy is a 
major contributor to maternal morbidity and mortality (Santelli et al., 2003). A WHO 
systematic analysis estimated that abortions were responsible for 7.9% of maternal 
deaths between 2003-2009, equivalent to approximately 193 000 deaths. Furthermore 
the authors identify that this is likely an underestimation due to illegality and 
religious and cultural stigma associated with abortion in some countries (Say et al., 
2014). 
1.1.2 Contraception used in the United Kingdom 
Women in the United Kingdom have a wide variety of contraceptive options 
available to them, but limited data on current use are available. Evidence from 2009 
suggests that one in four women under 50 are not using any method of contraception, 
of whom just under half in a sexual relationship with an opposite sex partner (Lader, 
2009). Table 1-1 demonstrates all methods in use by women aged 16-49. This data is 
based on the National Statistics Opinion Survey during 2008/09, and draws on 
answers from just 1093 women. These figures may well have changed but this 





Table 1-1 Contraception use in the United Kingdom 2008/9, adapted from Lader 2009 




Combined pill 16 






Safe period/rhythm method/Persona 2 
Cap/diaphragm 0 
Foams/gels 1 
Hormonal IUS 2 
Female condom 1 
Emergency contraception 1 
Total at least one method non-surgical 58 
Surgical 
Sterilised 6 
Partner sterilised 11 
Total at least one method 75 
Not using a method 
No heterosexual relationship 13 
Sterile after another operation 2 
Wants to get pregnant 2 
Pregnant now 2 
Going without sex to avoid pregnancy 1 
Unlikely to conceive because of menopause 1 
Possibly infertile 1 
Doesn’t like contraception 1 
Other reason 3 
Total not using a method 25 
 
The contraceptive pill and male condom are by far the most popular methods of 
contraception, accounting for 50% of contraceptive use between them. However, 
with this relatively small sample size it may be difficult to capture data on methods 
used by fewer women such as the diaphragm, contraceptive patch, and contraceptive 
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implant. In addition the contraceptive implant in particular has seen steady growth in 
popularity since 2008 when this data was collected (Cea Soriano et al., 2014b) (see 
figure 1-1). 
Figure 1-1 Annual incidence and prevalence of long-acting reversible contraceptive use from 2004 
to 2010, reproduced with permission from Cea Soriano et al 2014b 
 
Data from 2013 examining methods prescribed by general practitioners also suggests 
that combined oral contraception remains by far the most popular prescribed method 
of contraception in the primary care setting. Anonymised patient records of women 
aged 12-49 in the year 2008 from a medical research database were analysed. 574 
185 women were eligible, of whom 194 054 (34%) had used one of the included 
contraceptive methods during the study. These were the combined oral contraceptive 
pill, progestogen-only pill, copper IUD, levonorgestrel-releasing intrauterine system, 
progestogen-only implant, contraceptive injection and contraceptive patch. The study 
underlines the results from the National Statistics Opinion Survey, finding that oral 
contraceptives are used by 21.8% of women aged 12-49 (Cea Soriano et al., 2014a). 
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Figure 1-2 Prevalence of use of contraceptive methods in 2008 among women aged 12-49 
(reproduced from Cea Soriano et al 2014a) 
 
 
1.1.3 Long acting reversible contraception 
Contraceptive failure can be examined using either ‘perfect’ use, or ‘typical’ use: use 
of the method by an average person in a real life setting, including inconsistencies 
and imperfect use. Table 1-2 demonstrates the typical and perfect use failure rates of 
available contraceptive methods used in the United Kingdom. 
Table 1-2 Percentage of women in the United States experiencing an unintended pregnancy during 
the first year of use. Adapted from Trussell 2011 
Method used 
 Typical use Perfect use 
No method 85 85 
Fertility awareness based methods 24 0.4-5* 
Withdrawal 22 4 
Female condom 21 5 
Male condom 18 2 
Diaphragm 12 6 
Combined pill and progestin-only pill 9 0.3 
Contraceptive patch 9 0.3 
Contraceptive vaginal ring 9 0.3 
Contraceptive injection (Depo-Provera) 6 0.2 
Copper intrauterine device 0.8 0.6 
Levonorgestrel intrauterine system 0.2 0.2 
Contraceptive implant (Implanon) 0.05 0.05 
Female sterilisation 0.5 0.5 
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Male sterilisation 0.15 0.10 
*Depending on method used 
Methods shaded in blue are long acting reversible contraception methods 
 
The LARC (long acting reversible contraceptive) methods (shaded in blue) are 
demonstrably the most effective reversible methods to avoid unplanned pregnancy, 
mainly due to the low discrepancy between their typical and perfect use. A large 
prospective cohort study in St. Louis, USA examining the relative effectiveness of 
LARC found that participants using contraceptive pills, patches and vaginal rings, 
had a risk of contraceptive failure 20 times higher than those using LARC (Winner et 
al., 2012). The contraceptive injection, or Depo-Provera®, can be classed as a LARC 
method, but as it requires user input every 12-13 weeks it is not usually included 
when data is collected specifically about LARC (NHS Scotland Information Services 
Division, 2016b). The LARC methods therefore consist of the contraceptive implant, 
a subdermal rod that releases progestogen, the copper IUD (intrauterine device) and 
the levonorgestrel-releasing intrauterine device, also known as an intrauterine 
system, or IUS. Because LARC methods are the most effective at preventing 
unplanned pregnancy, national strategies for sexual health include goals to improve 
the uptake of LARC. In Scotland the 2015 update to the Sexual Health and Blood 
Borne Virus Framework noted the increase in LARC since the framework’s 
inception in 2011, and called for further increases (The Scottish Government, 2015). 
Recent data from Scotland suggests that the LARC prescribing rate for women of 
reproductive age is 52.1 per 1000 women (NHS Scotland Information Services 
Division, 2016b). Figure 1-3 demonstrates the use of LARC by age group. Whilst it 
is difficult to compare different methods of investigating contraceptive use, data 
from the national opinion survey suggests that up to 59% of women of reproductive 
age require effective contraception (Lader, 2009). It therefore makes sense, from a 
public health point of view, for a much greater proportion of these women to be 
using LARC methods. Evidence suggests that prevalence of LARC methods is 
increasing UK-wide: between 2004 and 2010 use of the progestogen-only implant 
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rose from 1.5 to 11.3 per 1000 women, and use of the LNG-IUS from 3.1 in 2004 to 
5.2 in 2010 (Cea Soriano et al., 2014b).  
However, despite their efficacy at preventing the main outcome contraceptive users 
wish to avoid, prevalence remains low. There are many reasons why patients choose 
not to use LARC methods, despite their demonstrably greater efficacy at preventing 
unplanned pregnancy. Evidence from Scotland in 2008 shows that pills and condoms 
are more familiar to women, who may hold incorrect beliefs about LARC, and 
suggests women may not appreciate the differences in efficacy with typical use 
(Glasier et al., 2008).  GPs (general practitioners) may be contributing to the low 
LARC uptake, as evidence from 2011 showed that 92% of GPs questioned (n=71) 
identified the contraceptive pill as their first-line method of contraception for a 
young nulliparous woman, despite 85% of respondents recognising that LARC were 
the most effective methods (Middleton et al., 2011). 
Figure 1-3 LARC methods prescribing rate per 1000 women by age group 2015/16. Reproduced 
from NHS Scotland Information Services Division 2016b 
 
A recent article argued that there has been an unnecessary prioritisation of LARC 
methods over short-acting methods, using a computer simulation model to critique 
Winner et al, arguing that much of LARC’s demonstrated efficacy in reducing 
unplanned pregnancy rates is due to a reduction in non-users and condom users, and 
that commencing all non-users on short-acting methods would have almost as 
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significant an effect on unplanned pregnancy (Karpilow and Thomas, 2017). 
However, there is overwhelming evidence that non-users do not use contraception 
for a multiplicity of reasons, notably thinking they will not get pregnant (Jones et al., 
2002; Moreau et al., 2005), believing that their partner wants them to be pregnant 
(Stevens-Simon et al., 2005), their partner being in control of whether or not they use 
contraception (Williams et al., 2008), feeling that pregnancy should not or cannot be 
prevented (Borrero et al., 2015) and numerous other individual, interpersonal and 
societal factors (Ayoola et al., 2007). It is therefore not as simple as a computer 
simulation might suggest, and moving both non-users and users of short-acting 
methods to LARC has the potential to significantly impact unplanned pregnancy 
rates.  
1.1.4 Contraceptive delivery: current service models 
In the United Kingdom all available contraception is free of charge for users. The 
NHS website states that patients can receive contraception from most GP surgeries, 
community contraception clinics, some genitourinary medicine clinics, sexual health 
clinics and some young people’s services (NHS Choices Website, 2015). There are 
no fixed rules about which of these services should deliver contraception, and as a 
result availability is not guaranteed, or necessarily easy to predict. In Scotland, the 
Primary Medical Services (Scotland) Act 2004 outlined the terms by which health 
services are contracted by the local NHS Board from GPs. The essential services that 
must be delivered under this contract are the management of patients who are ill or 
who believe themselves to be ill, the management of chronic disease, the 
management of patients who are terminally ill, and primary care services in core 
hours for accidents and emergencies. Contraceptive services are not deemed to be an 
essential service, and are instead deemed an additional service, which any practice 
can opt out of providing if they wish (2004). Nevertheless, evidence from the United 
Kingdom (there is no specific Scottish data available) suggests that GPs are the most 
common provider of contraceptive supplies.  
Data from the National Survey of Sexual Attitudes and Lifestyles in 2010-2012 
demonstrates that the source of contraceptive supplies used by the largest proportion 
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of women were GPs, with 59.1% of sexually active women reporting use of GP 
services in the last year. This is almost identical to the proportion obtaining 
contraception from GP services in 1999-2001 (French et al., 2009).  In 2010-12, 23% 
of women interviewed obtained supplies from community services, largely family 
planning clinics (14.4%). 8.5% obtained supplies from genito-urinary medicine 
clinics, reflecting an increasing move towards integration between these two 
specialist services, at least in some parts of the country (French et al., 2017). Figure 
1-4 demonstrates service use for contraceptive supplies and/or advice in the last year 
for women, based on answers to Natsal-3. 
Figure 1-4 Sources used to obtain contraception in the past year among women aged 16-44 who 
report vaginal sex in the past year and obtaining contraceptives. Reproduced from French et al 
2017 
 
In Scotland specialist sexual health services are the main providers of contraception 
after GPs (NHS Scotland Information Services Division, 2016b), though 
contraceptives may sometimes be given in a hospital setting. This is particularly true 
after termination of pregnancy (Cameron et al., 2012a), and contraceptive provision 
after abortion was a key priority of the Scottish Sexual Health and Blood Borne 
Virus Strategy, both originally and in the 2015 update (The Scottish Government, 
2011; The Scottish Government, 2015). Currently contraception is also provided 
very occasionally in the maternity setting (Cameron et al., 2017; Smith and 
McLellan, 2014). Emergency hormonal contraception (EHC) is also delivered 
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through all routes mentioned above, though the vast majority of EHC is delivered 
through pharmacies based in the community (Marston et al., 2005). In Scotland EHC 
is available free of charge in the pharmacy as well as the clinical setting (Cameron et 
al., 2012c).   
1.1.4.1 A note on delivery of contraceptive care in England and Wales 
Delivery of contraceptive services in England and Wales may be more fragmented 
due to the recent introduction of clinical commissioning groups, and commissioning 
of sexual healthcare and contraceptive services by various community, education, 
pharmacy or private sectors (National Institute for Health and Care Excellence 
(NICE), 2016). The Royal College of General Practitioners has raised concerns about 
the implications of clinical commissioning of sexual and reproductive healthcare in 
England, particularly with regards to ensuring LARC provision and holistic care for 
patients (Royal College of General Practitioners, 2014). A discussion of this is 
outwith the scope and relevance of this research. 
1.1.5 Contraceptive care: no missed opportunities 
Contraception is a unique healthcare intervention, in that it is delivered to a well 
population who may not consider themselves in need of it. Evidence from the United 
States shows that almost one in five women aged 18-29 believe themselves very 
likely to be infertile (Polis and Zabin, 2012), and that 41% of women with an 
unintended pregnancy had thought either that they couldn’t get pregnant at the time 
of the intercourse or that they or their partner were infertile (Nettleman et al., 2007). 
The perceived lack of need among the population combined with the unplanned 
pregnancy rate means that it needs to be as easy as possible for women to access 
contraceptive care with as few barriers as possible. The idea of contraception 
delivered opportunistically has been gradually adopted into policy in the area of 
termination of pregnancy. With a growing body of evidence that offering women 
contraception at the time of termination reduces unplanned pregnancy rates 
(Goodman et al., 2008; Bednarek et al., 2011; Cameron et al., 2012a), enthusiasm for 
the intervention has been reflected in policy and clinical guidance (The Scottish 
Government, 2011; The Scottish Government, 2015; Royal College of Obstetricians 
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and Gynaecologists, 2011). However, when this research was commenced in 2013, 
the idea of offering contraception opportunistically at other healthcare interventions, 
notably after pregnancy ending in a live birth, was just appearing in the international 
literature (Celen et al., 2011; Bhutta et al., 2011; Glazer et al., 2011; Levi et al., 
2012; Curry et al., 2012; Tocce et al., 2012a), but was not yet being discussed in the 
UK.  
Figure 1-3 shows the variety of sources women use to access contraception. 16.6% of 
women only obtained contraception from retail settings (French et al., 2017). 
Currently the only contraception methods available in the retail setting are condoms 
and emergency hormonal contraception (EHC) (Department of Health, 2005). French 
et al note an increase in the use of retail outlets since similar data was gained in 
1999-2001, and speculate that this increase may reflect the increase in use of EHC 
from pharmacies, suggesting that pharmacies therefore account for a significant 
source of contraception obtained at retail outlets (French et al., 2009). A possible 
expansion of contraception options could be to offer more contraceptive options in a 
pharmacy setting.  
1.1.6 Why expand contraceptive uptake? 
Unplanned pregnancy can be conceptualised as having three similar but separate 
antecedents. First, true contraceptive failure, the method used perfectly but 
pregnancy still occurring at the time of use. Secondly, a method used, but used 
inconsistently or imperfectly. Thirdly, no method used at the time of pregnancy 
occurring. The vast majority of unplanned pregnancies occur due to the second two 
(Jones et al., 2002; Larsson et al., 2002; Rasch, 2002; Schünmann and Glasier, 
2006). The user independence of the LARC methods is the primary reason why they 
are more effective at preventing unplanned pregnancy, as it is largely impossible to 
use them inconsistently or imperfectly once they are inserted. A reduction in 
unplanned pregnancy therefore could take two approaches: moving women using 
less effective methods to more effective methods, and moving women using no 
contraception to using any method – ideally the most effective methods.  
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Expanding contraceptive access to include the pharmacy would be likely to primarily 
achieve the second intervention, although some users might move from condoms to 
more effective methods, if they were more widely available. Documented systematic 
and medical barriers to women obtaining contraception include delayed initiation, 
clinician limitations and prescription requirements (Leeman, 2007). Removing some 
or all of these through pharmacy availability of some or all contraception options 
might increase uptake of the available methods.  
The early focus on opportunistic delivery of contraception at the time of childbirth 
examines LARC methods, mirroring evidence from method initiation at the time of 
abortion (Goodman et al., 2008; Bednarek et al., 2011; Cameron et al., 2012a). The 
advantage of offering contraceptive at this time is twofold: evidence shows that this 
is a population who may not have access to accurate information about how to use 
contraceptives postpartum, and therefore may not use them at all (Murphy and 
British Pregnancy Advisory Service, 2014). In addition postpartum women are 
interacting with trained health professionals and therefore there is an opportunity to 
provide them with LARC methods. Opportunistic intervention could therefore enable 
women who are non-users to become users of the most effective methods. 
Both offering the opportunity for non-users to become users through increased 
access, and increasing the uptake of the most effective methods which are far less 
likely to be used incorrectly and infrequently should act to reduce the unplanned 
pregnancy rate with a significant effect on both society and women’s lives.  
1.2 Research aims and objectives 
In summary, unplanned pregnancy remains a significant problem in the United 
Kingdom and in Scotland, despite a wide range of effective contraceptive options 
available. The effect of these unplanned pregnancies on women and society is 
significant and wide reaching. The models of delivering contraceptive care differ 
from country to country, and within NHS boards in Scotland, but women access 
contraception from GPs, specialist sexual health clinics and retail outlets. Although 
there is clear evidence for opportunistic contraceptive delivery in the field of 
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termination of pregnancy care that has been reflected in policy, there is limited 
evidence of similar enthusiasm for opportunistic contraceptive delivery elsewhere. 
This aim of this research is to examine the expansion of contraceptive delivery 
beyond methods that were available to women at the time the research commenced, 
with the intent of providing evidence for new effective times and places of delivery.  
The specific research objectives were as follows: 
To explore a retail setting that currently delivers limited contraceptive options, 
namely the community pharmacy, to see whether there is scope for further provision 
of contraception in this location.  
To explore the delivery of contraception in the postpartum setting, examining the 
need and evidence for this in a Scottish context. Specifically, is it possible for 
contraception to be routinely offered in the maternity setting as it currently is at 
termination of pregnancy?  
1.3 The importance of research contained in this 
thesis 
This research is important for a number of reasons.  
 Increasing the sexual healthcare, including contraceptive care, delivered by 
community pharmacies has been called for at a national governmental level 
(Department of Health, 2004; Department of Health, 2005). It is a reasonable 
suggestion that, as patients already obtain some contraceptives at the 
pharmacy (French et al., 2009; French et al., 2017), increasing the 
contraceptives available here could increase the contraceptive uptake. This 
research therefore explores the evidence available for this proposition, and 
examines this possibility in a UK setting. 
 There is good evidence that providing contraception, particularly the most 
effective methods, at the time of termination of pregnancy results in fewer 
unplanned pregnancies. This evidence is reflected in clinical guidance about 
contraceptive provision at the time of termination (Royal College of 
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Obstetricians and Gynaecologists, 2011). This research aims to investigate 
the possibility of similar contraceptive provision in the maternity setting, 
through an examination of service provision, an assessment of patient 
opinion, and an observational study.  
 Each of the possibilities outlined above describes contraceptive care that is 
currently beyond what is offered to patients. Examining evidence for these 
and investigating the ideas with appropriate research methodologies should 
provide general evidence about the possibilities for increasing future 
contraceptive delivery by looking outwith available service models.  
1.4 Outline of this thesis 
Chapter one provides an introduction to the subject, outlining the problem of 
unintended pregnancy in an global and national context, and introducing the current 
national contraception delivery systems designed to meet this need. It introduces the 
idea of expanding contraceptive delivery beyond current service models and suggests 
some options that will be further explored, namely contraceptive delivery from a 
pharmacy setting, and contraceptive delivery in the postpartum setting.  
Chapter two provides a literature review of one possible contraceptive expansion: 
delivery of contraceptive care within the community pharmacy setting. The review 
examines available literature about service acceptability, both from a pharmacist and 
public point of view, and explores available evidence for service delivery from the 
pharmacy. It goes on to identify a possible area of exploration in a Scottish context, 
namely delivery of the contraceptive injection in the community pharmacy. 
Chapter three presents published research undertaken in an urban sexual health 
centre to examine the demand for delivery of the contraceptive injection in a 
community pharmacy. A questionnaire was conducted with a potential recruitment 
population in order to assess feasibility of recruitment and service demand. This is 
outlined and results are presented.  
Chapter four outlines the methodology for a pilot project that was conducted, 
offering participants contraceptive injections at the pharmacy. It outlines the 
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strategies for identification of participating pharmacists, recruiting participants and 
designing how the pilot was conducted in practice.  
Chapter five reports the results of this pilot. Both quantitative and qualitative results 
are presented. The results and implications of this research are then discussed.  
Chapter six sets the scene for the delivery of contraception in the postpartum 
setting.   The current national context is examined. There follows a published paper 
outlining research conducted on this subject, both identifying the need for 
postpartum contraception, and asking postpartum patients their thoughts on being 
offered contraception at this time.  
Chapter seven focuses on a specific method of delivering postpartum contraception: 
insertion of intrauterine contraception at the time of caesarean section. A 
comprehensive literature review examines the evidence for this practice. An 
observational study that was conducted examining this option being made routinely 
available is then presented and discussed.  
Chapter eight summarises the findings from the research presented in preceding 
chapters, and compares the findings to the research objectives set out in chapter one. 
It sets out the changes in clinical practice that have occurred locally and nationally as 




Chapter 2 Delivering sexual health at the 
community pharmacy: mixed 
methods literature review 
2.1 Introduction 
In Chapter 1 I outlined the current unplanned pregnancy rate in Scotland, and argued 
that, in order to reduce as many barriers to contraception as possible for women, 
service delivery models can be expanded beyond those currently available. In this 
chapter, I will focus on the community pharmacist as a professional who has not 
traditionally delivered contraception, but whose potential to do so is gaining 
increasing attention. The term ‘community pharmacist’ will be used to denote a 
trained pharmacist who works in a retail community setting in a pharmacy, either 
independent or part of a chain. Community pharmacists are located within patients’ 
communities, particularly in communities of deprivation, or rural settings (Todd et 
al., 2015). The involvement of community pharmacists in the sexual and 
reproductive healthcare of women could remove barriers of time, location and 
access, making it more possible for women to receive this intervention.  
In 2004 a Department of Health White Paper entitled ‘Choosing Health: making 
healthy choices easier’ laid out a number of goals for improving the health of the 
nation. Within the chapter ‘a health promoting NHS’ special emphasis was put on the 
contribution to public health that pharmacists could make. “Working at the heart of 
the communities they serve, they have real opportunities to offer health messages and 
advice” (Department of Health, 2004). Sexual health was highlighted as a key 
component of this strategy. This idea was developed further in a 2005 White Paper, 
‘Choosing Health Through Pharmacy: a programme for pharmaceutical public health 
2005-2015’. The paper noted the importance of an evidence base for pharmaceutical 
public health, perhaps because the 2004 White Paper was criticised for lacking one 
(Raine et al., 2004). The 2005 paper highlights the plan to involve pharmacies in 
sexual health, the pharmacist’s role being defined as: offering emergency 
contraception under PGDs (Patient Group Directions – a legal framework allowing 
specified HCPs to supply and/or administer a medicine to a pre-defined group of 
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patients, without the patient having to see a doctor or have medication prescribed 
(National Institute for Health and Care Excellence (NICE), 2015)), supplying 
condoms, signposting to other sources of advice and support, and offering sexual 
health advice and screening as part of an integrated system (Department of Health, 
2001). Doctors working in sexual health have also noted the potential of the 
community pharmacist’s role in sexual healthcare (Quilliam, 2013; Rani, 2008; 
Taylor, 2008). 
2.1.1 Justification for the methodology 
Although literature shows increasing enthusiasm for sexual healthcare delivered 
through community pharmacies (Chin, 2011; Rafie et al., 2014; Maderas et al., 2008; 
Eades et al., 2011), a systematic review of the contribution of pharmacists to public 
health concluded that there was insufficient evidence for their role in sexual health 
(Brown et al., 2012). There has been only one short review of the contribution of 
community pharmacy to sexual health (Chin, 2011). There have been reviews of the 
contribution to public health generally (Brown et al., 2012; Anderson et al., 2009; 
Anderson et al., 2005), and to the delivery of emergency hormonal contraception 
specifically (Anderson and Blenkinsopp, 2006). There has been one recent 
systematic review of pharmacy provision of reproductive health commodities to 
young people under 25 (Gonsalves and Hindin, 2016), and one review of the 
pharmacy’s contribution to preventing unintended pregnancy, that focuses on United 
States data only (Farris et al., 2010). I planned to conduct research offering patients 
contraceptive care from their community pharmacy, and so it was crucial to assess 
the up to date evidence base surrounding this idea. This review will help to judge the 
potential of conducting contraception research within a community pharmacy setting, 
identify any gaps in the literature, and outline lessons learnt from research conducted 
in this field.  
This chapter therefore provides a comprehensive review of the literature of 
contraceptive services delivered by community pharmacists. The review strategy is 
described. The findings of the literature review are then detailed, looking first at 
pharmacists’ feelings on delivering sexual healthcare, then at patients’ and the 
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population’s opinions, and finally an assessment of this as a strategy for delivering 
healthcare. The final section outlines gaps in the literature and provides the reasoning 
for my research that constitutes chapters 3, 4 and 5 of this PhD.  
2.1.2 Review strategy 
Literature searches were conducted in Medline, EMBASE and PubMed. Papers were 
limited from 2001 onwards as this is the year that emergency hormonal contraception 
became available from pharmacists over the counter in the United Kingdom. This 
service marked a change in the relationship of pharmacists to sexual health, and 
literature from after that point is more relevant to the current landscape. Searches 
were adapted to suit the different formats of the individual databases.  
Search terms were: pharmacy OR community pharmacy OR community pharmacy 
services AND sexual health OR reproductive health OR contraception (exploded: 
contraception, barrier or contraception, postcoital or contraception or contraception, 
immunologic or contraception behaviour) OR birth control OR family planning OR 
family planning services. The search was limited to humans.  
No formal protocol for the review was followed, as this was not a systematic review. 
Rather than answering a specific research question as a systematic review aims to do, 
it was more important to encompass the breadth of literature available, including 
position papers and literature looking at both patients’ and pharmacists’ perceptions 
and knowledge, as well as any assessment of delivery of sexual healthcare by the 
pharmacy that has taken place.  Both qualitative and quantitative literature was 
examined, as each presents useful information for researchers on different aspects of 
the patient and pharmacist experience. Meta-analysis was not possible, and instead 
thematic analysis was used to draw out relevant themes. Papers were grouped 
together under these titles.   
Literature searching provided me with 1,159 titles. These were screened for 
relevance by title and abstract (where title was inconclusive) to obtain 130. I also 
screened references from four relevant reviews: two about public health in the 
pharmacy (Eades et al., 2011; Anderson et al., 2009), one about pharmacy provision 
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of sexual health to young people (Gonsalves and Hindin, 2016), and one scoping 
review of the public response to pharmacy prescribing (Famiyeh and McCarthy, 
2017). Examining the references of these reviews generated a further 23 papers. All 
153 papers were all read in full, and 10 were rejected as not meeting the inclusion 
criteria. Only papers in English were included. Research articles, non-research 
articles (e.g. editorials) and posters/presentations from meetings were included if 
relevant. Papers met the inclusion criteria if they examined the idea of any type of 
contraceptive service, including condoms and EHC (emergency hormonal 
contraception) being delivered by a pharmacy, whether looking at the idea in theory 
or evaluating a current service, from the point of view of pharmacists, patients, or 
other healthcare professionals. Articles or research only about pharmacist knowledge 
about contraception, with no attitudinal component, were not included, as they were 
not felt to be a useful proxy for pharmacists’ ability to deliver a service. 
2.1.3 Overview of the literature 
The availability of contraception from community pharmacies displays considerable 
geographic variation (Grindlay et al., 2013). Most of the literature available is from 
the United States, and from resource rich countries. A map showing the availability 
of oral contraceptives over the counter from the pharmacy is shown in figure 2-1 and 









Table 2-1 Global oral contraception prescription and screening requirements: country list (n=147) (Reproduced from Grindlay et al 2013)
Informally available without prescription Legally available without 







Only available with prescription 
Albania Liberia Afghanistan Kenya Ghana Australia Micronesia,  
Federated States  
of 
Algeria Macedonia Angola Kuwait Guinea Austria Namibia 
Argentina Madagascar Bangladesh Malawi Jamaica Azerbaijan Netherlands 
Armenia Mali Bosnia and 
Herzegovina 
Nicaragua Malaysia Belarus New Zealand 
Aruba Mexico Cambodia Pakistan Nepal Belgium Norway 
Bahamas Moldova China Paraguay Rwanda Botswana Poland 
Bahrain Mongolia Cuba Senegal South Africa British Virgin 
Islands 
Puerto Rico 
Bhutan Morocco Djibouti Serbia Tanzania Bulgaria Saudi Arabia 
Bolivia Mozambique Dominican 
Republic 
South Korea Tunisia Burkina Faso Singapore 




El Salvador Sudan Vietnam Cape Verde Spain 
Chad Nigeria Ethiopia Swaziland Ghana Croatia Sweden 
Chile Palestine Greece Syria Guinea Czech 
Republic 
Switzerland 






Costa Rica Peru Haiti Trinidad and 
Tobago 
Malaysia Estonia United Kingdom 
Democratic Republic of the 
Congo 
Philippines Honduras Turkmenistan Nepal Finland United States 
Ecuador Portugal Hong Kong Ukraine  France Zimbabwe 
Equatorial Guinea Romania India   Germany  
Gabon Russian 
Federation 
   Hungary  
Georgia Slovenia    Iceland  
Grenada Tajikistan    Ireland  
Indonesia Togo    Israel  
Iran Turkey    Italy  
Ivory Coast United Arab 
Emirates 
   Japan  
Jordon 
 
Kazakhstan Uruguay    Lithuania  
Laos Venezuela    Malta  
Lebanon Yemen    Marshall  
Lesotho Zambia    Islands  
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Much of the available literature focuses on whether regularly taken hormonal 
contraceptives (as opposed to emergency hormonal contraception) should be 
available from a pharmacy without a medical prescription, either “behind the 
counter” (subject to some restrictions on age, gender and status) or “over the 
counter” (not subject to any such restrictions). This research is largely conducted in 
countries where contraceptives are not available over the counter. There are a large 
number of surveys and some qualitative data seeking the opinion of users, potential 
users, pharmacists and health professionals. There is a variety of literature evaluating 
the current pharmacist delivery of emergency hormonal contraception. There are a 
number of papers on pharmacists already offering hormonal contraception without a 
prescription in pilot projects, and some ways to explore partnerships between 
community pharmacies and healthcare professionals in order to improve patients’ 
sexual health and increase access to contraception. 
2.2 Pharmacists’ thoughts about their role in 
dispensing contraception 
A number of studies have examined pharmacists’ thoughts about expanding their 
role regarding contraception – usually asking pharmacists their willingness to 
dispense hormonal contraception on a regular basis without a doctor’s prescription. 
Research from a variety of (resource rich) countries shows an enthusiastic response, 
indicating pharmacists embracing the idea of expanding their role, and welcoming a 
potential increase in status and autonomy.  
Surveys from 145 pharmacists across Canada, and qualitative interviews with a 
representative 19 demonstrated that 90% of pharmacists felt they had the skills for 
assessment, examination, decision-making and follow-up involved in independent 
prescribing of hormonal contraception. In addition they felt that doing so would give 
them more pride and autonomy and increase job satisfaction (Norman et al., 2015). A 
survey of student pharmacists in California, USA in 2003 demonstrated a willingness 
to provide novel reproductive health services, with 96% interested in providing 
hormonal contraception (the pill, patch or ring) when asked. Participants felt that 
pharmacists providing more services would benefit patients by giving them improved 
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access and opportunities for advice about hormonal contraception (Rafie and El-
Ibiary, 2011). Of 1250 pharmacists in Quebec, Canada, 99.3% believed they should 
be ‘very involved’ or ‘involved’ in the provision of emergency contraception, with 
97.4% believing they should be ‘very involved’ or ‘involved’ in the provision of 
contraception in general (Laliberté et al., 2012). A survey completed by 2,725 
pharmacists in the United States (with only a 19% response rate) showed that most 
respondents were comfortable and interested in providing direct access to hormonal 
contraception in the pharmacy (Landau et al., 2009). The main weakness of the 
research outlined above is that it asks people how enthusiastic they are about a 
proposed idea. Such information is of value when considering setting up new 
services but is not a guide to how likely those services are to be provided in practice, 
given the varied financial, political and practical elements involved in service 
expansion, particularly in the field of reproductive health. Of note in the Quebec 
survey, only 67.8% described themselves as currently ‘involved’ or ‘very involved’ 
in sexual health activities, with lack of time, space, skills and human resources all 
cited as barriers to providing more comprehensive services in the pharmacy 
(Laliberté et al., 2012). These findings were similar to those of Paluck et al, who 
surveyed 625 pharmacists in British Columbia, Canada. Counselling clients on 
sexual health aspects of health such as “STDs” and “AIDS” accounted for a very 
small portion of pharmacists’ workload, with 31% and 41% of pharmacists never 
doing this (Paluck et al., 1994). However this does not offer any evidence about their 
ability or willingness to offer such services, only that in the current set up they are 
not doing so.  
Pharmacists in North-East Scotland expressed a willingness to provide various 
services in the future, with 75% open to providing oral contraceptives under a PGD. 
However only 33% were willing to provide long-acting reversible contraceptive 
(LARC) methods (Gale and Watson, 2011). A report by the Scottish Government in 
2011 about EHC (and smoking cessation) in pharmacies included 121 surveys with 
community pharmacists from 13 out of 14 health boards in Scotland.  Although 
pharmacists felt EHC dispensing worked well and needed little improvement, 
suggestions for improvement did include expanding the service to include pregnancy 
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testing and long term contraception, and “new drugs which can be prescribed up to 5 
days” (ulipristal acetate) (Hametz et al., 2011). Despite a readiness to provide 
services pharmacists felt that they lacked adequate training and that pressure of time 
was a barrier to providing the services they wished to; themes that recur often in the 
literature (Gale and Watson, 2011; Laliberté et al., 2012; Rafie and El-Ibiary, 2011; 
Sweeney et al., 2015). 
Structured interviews with 20 California physicians and advanced practice clinicians, 
and a self-administered survey of 482 California physicians and mid-level providers 
showed that the majority of all types of respondents considered the prescription-only 
model of accessing hormonal contraception to be unnecessarily restrictive, believing 
that obtaining contraceptives directly from pharmacists would expand access and 
increase compliance (Rafie et al., 2012; Rafie et al., 2015). The State of California 
legislature recently expanded the ability of pharmacists to give “self-administered 
hormonal contraception” (California State Legislature Assembly, 2013). Although 
the evidence is that knowledge of this service spread slowly, with few pharmacists 
aware of it the following year (Richards et al., 2015), two years later enthusiasm 
seems high among pharmacists, with 71% of 257 pharmacists reporting they would 
be likely to expand access to hormonal contraception under the new legislature (Vu 
et al., 2015), and over 65% of student pharmacists in California feeling that they had 
been adequately educated to offer hormonal contraception (Rafie and El-Ibiary, 
2014). Following the California legislation (and similar legislation in Oregon), 
pharmacists and physicians in Colorado were asked about OTC (‘over the counter’) 
access to progestogen-only contraception. There were substantial differences about 
the different groups’ primary concerns, with physicians most concerned about the 
efficacy of this type of contraception, but pharmacists being concerned about patient 
self-assessment of contraindications (Yazd et al., 2016).  
Interviews with pharmacists in New Zealand who were giving free condoms to 13-24 
year olds under a pilot condom card scheme noted generally positive views, though 
the number of people who had actually used the scheme was low. The pharmacist 
enthusiasm was based more on their self-perception about their suitability as 
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contraception providers rather than interactions with young people (Ryder et al., 
2015).  Qualitative interviews with pharmacy support staff working for “Healthy 
Living Pharmacies” in England (a scheme where certain pharmacists proactively 
promote health by offering advice, services and signposting) showed a mixed 
response, with some feeling like these pharmacies were useful but others more 
sceptical, due to concerns over whether patients wanted to “speak to a stranger” over 
health concerns, and whether there was adequate time and training to provide a good 
service. Sexual health was felt to be a particularly difficult topic, “due to a perceived 
discrepancy between the target demographics… compared to regular pharmacy 
clientele” (Donovan and Paudyal, 2016). Similar reservations were displayed by 273 
pharmacists from Northern Ireland who completed self-administered questionnaires. 
Although generally they were comfortable discussing most aspects of women’s 
health including contraception, 23% of male pharmacists were embarrassed 
discussing women’s health issues, and 59% of men and 33% of women found it 
difficult to initiate a conversation on women’s health issues (McAree and Scott, 
2004). 
Some qualitative research with groups of patients, GPs and pharmacists in the United 
Kingdom noted limited enthusiasm among pharmacists for discussion of 
contraception, with one pharmacist stating that “deciding on which contraception is 
suitable for the patient is between the patient and their GP”. It is worth noting here 
that it was the decision-making portion of a discussion about contraception that 
pharmacists were not comfortable with. They were not asked about delivering 
contraception to established users. Time pressure was also noted as a barrier to 
providing a good contraception service (Sweeney et al., 2015). 
Pharmacists in Sudan who were filling prescriptions written by a clinician were not 
asked about expanding their role, but about what they currently did, with 73.4% 
noting that they gave information about contraception methods (Mohamed et al., 
2013). A small survey of 33 pharmacists in Virginia, USA found almost no support 
for the idea that contraceptives should be available over the counter (only one person 
thought pills should be and no pharmacists thought other methods should be), but 
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found some support for the idea that methods should be ‘behind the counter’ – 
available to women aged 17 and older only, with the offer of pharmacist counselling: 
nine pharmacists believed this about the progestin-only pill, and ten believed that 
pharmacists should be able to prescribe the progestin-only pill. This research was 
rare in asking about one of the more effective and long-term methods, the 
contraceptive injection. Nine pharmacists thought they should be able to prescribe 
the contraceptive injection; none thought it should be available over the counter 
(Richard et al., 2015). 
Making methods available over the counter does not guarantee availability, perhaps 
particularly in the United States, where pharmacists may decide not to carry any 
product based on perceived demand or personal beliefs (Mackin and Clark, 2011). 
Secondary analysis of data collected for a descriptive study about EHC was 
conducted in Iowa, US, before and after the US policy change in August 2006 to 
make oral emergency contraceptives available OTC. They found that the percentage 
of pharmacies offering EHC increased from 57.8 to 70%, based on 713 pharmacies. 
However, even after the change availability was only 70%, and myths about safety 
and method of action persisted (Mackin and Clark, 2011). 
2.2.1 Summary 
In summary, the literature suggests that pharmacists are generally enthusiastic about 
providing contraceptive services, although more ambivalence is displayed about 
EHC than regular contraceptives, and more ambivalence about LARC than short-
acting methods. This enthusiasm appears to be based on the idea that providing 
contraceptives is an appropriate role for pharmacies, and one that will enhance their 
status.  However, there has been limited opportunity to see whether this enthusiasm 
translates into practice, as most pharmacists don’t offer hormonal contraception in 
the UK, US or Canada.   
2.3 Patients’ and communities’ thoughts about 
pharmacists dispensing contraception 
As women are able to access regular contraception in only a limited number of 
countries, multiple papers examined in this section ask patients about their behaviour 
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in theory: would they hypothetically attend a pharmacy for contraception? There are 
undoubtedly difficulties with using research which asks participants what they would 
do in different circumstances, as there can be no guarantee that they would act as 
they say or think they would. However, such questionnaires are useful to generally 
assess feasibility and acceptability of services and are therefore important before 
spending resources on large trials or expansion of healthcare delivery systems. 
Intention does not absolutely predict behaviour but there does appear to be a 
relationship between them (Ajzen, 1991). It is worth drawing the comparison that 
support for the theoretical availability of EHC from the pharmacist that was 
demonstrated before this option was available (Folkes et al., 2001) has been reflected 
in high usage and satisfaction subsequently (Anderson and Blenkinsopp, 2006). 
A number of quantitative surveys, largely conducted in the United States, have asked 
women whether they would attend the community pharmacy to receive their 
contraception. A telephone survey of 811 women in the United States found that 
68% of women said they would use a pharmacy to access to the oral contraceptive 
pill, the contraceptive patch and the vaginal ring, as well as EHC. 41% of women 
questioned who were not using any contraception stated that pharmacy availability 
would mean they would start using a hormonal contraceptive (Landau et al., 2006). 
An online survey of 2046 American women found 62.2% were strongly or somewhat 
in favour of the OCP (oral contraceptive pill) being available OTC, and that 28% of 
women currently using no method would be likely to use the OCP if available OTC 
(Grossman et al., 2013). Similar results were found with younger women. 348 
women aged 14-17 were recruited to an online survey using social media, and 73% 
supported OTC access to oral contraception. 61% reported that they would likely use 
oral contraceptives in this way (Manski and Kottke, 2015). It is important to note that 
barriers exist for this patient population that are not present in the United Kingdom, 
as demonstrated by the fact that 76% of women in the telephone survey said they 
would benefit from not needing to pay for a clinician visit. However other 
advantages more relevant to the UK included convenient hours (85%) and beneficial 
location (84%) (Landau et al., 2006). A survey of 651 women attending abortion 
clinics in urban areas of the US found that although 47% in favour of OTC access 
 
  31
stated that this was because it would save money, 63% were in favour because it 
would save time (Grindlay et al., 2014).  
Fakih et al conducted an online survey with women from Michigan, USA, aged 25-
26. Only 21% (41/195) had a positive attitude towards pharmacists providing 
pregnancy prevention information, preferring instead to see a physician (Fakih et al., 
2015). Contraceptive information has traditionally been provided by physicians and 
nurses, so this conclusion is perhaps not surprising. Obtaining advice from a 
pharmacist would mark a distinct shift in how women have traditionally received this 
information. There is also the question of how much ‘information’ patients feel they 
need when obtaining routine contraception from a healthcare professional. If 
someone is a well established user of the method then it may not be necessary to 
provide them with a significant amount of information every time the method is 
dispensed: this may be an important difference between initial choice and 
maintenance, and may be relevant to delivery of any contraceptive service from the 
pharmacist (though there is no literature examining the difference). 
Qualitative research in the form of interviews or focus groups provides richer data on 
how participants feel, and allows the participants themselves to generate ideas. Three 
pieces of qualitative research have investigated women’s ideas about obtaining 
contraception from their community pharmacist. Focus groups with low-income 
women in Boston, USA demonstrated general support for OTC access to oral 
contraception, although women emphasised that they would be unlikely to pay more 
for OTC access, and advised that the cost should be lower than their current costs. A 
number of these women reported switching to less effective methods, or from dual to 
single methods, based on cost (Dennis and Grossman, 2012). The financial factor is 
less relevant in the UK, where all regularly taken contraception is free regardless of 
where it is dispensed, and visiting a doctor is also free. Focus groups with young 
women and women of colour in the US (who may face particular barriers to 
contraception) echoed the perceived advantages of access, with the main benefit 
being convenience. Women suggested that this convenience would make it easier to 
continue pill use, suggesting gaps in use could occur a result of forgetting to make an 
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appointment (Baum et al., 2016). In-depth telephone interviews were conducted in 
August 2015 with 30 women aged 18-19 in California, prior to the new legislation 
allowing direct pharmacy access for contraception. Almost all participants were 
supportive of the law, and believed it would lead to better access and increased 
convenience (Miller et al., 2016). The evidence suggests that women, whether 
current or potential users, are keen to have the option of obtaining oral contraception 
from their pharmacist.  
A questionnaire sent out to 637 women in Michigan, USA with a follow up rate of 
54%, found that 25% of respondents had had a negative experience with a 
pharmacist regarding contraception. Examples given of negative experiences are 
pharmacists not having contraception, or not wanting to dispense it (Higgie et al., 
2014). Although numbers and follow up are small, and in addition may reflect the 
limited amount of contraception currently offered by pharmacist, this research 
provides evidence against the assumption that it will be preferable and more 
convenient for all women to visit the pharmacy to fulfil their sexual health needs.  
There has been less work outside the United States asking patients about obtaining 
contraception OTC, and the work that has been done appears to demonstrate more 
ambivalence. A survey of 488 users of the OCP in the Republic of Ireland found that 
87.9% were in favour of OCP being available without prescription, with convenience 
and ease of access being the primary advantages (Barlassina, 2015). The Republic of 
Ireland is a predominantly Catholic country so these findings are perhaps 
unexpected, but the survey was conducted among current pill users. A survey of 592 
pharmacy attenders in Barnet, UK conducted in 1998 is one of the only pieces of 
literature conducted in the United Kingdom. It found that only 40% of participants 
believed it was the pharmacists’ role to give health promotion advice (Anderson, 
1998)  – but participants were not asked specifically about contraception, and this 
may not be something patients traditionally see as health promotion. Of note, 95% of 
respondents in this survey agreed that they felt totally at ease when asking the 
pharmacist for advice and would ask when they needed to do so. It is difficult to 
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determine however, whether this would be true of advice relating to contraception 
and sexual health.  
A street survey in an English city centre, aimed at optimising a random selection of 
people (although people with the ability to get out and about) rather than current 
pharmacy users, found that 78.9% of 300 people questioned agreed that 
contraception should be a pharmacy service. It is unclear however, whether this 
refers to the current dispensation of prescriptions, or the idea that pharmacists’ 
existing role should be expanded. A further 66.6% believed that pharmacists should 
be providing unsolicited advice on sexually transmitted infections. Participants 
identified barriers to seeking advice from the pharmacy including the pharmacist 
being too busy, lack of privacy, and doubts about pharmacy expertise.  Again, the 
value of these questions asked in a neutral setting is difficult to quantify. Would 
those respondents who felt pharmacists should be offering unsolicited advice on STIs 
for example, be happy to receive such advice themselves? The survey cannot tell us 
(Krska and Morecroft, 2010). 
2.3.1 Summary 
In summary, the literature from the United States suggests an appetite for access to 
regular hormonal contraception from the pharmacy. Those questioned believe that 
pharmacy access will save time, be more convenient, and improve access as a result. 
This attitude has so far not been demonstrated among patients in the United 
Kingdom, but that may be because patients have not been asked about this 
possibility.  
2.4 Emergency hormonal contraception in the 
pharmacy  
Much of the evidence about the ability of community pharmacists to actually offer 
contraception is drawn from the provision of emergency hormonal contraception 
(EHC) to patients without prescription. France was the first country to make EHC 
available without prescription, in 1999 (Schenk, 2003), and EHC has been available 
in the United Kingdom without prescription since January 2001 for a cost (Killick 
and Irving, 2004), and in Scotland without charge since 2008 (Cameron et al., 
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2012c). Although professional groups and clinicians were generally in favour of 
deregulation, there was considerable controversy about deregulation of EHC 
initially, and challenges were launched (but defeated) in both the House of Commons 
and House of Lords (Schenk, 2003). Although cost remained (and remains, in 
England) a barrier, the amount of EHC dispensed by pharmacies increased 
considerably following deregulation (Marston et al., 2005). Global access remains 
variable, with 20 countries allowing direct access to EHC OTC, and 76 allowing 
access from a pharmacist without a prescription (International Consortium for 
Emergency Contraception, 2017). As EHC has been available from pharmacies in 
some countries for almost twenty years now, there is a considerable body of 
literature on the subject, which will be examined here. Unfortunately most of the 
literature uses surrogate endpoints such as patient satisfaction with the service, 
pharmacist confidence in delivering EHC, or how quickly patients were able to 
attend. There is little data about EHC at the pharmacy that is actually powered to 
detect a reduction in unplanned pregnancy rates (Anderson and Blenkinsopp, 2006; 
Raine et al., 2005). 
2.4.1 Evidence for EHC in the pharmacy  
As prescription rules about EHC changed, pilot projects in the United Kingdom 
explored pharmacy dispensing under PGDs (National Institute for Health and Care 
Excellence (NICE), 2015). Projects in Lambeth and Lewisham, UK and North 
Yorkshire, UK trained and supported pharmacists to dispense EHC under a specific 
set of circumstances. Both projects noted the flexibility needed in the PGD as the 
projects progressed, but the overall success levels with the medication dispensed 
without difficulty by pharmacists and received by patients, with pharmacy soon 
accounting for the majority of EHC dispensed (Bacon et al., 2003; Lambeth 
Lewisham and Southwark Health Action Zone, 2002; Lloyd and Gale, 2005). This 
was highlighted in an analysis of a large UK multipurpose survey in 2005, which 
noted no difference in the types of contraception being used by patients since EHC 
was available OTC – the main difference was that a smaller proportion of women 




Similar analysis of general health data from surveys in France (4166 in 1999 and 
7490 in 2004) found that the availability of progestogen-only EHC without 
prescription in 1999 resulted in increased EHC use, but did not increase the numbers 
of women having intercourse or decrease the age of first intercourse, and did not 
decrease the numbers of women using the most effective contraceptive methods 
(though neither did it increase it) (Moreau et al., 2006a). OTC availability did not 
address health inequalities however; both before and after the change in prescription 
status, use remained higher among more educated women, and those in cities 
(Moreau et al., 2006b). Non-prescription status for EHC came to British Columbia, 
Canada in 2000. Data from prescriptions dispensed from 1996-2003 noted a 102% 
increase in EHC received by women compared to a 5 year pre-policy mean. The 
mean age remained standard and, in keeping with Marston et al in the UK, after the 
change in prescription status more pharmacies provided EHC than did physicians 
(Soon et al., 2005). Importantly for service delivery costs, an analysis of patient 
records of emergency departments in the South-East Thames region of the United 
Kingdom in 2000-2001 noted that after EHC became available OTC there was a 52% 
reduction in the number of women attending emergency departments requesting 
EHC (M et al., 2004). 
One of the earliest initiatives took place in Washington State, USA in 1998-1999, 
using collaborative prescribing agreements to enable pharmacists to prescribe EHC 
directly to women without a prior consultation with a prescriber. This was linked 
with extensive media outreach and advertising so that patients knew this was 
possible. Pharmacists dispensed over 1000 EHC pills per month, however feedback 
on patient satisfaction was minimal, and notably women felt they had received 
limited information about ongoing contraceptive use. Although the pregnancy and 
abortion rate dropped following the initiative, the authors note that this is likely due 
to a number of factors (Gardner et al., 2001; Hayes et al., 2000). A similar project in 
Ontario, Canada trained pharmacists to dispense EHC with the support of a physician 
and ran a publicity campaign to alert patients to EHC’s pharmacy availability. They 
found that 98% (6931/7074) pharmacy visits resulted in a prescription, and that 
patients were very satisfied with the service (based on a response rate of 21% to a 
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satisfaction questionnaire). They estimate that 520 pregnancies were prevented with 
the pilot project, but this is based purely on a baseline risk and there is no 
information on the pregnancy rates of women who accessed EHC. Of note also is the 
10.2% who wanted information on ongoing contraception, something they were 
unable to access from their pharmacist (Dunn et al., 2003). Ragland et al investigated 
counselling about EHC provided by student pharmacists and found that post-
counselling knowledge among the 87 recipients of EHC was higher than pre-
counselling knowledge – although this had fallen with the 43% who were followed 
up one to three months afterwards (Ragland et al., 2015).  
2.4.2  ‘Mystery shopping’ for EHC at pharmacies 
The ‘mystery shopper technique’, or ‘simulated client method’ is a research method 
where a researcher acts as a customer to gain real-life data on the practice of a 
service, without the provider being aware of the researcher’s investigative status. In 
the context of health research, a researcher acts as a patient seeking health services. 
If the deception is successful, providers’ normal method of practice can be observed 
(Madden et al., 1997). Research using ‘mystery shoppers’ with pharmacists 
providing EHC has identified gaps in knowledge among dispensing pharmacists, 
and/or a failure to discuss ongoing contraceptive methods; this has been 
demonstrated in Australia (Hussainy et al., 2015; Higgins and Hattingh, 2013; 
Queddeng et al., 2011), the United States (Wilkinson et al., 2012; French and 
Kaunitz, 2007; Nelson and Jaime, 2009; Bennett et al., 2003; Sampson et al., 2009; 
Cleland et al., 2016; Gaffaney et al., 2016; Bullock et al., 2015), Canada (Cohen et 
al., 2004), Thailand (Ratanajamit and Chongsuvivatwong, 2001; Ratanajamit et al., 
2002), Kenya (Liambila et al., 2010), Brazil (Tavares and Foster, 2016), and the 
United Kingdom (Glasier et al., 2010; Brant et al., 2014). Mystery shopper 
techniques have also identified other gaps in service provision, for example that EHC 
is more likely to be procured immediately from an urban than a rural pharmacy in 
California (Sampson et al., 2009), and Kansas (Samson et al., 2013), and by an 
English speaker more successfully than a Spanish speaker in California (Sampson et 
al., 2009). This technique has also been used to identify variations in pharmacies’ 
ability to fill an EHC prescription within 24 hours, with Shacter et al noting that 35% 
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of Atlanta pharmacists were unable to do this, compared to 4% of Boston 
pharmacists (Shacter et al., 2007). Brant et al also used this method to identify gaps 
in pharmacist knowledge in Massachusetts, USA about ulipristal acetate (Brant et al., 
2014), and Bullock noted a similar unfamiliarity with ulipristal acetate among 
pharmacists in Hawaii (Bullock et al., 2015). Legare noted the homogeneity of 
availability of EHC in different New York neighbourhoods (Legare et al., 2012).  
The mystery shopper technique is a useful way to identify problems that particular 
groups may face: Wilkinson et al used researchers to pose as 17-year-old adolescent 
females. They found that pharmacists introduced false barriers about EHC, in some 
cases using these as justification not to dispense the contraception, for example that 
patients had to be 18 to receive EHC, or that only women could receive it. None of 
these barriers should exist according to federal guidelines (Wilkinson et al., 2014). 
The disadvantage of the mystery shopper technique is that it carries a strong risk of 
confirmation bias, particularly as people conducting the research are often the 
shoppers themselves. Nevertheless, if a reasonable attempt at standardisation is 
made, it offers the opportunity to record actual unselfconscious practice from the 
patient’s point of view in an immediate way (Madden et al., 1997). The method is at 
its most useful when examining more objective outcomes, such as whether a 
particular intervention is spontaneously mentioned. The research performed in 
Scotland examining the dispensing of EHC found that ongoing contraception was not 
mentioned 57% of the time (Glasier et al., 2010). 
2.4.3 Pharmacist and other healthcare professionals’ 
attitudes to EHC 
A number of different surveys with pharmacists investigate both their attitude to 
EHC and their experience of dispensing it. A survey of 112 pharmacists in Durban, 
South Africa in 2001 found that 69% felt EHC should be available without a 
prescription, but 60% felt that increased availability of EHC would decrease the use 
of barrier contraception (Hariparsad, 2001). 300 community pharmacists in Texas, 
USA who completed a survey in 2003 displayed reasonable knowledge about EHC, 
but 27% of participants were opposed to dispensing it, reasons cited included 
religious beliefs (86%), moral concerns (81%) and a belief that use of EHC might 
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lead to an increase in unprotected sex (56%). Although respondents agreed 
pharmacist-initiated emergency contraception would enhance the role of community 
pharmacists, they were nevertheless largely unwilling to participate (Griggs and 
Brown, 2007). A survey of 85 community pharmacists in Rhode Island conducted in 
2007 found that 69% (n=59) strongly disagreed with the statement that EHC should 
be available OTC in Rhode Island, despite the fact that 59% (n=50) agreed or 
strongly agreed with the fact that EHC OTC would reduce unwanted pregnancies in 
Rhode Island (Orr and Kachur, 2007).  A pilot study including a three-hour focus 
group produced a self-administered questionnaire to send to 1424 registered 
pharmacies in New Mexico, USA in 2004. Of 523 respondents, only 13% (n=67) had 
participated in a training programme for EHC. 56% (n=295) agreed or strongly 
agreed with the statement; “I am concerned that oral emergency contraceptives will 
be used as a regular form of birth control”, and 25% (n=131) with the statement “I 
think oral emergency contraception is a form of abortion”.  Write-in statements also 
revealed strong beliefs among pharmacists that EHC meant the expulsion of a 
fertilised egg, which they classed as an abortion (Borrego et al., 2006).  
Self-completed surveys of 427 pharmacists across Australia in 2008-9, five years 
after EHC was made available OTC, noted that neither moral restrictions nor the 
perceived impact of EHC on sexual health influenced pharmacists’ decisions to 
decline provision of EHC (Hussainy et al., 2011). Semi-structured interviews in 2010 
with 145 pharmacists and pharmacy managers in and around Cairns, Australia found 
that most respondents were in favour of OTC provision of EHC and did not have 
moral or religious concerns. 34% of pharmacists believed that OTC EHC 
discouraged regular contraceptive use by young people (Downing et al., 2011). 
Focus groups conducted with 14 UK (United Kingdom) pharmacists about the 
deregulation of EHC in 2001 noted particular attitudes about EHC, notably concerns 
about the concept of ‘abusing’ the service available, although no pharmacists could 
offer examples of this (Seston et al., 2001). These concerns were echoed by 51 
pharmacists surveyed in Kuwait, 48% of whom were concerned that EHC 
encourages irresponsible behaviour. No pharmacist surveyed stocked it (Ball et al., 
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2006). 51.4% of 367 Puerto Rican pharmacists surveyed in 2006 supported a law that 
enabled them to dispense EHC without prescriptions, although their knowledge 
about its mechanism of action was generally lacking (Fuentes and Azize-Vargas, 
2009). Of 501 pharmacists in South Dakota, USA interviewed, 84% did not believe 
EHC should be available over the counter (Van Riper and Hellerstedt, 2005). 
In-depth interviews conducted in the North-East of England with pharmacists 
offering EHC noted approval by pharmacists, not only of their own role and job 
description but of what offering EHC could do for the pharmacy profession in 
general, notably enhancing their status among the public (Bissell and Anderson, 
2003) (Bissell et al., 2006). This was echoed by further interviews in 2006 with 
pharmacists in the North of England. “I think [EHC]’s great. I think it really has 
enhanced the profession.” (Cooper et al., 2008)  
Interestingly, a survey of both GPs and pharmacists conducted in London found that 
GPs had more knowledge about EHC, but were less prepared to prescribe it. Only 
55% had no reservations about offering EHC, compared to 75% of pharmacists (D 
Souza and Bounds, 2001). A self-administered survey in Sweden of both nurse-
midwives and pharmacy staff who were dispensing EHC found a much higher 
percentage of nurse midwives giving information on side effects, mechanism of 
action and efficacy, as well as advising a pregnancy test, than pharmacist dispensers 
(Aneblom et al., 2004). Contraceptive counselling, including for EHC, takes a level 
of expertise and confidence that may not be part of the pharmacist’s skill set without 
substantial training and opportunities to practice. These findings reinforce a general 
theme of pharmacists being enthusiastic about offering sexual health services, but 
present less evidence for their current skills and knowledge, particularly when 
compared to other healthcare professionals.  
2.4.4 Timing of access to EHC  
There is some evidence that women find it quicker to access the pharmacy, and are 
able to take EHC sooner after unprotected sexual intercourse (UPSI) when visiting a 
pharmacy than when visiting a clinic (Lewington and Marshall, 2006; Black et al., 
2008); this is important when effectiveness is inversely proportional to number of 
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hours after unprotected sexual intercourse it is taken (World Health Organisation, 
1998). However, obtaining EHC is only a surrogate outcome when the actual goal is 
reducing unplanned pregnancies. There is in fact no good evidence that increased 
provision of EHC from pharmacies reduces the likelihood of an unplanned 
pregnancy. A large randomised, single-blind, controlled trial in California divided 
women into three groups:  those who were given EHC in advance, those who could 
attend a pharmacy for EHC when they needed it, and a control group who attended a 
clinic providing family planning services when they needed EHC, as was standard 
practice. Those attending the pharmacy experienced no significant reduction in 
unplanned pregnancy rates compared to controls. This was a large study, powered for 
a difference in pregnancy rates. However it did rely on self-reporting of sexual 
intercourse, and at least in part on self-reporting of pregnancy rates (Raine et al., 
2005). Further reporting on the same study noted that 66% (127/194) found it very 
convenient to attend the pharmacy for EHC, compared with 56% (36/64) finding it 
very convenient to attend the clinic. However, 85% (258/305) found it very 
convenient to be provided with EHC in advance, and no option made a difference to 
unplanned pregnancy rates (Rocca et al., 2007). Another RCT (randomised 
controlled trial), also powered to detect a difference in unplanned pregnancy rates, 
noted no difference in pregnancy rates between women given EHC in advance to 
take when they wanted, and those attending clinics to obtain EHC as per usual 
practice (Raymond et al., 2006). These limitations are emphasised by a Cochrane 
Review in 2007, which noted that even advance provision of EHC only improves 
rates of EHC taken, and not pregnancy rates (Polis et al., 2007), suggesting that even 
the most minimal time between UPSI and EHC may not reduce unplanned 
pregnancies significantly. This idea was underlined by a comprehensive review in 
2014 of the policy in the USA to expand access to EHC at a state and federal level. 
Gross et al noted that doing so had had no statistically significant effect on birth or 
abortion rate – what it had done was shifted the venue in which EHC was provided, 
and therefore had resulted in some cost savings (Gross et al., 2014).  In conclusion 
improved access to EHC, as offered by pharmacy and even advance provision, may 
not be as significant an intervention for women as it might at first appear.   
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2.4.5 Ongoing contraception after EHC use 
It has been postulated that the most important intervention at the time of dispensing 
EHC is not the giving of the medication itself, but the opportunity to improve 
contraception use, either by increasing knowledge about the method already being 
used, or directing the recipient towards more effective methods (Black et al., 2008). 
Clinical guidance in the UK is that when a woman is given EHC, ongoing 
contraception should be discussed with all women, including typical use failure rates 
and the benefits of LARC over short-acting methods (Faculty of Sexual and 
Reproductive Healthcare, 2012). By definition those who are attending for EHC are a 
patient population who are not using a regular form of contraception correctly. 
Interviews with 232 women in Ghana when they were obtaining EHC found that 
over 40% used EHC as their main method of contraception and yet had sex at least 
twice a week (Chin-Quee et al., 2012). There is some evidence that a clinic, rather 
than a pharmacy setting, is more likely to discuss ongoing contraception with 
patients, and that this information is more likely to be correct. An observational 
study of 133 women in London found that when completing questionnaires four 
months after obtaining EHC, only 28% of those attending a pharmacy could 
remember a discussion of future contraception, compared to 90.4% who had attended 
a clinic. Although this method is obviously subject to the difficulties associated with 
remembering a consultation at a later date, there is no reason to think that the 
memories of the groups would differ significantly, and therefore recall bias should 
generally apply equally to both groups (Black et al., 2008).   A self-administered 
survey of 126 adolescents who attended the pharmacy for EHC in Washington, USA, 
found that among 31% needing new birth control, 21% had no intention of seeing a 
doctor in the next month (Sucato et al., 2001). However it is difficult to draw 
conclusions about what counselling they received from the pharmacist, or what they 
might have done had the pharmacy service not been available.  Surveys from 309 
pharmacists participating in this research showed that two thirds of them had referred 
at least one patient receiving EHC for ongoing medical care – but there is no record 
of whether they attended (Sommers et al., 2001). Qualitative interviews with users of 
EHC from the pharmacy by Bissell and Anderson found that some patients felt the 
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service should be confined to supplying EHC, rather than discussing long-term 
contraception: “You’d go elsewhere for that.” (Bissell and Anderson, 2003) 
A small number of pilot projects have attempted to link prescription of EHC to 
prescription of ongoing contraception. A study in Lambeth, UK, produced a PGD for 
pharmacists who had undergone additional training to supply oral contraceptives 
without prescription. Of 741 consultations about contraception, 45.5% (274) were 
made as a result of discussion during EHC prescription. 69% resulted in the 
supplying of oral contraceptives to either an established or first time pill user. Patient 
questionnaires revealed that patients were satisfied with this service, and both 
‘mystery shoppers’ and clinical audit demonstrated that pharmacists adhered to the 
PGD. However, of crucial importance in preventing unplanned pregnancy is the fact 
that only 1.2% of contraceptive consultations resulted in a referral for LARC 
(Parsons et al., 2013). A pilot study in Edinburgh, Scotland, randomised 168 women 
presenting for EHC to either standard care, receiving one packet of the progestogen-
only pill (giving them one month to arrange ongoing contraception), or an invitation 
to present the empty packet of EHC to a family planning clinic for a rapid access 
appointment.  At six to eight weeks post-EHC 56% of women who had received POP 
were using an effective method of contraception, compared to just 16% who had 
received standard care (though the follow up period was extremely short) (Michie et 
al., 2014). So there is some evidence of success in contraception uptake when 
pharmacists manage to link provision of EHC to ongoing contraception.  An RCT 
with 938 women in Jamaica who were not regular contraception users but who 
attended a pharmacy for EHC, randomised women to receive either normal care, or a 
coupon for 3-27% off the price of oral contraceptive pills purchased from the 
pharmacy. Within the 6 month period 15% of participants had adopted either the 
OCP, injectable or IUD as a regular method, but there was no significant difference 
between the trial arms (Chin-Quee et al., 2010).  Although prescription of long-term 
contraception is not an endpoint in itself, it is at least more likely to lead to 
prevention of unplanned pregnancy for a longer period than a one-off prescription of 
EHC.  Nevertheless, it must be remembered that the important outcome, which was 
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not examined in any literature linking EHC to ongoing contraceptive provision, is a 
reduction in unplanned pregnancy.  
2.4.6 Patients’ experience of EHC from pharmacies 
As EHC has been available from the pharmacy for a number of years, there is a body 
of research asking patients directly about their experience. In a survey of adolescents 
in Washington State who had obtained EHC from a pharmacy, only 58% stated that 
they would have attended a doctor if they couldn’t get emergency contraception from 
a pharmacist. Over 90% were happy with the level of information and privacy, and 
would recommend the service to a friend (Sucato et al., 2001). This is echoed by 
similar research from the United Kingdom. From 53 completed surveys from young 
people (average age 19.6 years) accessing EHC in the pharmacy, 41.5% (n=22) 
stated that if they could not get EHC from the pharmacy they would wait and see if 
they got pregnant. 18% (n=10) chose a community pharmacy for ease of access 
(Berry et al., 2016). Although there is insufficient evidence to conclude with 
certainty that some women would attend the pharmacist for regular ongoing 
contraception who would not attend a doctor or nurse, these papers provide some 
evidence for this idea. A survey of 426 Californian women accessing EHC at the 
pharmacy found that they had chosen this because they believed pharmacy access 
was faster (54%) and more convenient (47%) than attending a physician (Greene et 
al., 2006). However, focus groups with women in Australia about provision of EHC 
OTC found that, although women were happy about this development, they did not 
wish to have information about contraception or sexually transmitted infections 
delivered by pharmacists, largely because they believed that to be the role of the GP 
or family planning doctor (Hobbs et al., 2009). 
5020 questionnaires were distributed in community pharmacies in Manchester, 
Salford and Trafford. 430 were returned (a 9% response rate). 93% of respondents 
said they found it easy or very easy to obtain EHC, and 99% were satisfied or very 
satisfied with how their request was dealt with (Anderson et al., 2001). Focus groups 
as part of the same evaluation showed that participants found receiving EHC from 
the pharmacy convenient, discrete and straightforward. They did discuss the 
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embarrassment about having to attend for EHC, and the emphasis on being a 
‘responsible’ user, for example taking it after contraceptive failure (Bissell and 
Anderson, 2003). These concerns are perhaps less likely to be reflected in patients 
receiving regular contraceptive supplies from community pharmacy who may feel 
this reflects more ‘responsible’ behaviour. Focus groups with women in Australia 
who had received EHC from a pharmacy found both positive and negative 
experiences; although women felt that EHC should be available, a number reported 
concerns about how much privacy was available in the pharmacy setting (Hobbs et 
al., 2009). Focus groups with women from France, Norway, Sweden and Portugal 
identified some national differences. Although women were generally happy with the 
pharmacy dispensing EHC, opinions varied between nationalities about how much of 
an active role the pharmacist should play. Women from France felt that it was 
important that they ask the same questions a doctor would, whereas women from 
Norway displayed a reluctance to engage in discussion with their pharmacist. 
Women from all countries expressed doubts about the amount of knowledge 
pharmacists had about EHC (Gainer et al., 2003). Conversely, 419 women in the UK 
completing anonymous questionnaires after receiving EHC at the pharmacy stated 
that they were more likely to be satisfied with information about side effects from 
their pharmacist, compared to their doctor (91% versus 58%). As this was a sample 
of women who had chosen to attend the pharmacy, rather than a more random 
sample as in Gainer et al, this preference for pharmacy is perhaps unsurprising 
(Killick and Irving, 2004).  
531 adolescents from 49 states in the US who had engaged in unprotected 
intercourse completed an online survey, after recruitment through social media and 
adolescent-oriented websites.  Those living in states with pharmacist access to EHC 
were much more likely to have obtained it without a prescription, and those who 
obtained EHC in a pharmacist-access state were more likely to be satisfied with their 
experience (Rubin et al., 2011). A survey of 800 randomly selected women in 
Sweden found that 78% believed that access to EHC over the counter was positive, 
although only 27% of respondents had used it in this context (Larsson et al., 2004). 
In contrast, Seston et al conducted a stated preference discrete choice experiment 
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with 269 women attending primary care clinics in the North West of England, 
examining women’s preferences and trade-offs for aspects such as opening hours, 
staff seen and length of wait. They found that respondents preferred to be seen by a 
doctor or a nurse to a pharmacist, and that this choice was one of the most important 
factors for them (others being attitude of staff and privacy of consultation) (Seston et 
al., 2007). If women are dissatisfied with aspects of a service, they may choose not to 
visit it and risk unplanned pregnancy.  
Patients were also satisfied with the pilot projects whereby ongoing contraception 
was prescribed after EHC (Parsons et al., 2013), though women in the Scottish study 
voiced some concerns, notably that they went away with questions that they didn’t 
feel able to ask the pharmacist, and that they were unsure whether it was the role of 
the pharmacist to undertake contraception consultations (Michie et al., 2016). 
However a small study of 86 women in the USA who had received EHC noted that 
the majority were very satisfied with the pharmacist counselling, with 93% agreeing 
that the counselling would enable them to use EHC in the future. (Battle et al., 2013). 
(In both cases the low recall of patients about EHC at one to three months after 
counselling in Ragland’s study is worth remembering here (Ragland et al., 2015).) 
Importantly, patient satisfaction is only another surrogate outcome. It is useful as an 
assessment of healthcare services currently offered, but it cannot tell us about how 
valuable the service is, when the objective must be a reduction in unplanned 
pregnancies at a population level. The research already mentioned, casting doubt on 
the fact that rapid access reduces unplanned pregnancy rates (Raine et al., 2005; 
Raymond et al., 2007; Polis et al., 2007), is crucially relevant here, though is rarely 
mentioned in discussion of broadening access to EHC via pharmacy provision 
(Department of Health, 2005). 
2.4.7 Summary 
In summary, pharmacists in a number of countries currently successfully deliver 
EHC. Women can obtain it more quickly than they would if they attended a clinic, 
and report a good experience obtaining EHC from the pharmacy. This was the 
conclusion of a structured literature review in 2006 (Anderson and Blenkinsopp, 
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2006). However, the evidence is that this rapid access does not reduce unplanned 
pregnancy rates (Polis et al., 2007). This may be in part because discussion about 
ongoing contraception is limited after pharmacy dispensation of EHC. Preliminary 
research examining the potential of pharmacists to dispense or advise about ongoing 
contraception choices has not yet demonstrated the long-term efficacy of this 
strategy. Pharmacy access to EHC is clearly quicker, but other aspects of care such 
as discussion of the method and ongoing contraception may still favour a clinical 
setting. 
2.5 Ongoing contraception services delivered or 
facilitated by the pharmacy 
A small number of pilot projects have examined pharmacist provision of 
contraception that has not already been prescribed by a doctor. The project in 
Lambeth, UK has already been discussed in the context of EHC: five community 
pharmacists who had undergone additional training provided oral contraceptive pills 
via a PGD. An audit showed PGD adherence, and questionnaires demonstrated high 
levels of customer satisfaction. However 93% of patients left with oral contraceptive 
pills, and only 1.2% were referred for a more effective LARC method (Parsons et al., 
2013). The Direct Access study took place in Washington, USA from 2003-2005, 
and gave women the option of accessing combined hormonal pills, patches and rings 
from their pharmacist. 195 women were prescribed hormonal contraceptives, 70% of 
which were still using the method after 12 months (follow-up rate 65%). Agreement 
between women’s self-assessment and nurse practitioner assessment for risk factors 
was over 90%. 97.7% of participants stated that they were satisfied or very satisfied 
with obtaining hormonal contraception from the pharmacist, and at 97% would feel 
comfortable continuing to do so (Gardner et al., 2008). A pilot RCT in North 
Carolina, USA investigated women receiving their contraceptive injection from the 
community pharmacy: a more effective method than the contraceptive pills trialled in 
Lambeth. Women were randomised to receive two injections either from the clinic 
that recruited them or from a trained community pharmacist. There was no 
significant difference in patient satisfaction with location, convenience, privacy or 
provider respect among either group. However although follow up rates were small 
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(36%, n=9, in the pharmacy group and 48%, n=12, in the clinic group for the second 
injection), the relative risk of returning to the pharmacy compared to the clinic for 
the second injection was 0.73, and for the third injection 0.75. The small study 
demonstrated feasibility, but may indicate that women, at least initially, prefer to 
return to clinic than attend community pharmacy for contraceptive injections 
(Picardo and Ferreri, 2010). 
The Picardo study took place in a setting where contraception incurs costs, and also 
used one pharmacy 1.5 miles away from the original Planned Parenthood clinic. One 
of the advantages of community pharmacies compared to clinics, cited by both 
patients and pharmacists, is direct access (Anderson and Blenkinsopp, 2006; 
Anderson and Thornley, 2014; Barlassina, 2015; Bissell and Anderson, 2003; Bissell 
et al., 2006; Black et al., 2008; Saramunee et al., 2014). It may be more useful 
therefore, to provide patients with options for community pharmacies in a wide 
variety of locations, in the explicit hope that they would be able to receive their 
contraceptive injection nearer to their work, home or where they shopped, and 
therefore increase convenience. This variety was present in a similar intervention in 
California, where 27 pharmacists in 26 independent and chain pharmacies partnered 
with 19 clinics/physician offices. Over a two year programme, established users of 
the contraceptive injection DMPA-IM (intra-muscular depot medroxyprogesterone 
acetate) were given the option of attending a trained participating pharmacist for 
their repeat injections. 69 women received their injections at the pharmacy, several 
(number not specified) returning five or six times. Unfortunately there is no data 
about how many women were offered this service and chose not to use it, or how 
many were eligible and not offered it. The success of the project seems to have been 
due in part to the enthusiasm of two pharmacists, one in particular who developed 
excellent links with his local physicians (Monastersky and Landau, 2006).  
A similar project was developed in Uganda, where 139 DSOs ‘drug shop operators’ 
(not necessarily trained pharmacists, but staff working in a drug shop) were trained 
to administer the DMPA-IM injection to patients. A drug shop (also known as a 
patent medicine vendor shop, similar to a UK pharmacy) is mandated to sell only 
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unrestricted and unclassified medicines – which would include oral contraceptives 
but not the contraceptive injection. However, in practice drug shops often do provide 
injections. Interviews with 585 recipients during the project showed that 57% of 
women interviewed had received their last injection elsewhere and had therefore 
switched to receive their injection at the drug shop. Reasons mentioned were 
convenient location (43%), shorter waiting times (12%) and flexible opening hours 
(11%). 98% of those interviewed intended to use the drug shop as the location of 
their next injection (Akol et al., 2014). Surveys in Nigeria showed that, although it is 
not currently legal for drug shops to offer injectable contraceptives, 14.9% of 396 
DSOs who completed the survey reported administering them. Out of 393 women 
surveyed, 19.6% had received an injection from a DSO, and 67% rated the service as 
good (Ajuwon et al., 2013). By contrast evidence from Ghana from 2014 however, 
suggests that DSOs sell and give information about the contraceptive injection, but 
none of the 94 DSOs studied had given the contraceptive injection, necessitating 
patients to obtain their prescription and then attend a healthcare clinic at a further 
visit (Lebetkin et al., 2014). In the context of sub-Saharan Africa, receiving 
contraceptive injections from DSOs, few of whom are trained pharmacists, is well 
received by women. A technical consultation in 2013 reviewed the evidence and 
concluded that, with appropriate training and monitoring, DSOs can effectively and 
safely administer contraceptive injections, and that this should be reflected in 
national and international family planning standards and policies (Stanback et al., 
2014). 
The introduction of the Affordable Care Act (ACA) in 2010 in the United States 
affected the way some women accessed contraception, with a greater number of 
women receiving a prescription from family planning providers, which they then 
filled at a pharmacy, rather than receiving the contraception from the family planning 
provider.  Focus groups conducted in Massachusetts, USA noted that women 
responded positively to this change, noting the ease of filling prescriptions at the 
pharmacy, the convenience of locations being nearer to their home, and the 
professionalism of pharmacists asked about contraception (McIntosh et al., 2012). 
 
  49
Although regular hormonal contraception is not available OTC in the USA or the 
UK, it is available elsewhere. A survey of 1502 women from Kuwait, where it is 
possible to buy OCPs OTC found that 25% of women used OCPs without physician 
consultation. The paper notes that women attending the pharmacy for OCP were 
rarely told about how to use the pill or side effects, but it must be noted that this data 
is based on patients’ recall of information (Shah et al., 2001). Some women in the 
United States also have the option of hormonal contraception over the counter: 
women who live near the U.S./Mexican border can get contraceptive pills OTC from 
Mexico. A 2010 study of 532 clinic users and 514 pharmacy users found that among 
pharmacy users, for 27% of those surveyed, avoidance of having to get a doctor’s 
prescription was a determining factor (Potter et al., 2010). Further research with the 
same cohort also showed that obtaining contraception OTC meant patients were 
more likely to continue using the method (Potter et al., 2011).  
Concern has been expressed in the literature that obtaining contraception OTC would 
mean a reduced screening rate for patients for cervical changes or breast 
abnormalities, with fewer reasons to attend a clinic. However a study comparing 514 
US women who received their contraception OTC in Mexico with 532 women who 
received it from a family planning clinic in the US, noted no difference in screening 
rates for STIs, cervical smears or breast exams (Hopkins et al., 2012). By contrast a 
study using data from the 2000 Mexican National Health Survey, a large door-to-
door survey collecting information on blood pressure, smoking and contraceptive use 
from women aged 20 and over, found that 10% of pill users under 35 and 33% of pill 
users over 35 had health conditions that were relative or absolute contra-indications 
to pill use, according the WHO medical eligibility criteria (Yeatman et al., 2006). If 
contraception were available over the counter the reliance would be on both patients 
and pharmacists to identify exclusion criteria. Shotorbani et al paired up 399 women 
completing a self-administered questionnaire and healthcare providers, and found 
that participant-provider agreement was over 90% (Shotorbani et al., 2006). 
Research using the mystery shopper technique in Kingston, Jamaica, found that 
although in most cases pharmacists correctly denied the OCP to women in whom it 
was contraindicated (11/15 interactions with a heavy smoker and 14/15 interactions 
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with a hypertensive woman), they also denied it in 10/15 interactions with an eligible 
adolescent, suggesting that OTC access is safe, but may not eliminate all barriers to 
access (Chin-Quee et al., 2006). Grossman recruited women at shopping venues and 
asked them whether they thought they were eligible for the contraceptive pill: only 
6.6% of 1,271 participants thought they were eligible when they weren’t, largely due 
to undiagnosed hypertension (Grossman et al., 2008). An expert review of the 
evidence in 2011 concluded that compelling evidence exists about the safety and 
effectiveness of providing oral contraception OTC, and that this is reflected in a 
public perception that this would be safe (Grossman, 2011). 
2.5.1 Partnership working 
The White Paper ‘Choosing health through pharmacy’ asserts that pharmacies should 
“work in partnership with health organisations and the wider public health 
community across primary, community, social care and hospital settings’ 
(Department of Health, 2005). However, although it is certainly a reasonable 
hypothesis that partnerships between pharmacy and the wider community, and with 
GP practices and sexual health centres in particular, are a useful way to involve 
pharmacists in improving health behaviours, there is only very limited evidence that 
such partnerships deliver a high standard of patient care. The White Paper 
acknowledges this deficit, saying that this is because, in a developing area of public 
health “the available evidence, as generated from research studies, will inevitably lag 
behind the reality of good practice and service innovation” (Department of Health, 
2005). Unfortunately, over a decade later, there remains a paucity of research on 
delivering sexual health through partnerships with community pharmacy. A novel 
service in Glasgow, Scotland set up a sexual health service in the premises of a busy 
community pharmacy (McAllister et al., 2002). The service was staffed by a nurse or 
health promotion officer, so did not expand or increase the pharmacists’ role, though 
it is possible that services being in such close proximity to one another would expand 
the pharmacists’ education through informal information exchange. The service was 
felt to be moderately successful, although numbers were initially small. A further 
paper about the same service notes the difficulties inherent in partnership working 
between the health and commercial sectors (Mackie et al., 2002).  
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In the North-East of England, educational seminars were provided for pharmacists 
giving EHC that emphasised the efficacy of a copper IUD (intrauterine device) at 
preventing unplanned pregnancy, and a straightforward ‘fast-track’ pathway was 
developed for pharmacists to use to refer women to their local sexual health centre. 
This change in education resulted in a 2.73 fold increase in the number of women at 
the sexual health centre having a copper IUD fitted for emergency purposes, with the 
majority being referred by a pharmacist (Clement and Mansour, 2014). This example 
of partnership working may well have been so successful due to its specific and 
measurable outcome: increasing the knowledge of pharmacists’ about the efficacy of 
the copper IUD, and providing easier access for them to refer patients. In addition, 
whilst not looking at unplanned pregnancy rates, this important intervention 
increased the uptake of one of the most effective methods, both of emergency and 
ongoing contraception (Trussell, 2011). The California intervention by Monastersky 
et al, where physicians could refer patients for repeat contraceptive injections at 
participating pharmacies, does seem to have worked much more smoothly when one 
pharmacist worked closely with his physician colleagues, an example of 
clinician/pharmacist partnership working to deliver good contraceptive care 
(Monastersky and Landau, 2006).  
2.5.2 Summary 
A number of different approaches have demonstrated modest success in the 
involvement of pharmacists in contraception care, though none have used a reduction 
in unplanned pregnancy as an endpoint. Delivery of the contraceptive injection by 
DSOs in Sub-Saharan Africa is useful, and small studies from the USA have 
suggested that this may be a service pharmacists can successfully deliver. Other 
ways of partnership working such as placing healthcare professionals within a 
pharmacy, or close fast-track links to enable pharmacists to refer patients for the 
copper IUD, also seem to work. Studies on a larger scale with each of these 
approaches would provide more information.  
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2.6 Long Acting Reversible Contraception (LARC) at 
the pharmacy 
The overwhelming majority of studies investigating contraception from the 
pharmacy, either in theory or in practice, concentrate on short-acting methods such 
as the pill, the patch and the ring, or on EHC. There is almost no literature that 
investigates the possibility of patients receiving LARC from their community 
pharmacy. The studies mentioned in section 2.5 investigating the contraceptive 
injection at the pharmacy are the only ones (Picardo and Ferreri, 2010; Monastersky 
and Landau, 2006; Akol et al., 2014; Ajuwon et al., 2013). However, longer acting 
methods are known to be more effective at preventing unplanned pregnancy 
(Trussell, 2011; Winner et al., 2012). Another successful intervention is the 
development of a pathway for pharmacists to refer patients to clinicians for 
emergency IUDs: an example of presentation to the pharmacy resulting in patients 
obtaining a LARC method as well as having access to the most effective emergency 
method (Clement and Mansour, 2014). Although pharmacists have rarely been asked 
about delivering LARC, a survey of 94 community pharmacists in Scotland noted 
only 33% (n=31) interested in “the administration of long acting reversible 
contraceptives (e.g. by injection)” (Gale and Watson, 2011). 
2.7 The need for further research 
Before a substantial amount of public money is used to equip pharmacies to deliver 
contraception there is an urgent need for well-designed research examining the best 
and most effective approaches. Ideally, quantitative research looking at access to 
contraception, including emergency contraception, should use an endpoint most 
relevant to patients and the community, i.e. a reduction in unplanned pregnancy 
rates.  This might compare rates in a group using the novel access method versus a 
control, or at least compared to similar unplanned pregnancy rates in the relevant 
population group. Surrogate endpoints such as access to contraception must be 




The enthusiasm in the literature for pharmacists to offer regular contraception 
without a prescription is not echoed in government literature (Department of Health, 
2005).  Despite debates about whether regular hormonal contraception should be 
offered in the pharmacy existing in British medical journals almost ten years ago 
(Grossman, 2008; Jarvis, 2008), there is no evidence in the literature of any growing 
support for this idea in the UK. If the medication is to be offered OTC then certain 
criteria must be met: 1) the patient must recognise and diagnose the condition in 
themselves, 2) they must be able to assess the information about the medicine 
correctly, 3) the medicine must be as effective as when used as recommended and 4) 
the drug must be safe (Brass, 2001). Although each of these conditions seems easily 
fulfilled by making contraception over the counter, crucially the short-acting 
methods which most of the literature concentrates on are not as effective as LARC 
methods at preventing unplanned pregnancy.  
2.8 The literature review in the context of this thesis 
The contraceptive injection has traditionally been a method requiring patients to 
attend a healthcare professional every 12-13 weeks. Although some would classify it 
as a LARC method, users need to visit a HCP (healthcare professional) more often 
than with other shorter-acting methods such as the OCP, because current guidance is 
to offer users a year’s supply if they are unlikely to change methods in a year 
(Faculty of Sexual and Reproductive Healthcare, 2016). In addition, there is no 
reminder to patients, such as using the last pill or patch, which encourages them to 
book a further appointment (Davidson et al., 1997). Frequency of having to attend a 
healthcare provider may be part of the reason why discontinuation method of this 
method is high when compared to other methods (Davidson et al., 1997; Paul et al., 
1997; Kaunitz et al., 2014). The contraceptive injection is therefore a method where 
receiving an injection from an available and convenient provider, such as a 
community pharmacist, seems particularly appropriate. Trials with involved, 
committed pharmacists such as the one seen in California seem to have the best 
evidence (though still very scant) for pharmacists contributing effectively to 
contraception uptake by patients (Monastersky and Landau, 2006). There is scope to 
examine the feasibility of community pharmacists delivering contraceptive injections 
 
  54
in other countries and settings. (Of note a healthcare professional used to be required 
to give this method, though a subcutaneous form became licensed for self-injection 
in September 2015 (Faculty of Sexual and Reproductive Healthcare, 2015a).)  
Before embarking on a definitive randomised controlled trial, there would need to be 
initial work exploring feasibility, especially given the lack of conclusive evidence of 
success in the research already done. This would require a pilot study, and perhaps 




Chapter 3 Background research for a pilot 
study examining contraceptive 
injection at the pharmacy: a patient 
survey 
3.1 Introduction  
Chapter 2 examined the evidence available for delivering contraception from the 
community pharmacy setting. There is enthusiasm for the concept in United 
Kingdom governmental policy (Department of Health, 2005) and, as detailed in 
Chapter 2.3, the majority of women questioned in the United States think that 
contraceptive services should be available from their pharmacy. Most pharmacists 
themselves are also open to the idea, as shown in Chapter 2.2. However, evidence 
actually assessing services delivering contraception from the pharmacy is far from 
conclusive. In addition the majority of the literature concentrates on short-acting 
contraceptive methods such as the contraceptive pill (Shah et al., 2001; Potter et al., 
2010; Parsons et al., 2013). Other methods such as the contraceptive injection, 
implant and intrauterine device are more effective at preventing unplanned 
pregnancy (Trussell, 2011; Winner et al., 2012). There is a small amount of evidence 
that delivery of the contraceptive injection from the community pharmacy is 
appealing to a group of patients, though no study has shown that it improves 
unplanned pregnancy rates (Monastersky and Landau, 2006; Picardo and Ferreri, 
2010; Maderas et al., 2008). The typical failure rate for the contraceptive injection is 
6%, compared to 9% for the more popular oral contraceptive pill (Trussell, 2011), so 
increasing uptake of this method among patients using less effective methods could 
reduce unplanned pregnancy rates.  
3.2 Justification for the methodology 
Although there is very limited literature about delivery of LARC from community 
pharmacies, a review of the literature suggests there may be some potential for 
delivery of the contraceptive injection. The location of pharmacists within the 
community, particularly communities of deprivation, as well as longer opening hours 
than many general practices, makes them a place that is easily accessible for people. 
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If women could receive the injection from the pharmacy this might reduce barriers to 
regular injections, improving continuity and potentially uptake of this effective 
method. However, before proceeding with any research, even an initial feasibility 
study, it was important to examine the willingness of our patient population to attend 
the community pharmacy for contraceptive injections. Although this would seem to 
give patients a convenient way of accessing one of the more effective types of 
contraception, there is limited evidence about this practice, and none from the United 
Kingdom.  As a preliminary step, we decided to therefore conduct a survey among 
our patients, to assess their readiness to attend. This would ensure that conducting 
research with this population was feasible, and that recruitment would be possible.  
We conducted a survey with patients attending a large urban sexual health centre in 
Edinburgh, exploring their feelings about attending the community pharmacy to 
receive the contraceptive injection.  
3.3 Patients’ preparedness to attend a pharmacy for 
contraceptive injections: a survey 
Published in full: Heller R, Cameron ST. Evaluating the attractiveness of the 
availability of injectable progestogen contraceptives at the community pharmacy 
setting in the United Kingdom. International Journal of Pharmacy Practice 2016 
Aug;24(4):247-52. Published with permission of the editor and co-author.  
3.3.1 Introduction 
There is growing recognition of the potential that community pharmacists could play 
in delivering sexual health services within the UK. Pharmacies are located directly in 
communities and have extended evening and weekend hours. Examples of sexual 
health services delivered successfully by community pharmacists include provision 
of emergency contraception (EC) (Black et al., 2008; Marston et al., 2005), and 
treatment of partners of individuals with uncomplicated Chlamydia infection 
(Cameron et al., 2010). In addition there have been pilot projects of provision of the 
combined oral contraceptive pill from the pharmacy (Parsons et al., 2013), and 
pharmacists providing ‘bridging contraception’  (a one month supply of a 
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progestogen-only pill) alongside oral EC (Michie et al., 2014). A pharmacist in the 
UK has also been trained to fit contraceptive implants and give the DMPA-IM 
injection (Pharmaceutical Journal News Team, 2011). Community pharmacists in the 
UK currently administer other subcutaneous injections and are essential for delivery 
of national flu vaccination programmes (Hind et al., 2004; Brown et al., 2012; 
Anderson and Thornley, 2014). Pharmacists administer these medications under a 
Patient Group Directive, a legal framework that allows certain registered health 
professionals to administer specified medicines to a pre-defined group of patients 
without the necessity of seeing a doctor. Patient Group Directives were first 
introduced through legislation in 2000, and are currently covered under The Human 
Medicines Regulation 2012 (National Institute for Health and Care Excellence 
(NICE), 2015). This questionnaire was administered in Scotland, where sexual health 
services differ somewhat at an administrative level from other parts of the UK. 
However the same ‘no cost’ services to the public are provided (through the National 
Health Service) including contraceptive methods.   
The contraceptive injection depot medroxyprogesterone acetate (DMPA) is given 
every 12 weeks, but discontinuation rates of this contraceptive method have been 
noted to be particularly high (Davidson et al., 1997; Paul et al., 1997; Potter et al., 
1997). In one study, discontinuation rate due to dissatisfaction was 42.3% (Moreau et 
al., 2007). Although not the only factor, remembering to return to clinic every three 
months, as well as the inconvenience of having to do so has been cited by users as a 
contributory factor to discontinuation (Davidson et al., 1997). A subcutaneous 
formulation of injectable contraception (Sayana Press®, Pfizer Inc.) is now available 
in the UK. This preparation is a lower dose (104mg compared with 150mg for IM-
DMPA) but is similar in other aspects including efficacy, injection interval, return to 
fertility and bleeding pattern (Faculty of Sexual and Reproductive Healthcare, 2013). 
The subcutaneous preparation comes packaged in a simple delivery system known as 
uniject, consisting of a polyethylene reservoir pre-filled with micronised DMPA and 
an integral fine subcutaneous needle. This may facilitate administration of injectable 
contraception and so expand the range of health professionals who can administer it, 
including community pharmacists.  Self-administration of subcutaneous DMPA has 
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been shown to be feasible in several trials (Cameron et al., 2012b; Prabhakaran and 
Sweet, 2012; Williams et al., 2013), and Sayana Press® has recently been licensed in 
the United Kingdom (UK) for this purpose (Faculty of Sexual and Reproductive 
Healthcare, 2015a). 
For women that are already established users of the contraceptive injection, receiving 
repeat injections from their community pharmacy may be an attractive option. 
Administration of subcutaneous DMPA by community pharmacists (using a more 
complicated system of syringe and needle) has already been shown to be feasible in 
pilot studies conducted in the United States (Picardo and Ferreri, 2010; Monastersky 
and Landau, 2006). 
We wanted to establish whether the option of receiving the injectable contraceptive 
from a community pharmacist was acceptable to women, particularly in the case of 
those who are using less effective methods. 
3.3.2 Methods 
From 3rd February to 11th July 2014, an anonymous, self-administered questionnaire 
was offered to women attending a single-site walk-in clinic at an integrated sexual 
and reproductive health (SRH) service located in the centre of Edinburgh, UK. The 
site was selected as it sees a high volume of patients and, as research is often 
conducted from this centre, reception staff are used to handing out research materials 
to patients.  Women attend this walk-in clinic largely for contraception and sexually 
transmitted infection screening. Clinic reception staff were asked to hand out a 
questionnaire to all women of reproductive age (16 to 50 years) attending the clinic, 
to complete while they were waiting to be called to see the doctor or nurse.  Women 
attending the termination of pregnancy (TOP) service or the menopause clinic were 
not invited to participate. Women were asked to place completed questionnaires in a 
closed collection box. 
Questionnaires were piloted with five service users and consisted of a brief written 
introduction that outlined the injectable method of contraception and introduced the 
idea that it might be possible to receive injections at a community pharmacy in the 
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future. It was explained to women that the injection would be subcutaneous (“under 
the skin rather than into the muscle”). Questions required simple tick-box responses, 
with a space to expand upon responses if wished. Questionnaires asked women if 
they were current, previous or never users of the injectable, which method of 
contraception they were currently using, and whether availability of the injectable 
from a local pharmacist would influence their decision to use this method. They were 
also asked to select perceived advantages or disadvantages of receiving their 
contraception from the community pharmacy from a predefined list of options. 
3.3.2.1 Data analysis 
All data was entered into Microsoft Excel for analysis. All questionnaire responses 
were entered including those where not all questions had been answered. Responses 
to questions were expressed as numbers and percentages, with percentages rounded 
to the nearest integer. Questions were analysed separately, i.e. if a questionnaire was 
not fully answered analysis was performed on the questions that were answered.  
The local Quality Improvement Team for sexual and reproductive health approved 
the project. The scientific officer of the local ethics committee reviewed the project 
proposal and confirmed that ethical approval was not required. 
3.3.3 Results 
During the study period 1605 women attended appointments at the walk-in clinic. 
The number of women attending is likely to be smaller as some women may have 
attended more than once. In theory all of these women may have received a 
questionnaire although the reception staff handing out the questionnaires confessed 
to usually forgetting – so this is unlikely. Unfortunately due to a high workload for 
the staff handing out the questionnaires we do not know how many women were 
offered a questionnaires and declined.  240 questionnaires were distributed and 220 
were returned (91%). 163 were fully completed (74%) and the remaining 57 were 
partially completed. 3 only had information completed about the contraception being 
used by the participant, and 54 had answers completed stating whether they would 
attend the pharmacist for the contraceptive injection but no reasons completed 
why/why not.  
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The main contraceptive methods being used by respondents are outlined in table 3.1. 
As a percentage of 220 returned questionnaires there were 8 current users of the 
injectable in the women surveyed (4%), 23 previous users (10%) and 187 who had 
never used it (85%). Of those that had never used it, 33 (18%) had considered using 
it in the past but decided against it.  
Table 3-1 Contraceptive method in use by participants 
Method in use at time of completing 
questionnaire* 
n (%)  
n=220 
n (% of users 








Combined oral contraception 
(pill/patch/ring) 
60 (27%) 15 (25%) 
Condoms 43 (20%) 12 (28%) 
Not using any contraception 34 (16%) 8 (24%) 
Contraceptive implant 30 (14%) 16 (53%) 
IUD/Mirena IUS 27 (12%) 11 (41%) 
Progestogen only pill 9 (4%) 2 (22%) 
Current depot users 8 (4%) 1 (13%) 
Withdrawal method  2 (1%) 0 
Contraception is not necessary for me 3 (1%) 0 
Trying for a pregnancy 1 (0.5%) 0 
Diaphragm 1 (0.5%) 0 
Vasectomy  1 (0.5%) 0 
*for respondents using more than one method, most effective method 
being used 
 
Of 23 previous users, the most common reason for having stopped the injectable was 
irregular bleeding, cited by 10 women (44%). 6 respondents (26%) indicated that 
having to see a doctor or nurse every 3 months was a reason for stopping this 
contraceptive method. Of the 33 women who had considered using the contraceptive 
injection but decided against it, 24 (73%) cited having to see a doctor or nurse every 
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3 months as one of the reasons they had decided not to use it. Other reasons are 
further detailed in 3.2 
Table 3-2 Reasons for stopping the contraceptive injection, or deciding not to use it 
Reasons for stopping (completed by 23 ex-users of this method) 
Reason  n (no of times ticked)  
(%) (percentage of respondents 
selecting it*) 
Irregular bleeding 10 (44%) 
Weight gain 6 (26%) 
Acne 6 (26%) 
Having to see a nurse or doctor every 12 
weeks 
6 (26%) 
Reasons for deciding not to use the method (completed by 33 women who 
had considered using the contraceptive injection but decided not to) 
Worry about weight gain 28 (85%) 
Having to see a doctor or nurse every 3 
months 
24 (73%) 
Don’t want a method where your period 
stops 
22 (67%) 
Delay in return to fertility 15 (45%) 
Worry about bone health 14 (42%) 
Prefer something more long acting 14 (42%) 
Other people put me off 9 (27%) 
Not familiar with this method 8 (24%) 
 
Out of 212 current non-users, 65 (31%) said they would consider using the 
contraceptive injection if they could get this from their local pharmacy. 58% of them 
(n=37) were using less effective methods or no methods. The methods that all 65 
were using are in table 3.1. In response to why this would be a good option for them, 
most respondents ticked more than one option from a list. The main reasons were 
quicker appointments (52%) and easier access (47%) Further reasons are detailed in 
table 3.3. Just one current contraceptive injection user said that they would be 
interested in getting future contraceptive injections from a community pharmacy.  
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143 respondents (65%) said that they would not consider using the contraceptive 
injection even if it could be given by a community pharmacist. The reasons largely 
related to the method itself rather than the place of delivery. 53 (37%) said that they 
did not wish to use this method at all, and 32 respondents (22%) ticked ‘other’ and 
stated that they wanted a hormone free method. Only 11 (8%) stated that they would 
prefer to see a nurse or doctor. Reasons are further outlined in table 3.3. We did not 
include cost as a factor because in the United Kingdom all contraception is free to 
users, as is seeking advice from a pharmacist, doctor or nurse. Obtaining 
contraception from a pharmacist would therefore represent no financial advantage or 
disadvantage to patients. 
Table 3-3 Perceived advantages and disadvantages of receiving contraceptive injections from a 
pharmacist in the community 
Perceived disadvantages (completed by 143 respondents who would not 
choose this option) 
Perceived disadvantages  n (no of times ticked)  
(%) (percentage of respondents 
selecting it*) 
Would not consider using this method 
ever 
53 (37%) 
Other: “want hormone free method” 32 (22%) 
Other reasons given** 25 (17%) 
Prefer to see a nurse or doctor every 12 
weeks 
11 (8%) 
Prefer coming to this clinic 7 (5%) 
Prefer an injection into the muscle to 
under the skin 
4 (3%) 
Do not trust a pharmacist to give it 0 (0%) 
Did not answer 47 (33%) 
Perceived benefits (completed by 65 respondents who indicated interest in 
this service) 
Perceived benefits n (no of times ticked) 
(%) (percentage of respondents 
selecting it*) 
Better opening hours 25 (38%) 
Easier to get to 31 (47%) 
Closer to my home 20 (30%) 
Quicker appointment 34 (52%) 
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Prefer an injection under the skin  14 (21%) 
Did not answer 17 (26%) 
* Percentages add up to >100 as most respondents selected more than one 
option. 
** Other reasons given included “scared of jags”, “out at sea for work so 
will not be able to get injection”, “Mirena is better option for me” and 
concerns about bone health and a delay in return to fertility. These all 
represented reasons why the method would not be considered, regardless 
of location of delivery.   
 
3.3.4 Discussion 
Our survey suggests that almost one in three women who is not currently a user of 
the contraceptive injection would consider using this method if they could receive 
injections from their local pharmacy. Quicker appointments, better opening hours 
and the pharmacy being easier to get to were all stated as reasons why women 
thought this would be a good option for them.   
Questions examined only what people said they might do in theory, so it is possible 
that this may not truly reflect the proportion of women who would choose to go to 
the pharmacist for contraceptive injections if this were a current option. We also 
captured only a small number of current users. This may be an indication that regular 
users of DMPA are choosing to attend their GP or practice nurse, rather than a sexual 
and reproductive health clinic. It may also reflect the local service policy of actively 
encouraging women who need a repeat injection to attend their local GP practice for 
this, so that SRH consultations can be prioritised for individuals with more complex 
sexual health needs.  It does mean however that the survey findings cannot estimate 
what proportion of total current users would switch to go a pharmacy if this option 
was available.  It would be worthwhile repeating this survey in a primary care setting 
to see if results differ. Since we relied on reception staff handing out questionnaires 
to women, only a small proportion of women that were eligible were handed 
questionnaires. We did not capture information on demographics of respondents. 
Due to busy clinics and a high workload reception staff were unable to keep track of 
how many eligible women were not offered questionnaires. The list of possible 
advantages and disadvantages of receiving contraception at the pharmacy were 
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created based on what we anticipated women’s views would be and not on 
qualitative research with users. 
Interestingly, a quarter of ex-users stated that having to visit a doctor or nurse every 
three months had been a reason that led to them stopping this method of 
contraception, suggesting that some women might continue using the contraceptive 
injection if they did not have to make a regular appointment with a doctor or nurse. 
In keeping with the existing literature, the main reason cited for stopping was 
problematic bleeding (Davidson et al., 1997; Paul et al., 1997; Potter et al., 1997). 
Among the women that had given consideration to using the contraceptive injection 
in the past, but elected not to use it, almost three quarters of respondents stated that 
the fact that you had to see a doctor or nurse regularly had been a factor in them 
deciding not to use it. This gives a strong indication that removing this aspect of the 
contraceptive injection might make it a more attractive option to women who are 
considering using this as their method of contraception.   
Although almost one in three women indicated that they would be interested in the 
contraceptive injection if the option to receive it from pharmacies were available, 
this may be an overestimation of the proportion of women choosing this if available. 
When asked about the reason they had decided not to use, or stopped using, the 
contraceptive injection, respondents mainly cited many reasons unrelated to delivery 
of the contraception, notably irregular bleeding and weight gain. As with all 
contraception, women’s decision to use a method is likely to be influenced by a 
number of factors, and perceived disadvantages may be more or less relevant when 
weighed up against perceived advantages. Our survey does seem to suggest that 
availability at a pharmacy would be a perceived advantage to a fair proportion of 
women who are using less effective methods. Very few women stated that they 
preferred to see a doctor or nurse or attend a clinic.  
This research captures patients’ opinions on a novel potential option for delivering 
contraceptive injections in the community and demonstrates that a significant 
proportion of women would welcome the possibility of receiving this method from a 
community pharmacy. The availability of contraception injections from a local 
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pharmacy would increase access for women and might make this longer acting 
method more attractive to a greater number of women, notably to women who are 
put off by the necessity of regular appointments with a doctor or nurse, who may opt 
instead for less effective methods. It may also mean that women might be less likely 
to discontinue the method once they start using it and this could potentially prevent 
more unintended pregnancies. Although a pilot study of pharmacists administering 
the contraceptive injectable in the US did not observe any difference in continuation 
rates of the method compared to standard practice, the study was a pilot of just fifty 
women randomised to clinic or pharmacy (Picardo and Ferreri, 2010). The study did 
confirm that women found the pharmacy convenient, that pharmacists were 
respectful and overall women were very satisfied with receiving the injectable from 
this setting. 
Studies indicate that both providers and women prefer a subcutaneous injection of 
DMPA delivered via Sayana Press®’s uniject system to an intra-muscular injection 
DMPA (Burke et al., 2014b; Burke et al., 2014a). Whilst self administration of the 
subcutaneous DMPA remains highly acceptable to women (Cameron et al., 2012b; 
Prabhakaran and Sweet, 2012; Williams et al., 2013), the option of receiving 
injections from pharmacists nevertheless expands the options for increasing access to 
this method and may be particularly attractive to women who don’t want to self-
administer injections.  
Our survey did not specify whether injections from the community pharmacy would 
be repeat or first injections of this method. It would make sense for a pilot project to 
explore continuation injections from the pharmacy, following method initiation from 
a clinician. 
3.3.5 Conclusions 
Our survey indicates that for a significant proportion of women who are not using the 
contraceptive injection, the ability to receive repeat injections at a local pharmacy 
would be an attractive prospect. This could be a simple strategy that might increase 




Further research piloting pharmacists as providers of this method of contraception is 
therefore warranted.  Our survey did not specify whether injections from the 
community pharmacy would be repeat or first injections of this method. It would 
make sense for a pilot project to explore continuation injections from the pharmacy, 
following method initiation from a clinician.  
~ End of published paper ~ 
3.4 Conclusion 
Both the literature review presented in Chapter 2 and the survey presented in this 
chapter set out the background exploration that was done before embarking upon a 
pilot project delivering the contraceptive injection from community pharmacies. 
Although most of the evidence in the literature review is from the United States, it 
suggests acceptability among a wide variety of patient populations, citing 
convenience and time saved as possible advantages to attending the pharmacy.  
This chapter describes a survey undertaken with Edinburgh patients, to examine their 
willingness to attend a community pharmacist to receive the contraceptive injection. 
It is reassuring that patients appear to trust their pharmacist to give their 
contraceptive injection. This echoes other research published about influenza 
vaccines given by pharmacists. Questionnaires completed by 898 patients in 
Scotland as part of a pharmacy influenza vaccination scheme, demonstrated similar 
views, with 99.8% of respondents (n=896) answering that the injection was 
administered as well as by other health care professionals (Hind and Downie, 2006). 
Although this is the only evidence published on patients’ willingness to attend their 
pharmacy for a contraceptive injection, there are no documented concerns about 
receiving other injections from a pharmacy, and no documentation from patients that 
this procedure should only be undertaken by a doctor or a nurse. 
The last large national survey of contraceptive use was published in 2009. At this 
point 3% of women aged 16-49 in the United Kingdom were using the contraceptive 
injection as their contraceptive. It was most popular among the more fertile age 
groups, with 9% of 25-29 year olds who used contraception using the injection and 
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6% of 20-24 year olds (Lader, 2009). Given these numbers, if only a small number of 
women chose to attend a pharmacy for their contraceptive injection, the reduction in 
visits to clinicians in an overstretched healthcare system would be significant.   
Importantly, our survey suggests that a number of patients currently using other, less 
effective methods of contraception might change to the more effective injection if the 
convenience of pharmacy availability was possible. These responses provide some 
evidence for our hypothesis that pharmacy availability could improve continuity and 
uptake of this method, and suggest that recruitment will be possible for a pilot trial. 
Although there may still be as yet unidentified barriers to this practice, patient 
acceptability is unlikely to be a significant one. 
The background research will help to inform the methodology design of the pilot 




Chapter 4 Delivering injectable contraception 
at the community pharmacy: 
research background and 
methodology 
This chapter sets out the background for the pilot study, outlines the process by 
which the study was conducted, and explains the research methodology. The 
identification of both pharmacy and patient participants is outlined then the processes 
of recruitment, training and documentation are explained.  
4.1 Justification for the research 
As has been outlined, the DMPA contraceptive injection (or Depo Provera®) is an 
effective method when users are able to receive regular doses at the correct time 
intervals (Faculty of Sexual and Reproductive Healthcare, 2016). However, 
discontinuation rates are high compared to other effective methods (Kaunitz et al., 
2014; Trussell, 2011), with one population study showing that only the cervical cap 
or diaphragm and the contraceptive sponge (both among the least effective methods), 
had higher discontinuation rates than Depo-Provera®, in which the discontinuation 
rate due to dissatisfaction was 42.3% (Moreau et al., 2007). An observational study 
using a primary care database noted that users of the contraceptive injection were the 
least likely to use just that method in one year, compared to users of all other 
methods (Cea Soriano et al., 2014a). Although the primary reason for discontinuing 
the contraceptive injection is usually given as experiencing side effects (Potter et al., 
1997; Paul et al., 1997), the inconvenience of having to attend a healthcare provider 
may be a contributory factor, and the balance of positive and negative factors may 
change according to how convenient a method is. A study of users of Depo-
Provera® not long after FDA approval in the US noted a 17% rate of “default 
discontinuers”, who failed to return for further injections – this could be due to the 
time burden of returning to clinic (although in the UA cost may also be a factor) 
(Potter et al., 1997). Compared to either LARC methods (which last for years) or 
short-acting methods (where the advice is to give patient’s a year’s supply at a time 
(Faculty of Sexual and Reproductive Healthcare, 2016)), using the contraceptive 
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injection in its traditional form entails more time spent visiting a healthcare provider 
than any other method.  
Research conducted with our own patient population as outlined in Chapter 3, 
supports the idea that this may contribute to discontinuation rates, with 26% of ex-
users identifying regular visits to a healthcare provider as the reason that they 
stopped using the method.  This research also showed that 31% of non-users of the 
injection would potentially be interested in receiving contraception injections from 
the community pharmacy (Heller and Cameron, 2016). 
4.2 Background to the research hypothesis 
My hypothesis was that offering women contraceptive injections from a variety of 
community pharmacies would increase accessibility to the method, which would 
increase continuation rates, and ultimately decrease the unplanned pregnancy rate 
among users. If accessing this contraceptive method was more straightforward, it 
might be more attractive to users of other, less effective methods. The most robust 
way to test these hypotheses would be an RCT, the highest standard of evidence 
about scientific practice. A suitable design would be a two-armed study where 
women were randomised to receive contraceptive injections from primary care or 
sexual health clinics as per standard practice, or to receive contraceptive injections 
from a pharmacy. A variety of pharmacists would enable participants to choose one 
with relative proximity to them. Evidence from the literature would suggest that 
under current service models, 65% of women discontinue the contraceptive injection 
in less than 24 months (Paul et al., 1997). It would be reasonable therefore to 
continue this trial for three years. This would enable women to decide to continue or 
discontinue as they wished, for two years, and then be followed up for a further year. 
In order to produce the highest level of evidence, an RCT would be powered to 
detect a difference in unplanned pregnancy rates. However, this would be extremely 
challenging, as numbers of unplanned pregnancies are likely to be small. Evidence 
from primary care suggests that the majority of women who change from injectable 
contraceptives switch to oral contraceptives (Cea Soriano et al., 2014a), the typical 
failure rate of which is approximately 9% over the first year of use, compared to a 
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failure rate for the contraceptive injection of 3% (Trussell, 2011). Therefore even 
people discontinuing injectable contraceptives are likely to have low rates of 
unplanned pregnancy (although higher than those who continue it). An RCT powered 
to detect a change in unplanned pregnancy rates would therefore be extremely large, 
which is one of the reasons so few studies use this endpoint. A very large RCT over a 
number of years would be extremely resource intensive. Before proceeding with such 
an RCT it is therefore good practice to perform a pilot study to determine the 
recruitment and consent rate, establish the acceptability of the service and identify 
appropriate outcome measures (Lancaster et al., 2004).  
Two small studies in the United States have already examined the feasibility and 
acceptability of administering the subcutaneous contraceptive injection in the 
pharmacy setting. One in North Carolina randomly allocated 50 women to receive 
either their usual follow up contraceptive injections at Planned Parenthood, or at a 
pharmacy close by. They found recruitment straightforward, but noted that women 
receiving injections at the pharmacy were no more likely to return for follow up 
injections than were women who received injections at Planned Parenthood (Picardo 
and Ferreri, 2010). A demonstration programme in California gave established 
contraceptive injection users the option of attending a participating pharmacist for 
repeat injections. The experience was a mixed one. Some pharmacists developed 
excellent links with patients and the clinic, but the research emphasises the provider 
support necessary to make the program run successfully (Monastersky and Landau, 
2006). The question of feasibility and acceptability in a UK setting has not been 
addressed, crucially in a setting where all contraception and healthcare delivery is 
free. The reasons for carrying out this particular pilot study were therefore to 
determine how easy it would be to recruit patients for this service, to examine 
acceptability and feasibility both for pharmacists and patients, and to identify any 
barriers in place to both research and service delivery in this field.  
The research question of self-administration was not addressed in the study design, 
as at the time the research was conceived self-administration of the contraceptive 
injection did not have a product licence in the UK, despite studies showing its high 
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levels of patient satisfaction and feasibility (Keith et al., 2014). In September 2015, 
whilst the research was being conducted, DMPA-SC (Sayana Press®) became 
licensed for self-injection (Faculty of Sexual and Reproductive Healthcare, 2015a). 
4.3 Designing the pilot study 
The US pilot study used a community pharmacy near the clinic that recruited patients 
were attending (Picardo and Ferreri, 2010). However, my belief was that a 
significant advantage offered by community pharmacies was their proximity to 
patients, and therefore their easier accessibility and greater convenience. To establish 
this I therefore planned to select a number of pharmacists across the city, so that 
patients would be able to receive contraceptive injections from a pharmacist near 
them. It was not a component of the research that patients should be offered a choice 
of contraception at the pharmacy, as the assessment of feasibility was being made for 
this method only. Where pharmacists have demonstrated more ambivalence towards 
offering contraception, it has been about making the choice of contraceptive with 
patients (Sweeney et al., 2015). In addition, the precedent set for other contraceptives 
that require repetition, such as the contraceptive pill and patch, is a visit to a 
healthcare professional at least annually (Faculty of Sexual and Reproductive 
Healthcare, 2016). The choice was therefore made to offer only repeat contraceptive 
injections at the pharmacy, after research staff introduced women to the method in a 
clinical setting. Participants would receive three injections from a pharmacist, and 
then re-attend a nurse or doctor to discuss their contraceptive choice, sexual health, 
and make any changes to their care as necessary. This timescale was validated during 
the life of the research, when the guidelines for self-injection using Sayana Press® 
were produced by the Faculty of Sexual and Reproductive Healthcare, and stated that 
recipients should see a doctor yearly (Faculty of Sexual and Reproductive 
Healthcare, 2015a).  
4.4 Identification and recruitment of pharmacies 
Recruitment of pharmacists was not conducted according to an a priori hypothesis, as 
there was nothing in the literature to guide this research. The aim instead was to 
choose pharmacists whom we thought would be able to work productively with the 
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research team, who had an interest in providing the service, and who would be able 
to offer convenient and straightforward access to as many participants as possible. In 
order to identify pharmacies that were usefully located, the postcodes of all patients 
who had attended sexual health clinics in Edinburgh and West Lothian for the 
contraceptive injection over the two years before the project started were identified. 
All patients who had received two or more contraceptive injections were then 
mapped by their residential postcode. Postcode areas in Edinburgh and West Lothian 
of high-density contraceptive injection use were therefore identified (figure 4.1). 
Finally Edinburgh and West Lothian pharmacies were then identified in areas of 
high-density contraceptive injection use. As patients attending our service for 
contraceptive injection came from these places, it seemed likely that recruitment 
would be most successful here.  
A number of pharmacists throughout Edinburgh and West Lothian already 
participate in the ‘partnership voucher scheme’, a scheme where partners of patients 
positive for Chlamydia trachomatis can exchange a voucher for 1g of azithromycin at 
a community pharmacy (Cameron et al., 2010). Pharmacists involved in this scheme 
had established partnership working with our sexual health service and were familiar 
with sending paperwork there for remuneration. In addition they had already shown a 




Figure 4-1 Contraceptive injection use mapped by postcode with pharmacies in Edinburgh 
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Twelve pharmacies were initially chosen based on their participation in the 
Chlamydia voucher scheme and their proximity to numbers of users of the 
contraceptive injection (figure 4.1). Priority was also given to pharmacies that were 
based in large shopping centres, based on the idea that attending these might be 
particularly convenient. All identified pharmacists were invited to attend an 
information evening to learn more about the project. Representatives from all 
pharmacies attended the event which consisted of information about Sayana Press® 
and a demonstration on how to give the injection. The role of the pharmacists 
involved was outlined, and information from attendees was sought about the running 
of the research. After discussion and consultation pharmacists felt that participants 
telephoning in advance to arrange their injection would be most feasible.  
Following this evening everyone who had attended was contacted and asked if they 
would like to be involved. Two pharmacists opted out, citing pressure of work (n=1) 
or feeling the project was not suitable for their premises (n=1). The other ten wanted 
to be involved with the project and this was felt to be a suitable number to proceed 
with. It was important to achieve a balance so that women had a choice of 
pharmacists to attend and yet each pharmacist gave a reasonable number of 
injections to maintain competence. A further pharmacist who was not originally 
invited to attend but who has worked closely with the team on other research 
pertaining to sexual health was also invited to participate, and responded 
enthusiastically.  With this number involved, the pharmacies involved were mapped, 
and a good area of the city seemed to be covered. Recruitment of pharmacists 
therefore ended.  
4.5 Training of pharmacists 
A patient group direction (PGD) had already been created in NHS Lothian, enabling 
pharmacists to give the subcutaneous contraceptive injection without a doctor’s 
prescription. This PGD identified who was eligible to receive the contraceptive 
injection from pharmacists, and necessitated pharmacists using it being familiar with 
the exclusion and inclusion criteria for the contraceptive injection, as well as side 
effects and risks of delivery. All pharmacists involved were trained in a) giving of 
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subcutaneous injections (necessary to participate in the project) and b) anaphylaxis 
training (arrived at after discussion within the research team and discussion with the 
pharmacists themselves on the initial open evening). Pharmacists themselves were 
the determiners of when they were sufficiently trained and therefore comfortable to 
give the injection to patients, in collaboration with the research team.  Some 
pharmacists already had anaphylaxis training due to ongoing administration of 
influenza vaccines as part of their regular daily workload. The remaining pharmacists 
attended a session in how to respond to anaphylaxis given by a member of NHS 
Lothian’s emergency care training team.  
Pharmacist payment 
Upon completion of each injection, pharmacists completed paperwork identifying the 
patient and when the injection was given. This was sent to the research team and a 
payment of £20 per injection plus the cost of one Sayana Press® injection (£6.90) 
was paid to the pharmacy for participation in the research.  
4.6 Patient population and recruitment 
The inclusion criteria for participation in this research was patients that were already 
using the contraceptive injection, and had been doing so for at least six months, and 
so were receiving their third injection or more at the time of recruitment. This 
decision was made due to the high attrition rate of users of the contraceptive 
injection (Moreau et al., 2007). Women who discontinue a contraceptive method 
after a short period of time are likely to do so within the first two months of use 
(Rosenberg and Waugh, 1998). Patients who had been using the contraceptive 
injection for a minimum of six months would therefore be more likely to continue it 
as their chosen method, and less likely to leave the project due to changing methods. 
The patient group direction also only applied to patients who had reached menarche, 
were not breastfeeding or <6 weeks postpartum and who were between 16 and 45 
years of age. Women not meeting these criteria were therefore not eligible for 
inclusion, as pharmacists would not have been able to administer their contraceptive 
injection.   
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4.7 Data gathered 
Each patient was followed up by a phone call or text message after they were due at 
the pharmacy for each injection. Data was collected about which pharmacy they had 
attended, whether they had encountered any problems, and whether they were happy 
to attend a pharmacy for their next injection, or whether they would like to attend the 
clinic and see a doctor or nurse. If they preferred this then I would see them for their 
next injection in order to answer any questions they had. If patients discontinued the 
method they were briefly asked why, and what alternative method they were using 
instead.  
If participants encountered any difficulties getting an appointment with a pharmacist 
they had the contact details of the research team to phone for an appointment, to 
ensure no participant was put at risk of missing their injection. Any participant who 
chose to withdraw from the research was seen for their initial injection (or first 
appointment for alternative contraception) by the research team. If participants 
continued with the research until the end, after a year of injections (initial injection at 
clinic followed by 3 injections at the pharmacy) participants were invited to attend 
the clinic for their fifth injection and to complete a questionnaire about their 
experience. This was also offered to any patients withdrawing from the project who 
had had at least one injection at a community pharmacy. The questionnaire asked 
about the disadvantages and advantages of attending the community pharmacy, and 
also contained free text boxes wherein participants were encouraged to write their 
feelings about the project. 
Each pharmacist involved in the project was interviewed individually using a semi-
structured interview format, between October 2014 and May 2015. A topic guide 
outlined the key areas to be covered in the interview. Interviews usually took place in 
the clinical room for patients, or in the pharmacy staff room. With the written 
consent of participants, these interviews were audio recorded and transcribed. New 
ideas that arose in interviews were explored in subsequent interviews. Data analysis 
was conducted as interviews progressed, and then afterwards.  
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Chapter 5 Delivering injectable contraception 
at the community pharmacy: results 
and discussion 
 (A modified version of chapters 4 and 5 has been published by the European 
Journal of Contraception and Reproductive Health Care, under the title ‘The 
feasibility of contraceptive injections at the community pharmacy’, August 2017.) 
5.1 Introduction 
Literature presented in chapter 2 demonstrates that both patients and pharmacists are 
generally open to the idea of patients receiving their contraception from the 
pharmacy. However, there is limited evidence available that this would improve on 
current services, and no evidence that increased contraceptive services from 
pharmacies reduce unplanned pregnancy rates. A small number of pilot projects from 
the United States (Picardo and Ferreri, 2010; Monastersky and Landau, 2006) and 
Sub-Saharan Africa (Ajuwon et al., 2013; Akol et al., 2014; Stanback et al., 2014) 
suggest that the pharmacy may be a particularly suitable place for patients to receive 
their contraceptive injection. Chapter 3 detailed research to assess the feasibility of 
piloting this service in Edinburgh, indicating that patients were open to this idea 
(Heller and Cameron, 2016). Chapter 4 explained the methodology of the research, 
and in chapter 5 I present and discuss the results.  
5.2 Results: demographics of participants 
78 women were approached for study participation during the recruitment period: 1st 
October 2014 to 15th March 2016. 50 were recruited; the main reason for declining 
participation was that patients preferred to continue receiving their injection at the 
sexual health clinic they had previously attended. Those recruited had an age range 
of 17-48 and a median age of 28. The BMI range was 17.9-45.7, with a median BMI 
of 26. Women belonged to all socioeconomic groups; see table 5-1 for Scottish 
Maternal Index of Deprivation scores (The Scottish Government, 2012a). Most 
participants were nulliparous; table 5-1 also demonstrates the parity of participants.  
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Table 5-1 Demographics of participants 
Age median (range) 28 (17-48) years 
BMI (body mass index): 
median (range) 
26 (17.9 – 45.7) 
kg/m2 
Parity 
0  37 (74%) 
1 4 (8%)  
2 7 (14%) 
3 1 (2%) 
4 1 (2%) 
Previous termination of pregnancy (TOP) 
0 40 (80%) 
1 10 (20%) 
SIMD (Scottish index of maternal deprivation) (The Scottish 
Government, 2012a) 
SMID 5 (affluent) 11 (22%) 
4 10 (20%) 
3 11 (22%) 
2 15 (30%) 
1 (deprived) 3 (6%) 
Months using contraceptive injection 
6 7 (14%) 
7-12 9 (18%) 
13-24 13 (26%) 
25-36 9 (18%) 
37-48 4 (8%) 
>48 11 (22%) 
 
5.3 Results: injections received at the pharmacy 
Of 50 patients who completed the project or withdrew (including three who were 
subsequently lost to follow up), 24 received at least one injection at a community 
pharmacy. Seven received one injection, ten received two injections and seven 
received three injections. 26 of the 50 participants (52%) did not receive any 
injections at the pharmacy, 22 withdrew before the research was completed, and four 
continued the project to the end in the intention of receiving an injection at the 
pharmacy but were not able to do so, and received all their injections at a clinic. 48 
injections were delivered in a pharmacy out of a possible 150 (32%). Figure 5-1 
demonstrates where participants received their injections. 
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Figure 5-1 Flowchart of outcomes of participants 
 
 
As figure 5-1 demonstrates, the withdrawal rate was high, with 27 participants (54%) 
choosing not to continue with the study until its end. Three were lost to follow up 
after having received their second injection. Some reasons for the high withdrawal 
rate will be discussed further, but the reasons participants themselves gave are 































Table 5-2 Timings and reasons for withdrawals 
Withdrew before first injection at pharmacy due (n=3) 
Left area 1 
Changed contraceptive method 1 
Unacceptable side effects  1 
 
Withdrew before second injection at pharmacy due (n=19)  






Left area 0 0 
Prefer to attend clinic 1 6 
Discontinued contraceptive injection 1 2 
Outwith protocol due to age 0 2 
Unacceptable side effects  0 4 
Prefer self injection 2 1 
 
Withdrew before third injection at pharmacy due (n=4) 






Prefer to attend clinic 0 1 
Discontinued contraceptive injection 1 1 
Unacceptable side effects 0 1 
 
By the end of the study there were 21 participants remaining that had not withdrawn 
or been lost to follow up.  Seven had received all three injections at the pharmacy, 
eight had received two injections at the pharmacy, two had received one, and four 
participants stayed in the project but did not manage to receive any injections at the 
community pharmacy.   
5.4 Results: participant experience 
Of 24 participants who had received at least one injection at a community pharmacy, 
22 completed an exit questionnaire. This represented 44% of participants, 92% of 
those who had experienced the intervention. Participants were asked about the 





Table 5-3 Advantages of attending the community pharmacy 
What did you find to be the benefits of attending the pharmacy? 
(Respondents could tick as many as they wished, n=21 questionnaires completed) 
Better opening hours 10 
Nearer to me 13 
Easier to get to a pharmacy 15 
Flexibility of attending different pharmacists 6 
Shorter waiting time 11 
Quicker appointment 14 
Can do other things at the same time 7 
Other (write in space):   
Not registered with a GP so very helpful 1 
What one thing was the best thing about attending the pharmacy? (Respondents 
asked to select one but 3 selected more than one, n=21 questionnaires completed) 
Better opening hours 5 
Nearer to me 4 
Easier to get to a pharmacy 5 
Flexibility of attending different pharmacies 2 
Shorter waiting time 2 
Quicker appointment  5 
Could do other things at the same time 2 
 
Table 5-3 demonstrates the variety of responses; there was no consensus among 
patients on the preferred aspect of attending a pharmacy, instead they highlighted 
different aspects that they found useful. This was also seen when participants 
identified the negative aspects of attending a pharmacy, a similar diversity of 
answers is shown in table 5-4.  
Table 5-4 Disadvantages of attending the community pharmacy 
What was the worst thing about attending the pharmacy? 
(Respondents could tick as many as they wished, n=21 questionnaires completed) 
Wasn’t able to discuss problems I had with the method 1 
Feel more comfortable seeing a nurse or doctor 1 
Wasn’t able to discuss other medical problems 1 
Better opening hours at doctors/sexual health clinic 1 
Doctors/sexual health clinic is nearer to me 1 
Easier to get to GP/sexual health clinic 1 
Longer waiting time at the pharmacy 2 
Longer appointment at the pharmacy 1 
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Can do other things at the same time in the sexual health clinic  1 
No downside to attending the pharmacy 10 
Other: the pharmacist wasn’t there every day 1 
Other: I thought the opening hours would be better  1 
Other: the injection was painful 2 
If you had to select one thing that was the worst thing about attending the pharmacy 
what would it be? (Respondents asked to select one, n=21 questionnaires completed) 
Wasn’t able to discuss problems I had with the method 1 
Feel more comfortable seeing a nurse or doctor 2 
Wasn’t able to discuss other medical problems 2 
Better opening hours at doctors/sexual health clinic 1 
Doctors/sexual health clinic is nearer to me 1 
Easier to get to GP/sexual health clinic 1 
Longer waiting time at the pharmacy 1 
Longer appointment at the pharmacy 0 
Can do other things at the same time in the sexual health clinic  1 
No downside to attending the pharmacy 9 
Other: the injection was painful 1 
 
Participants also had free text boxes where they were encouraged to tell us anything 
more about the project that they felt we should know. Responses reflected the mixed 
experience participants had and perhaps the different pharmacies involved.  
Some participants found the service excellent, and commented to the research team 
that they thought it should be available as a service generally. For a small group of 
participants (eight had nothing but positive things to say) the service worked exactly 
as we had hoped it would.   
 “Very easy and positive experience! Pharmacist great” (32 year old, 6 
months using injection, 3 injections at pharmacy) 
“I found going to the pharmacy better than the GP. The pharmacist was 
very friendly and flexible with times.” (25 years, 6-12 months using 
injection, 3 injections at pharmacy) 
“Loved taking part in the trial as it has been so much more convenient 
than visiting the nurse every 3 months, and also don’t feel that I’m 
wasting the nurse’s time by taking up an appointment.” (23 years, 12-24 
months using injection, 3 injections at pharmacy) 
“I thought the service was fantastic. I have a job which unfortunately 
leaves me with very little spare time and next to no spare time during 
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regular office hours so this worked perfectly… Sad that the study has 
come to an end!” (28 year old, >4 years injection user, 3 injections at 
pharmacy) 
Most participants chose one pharmacy and received all their injections there, 
presumably because it was conveniently located for them. Only four participants 
moved pharmacies during their time in the research. For one this was a considerable 
plus of the research:  
“I found it very useful being able to attend different pharmacies and 
much easier to book an appointment. Some pharmacists did seem a bit 
anxious but I guess that will improve with time and practice. I had a 
good experience and think it is a really great idea.” (25 years, 6-12 
months using injection, 3 injections at pharmacy) 
It became clear to the research team as time progressed that participants’ experiences 
were variable according to what pharmacy they chose to use. Although numbers 
were too small to draw any firm conclusions, participants’ attending some 
pharmacies gave wholly positive comments, whereas others had a more 
unpredictable experience. This was evident in the written feedback. One participant’s 
comments highlight the different experience at two different independent 
pharmacies. 
“First pharmacy attended had poor knowledge of drug. Appointments 
made for injection but drug not ordered so had to make multiple repeat 
appointments. Moved to [different] pharmacy – different experience, 
seamless and no problems.” (43 year old, > 4 years using injection, 3 
injections at pharmacy) 
Some participants had a more difficult experience, with problems focusing around a 
few themes. A high number of participants commented that when they phoned the 
pharmacy to make an appointment the staff answering the phone did not know about 
the service and were unsure how to advise them. This comment was made even by 
women who found the service convenient, and were generally positive about it. The 
difficulty was commented on in the larger, chain pharmacists, and was more marked 
at the beginning of the project, but continued throughout the research. Participants 
found this frustrating and inconvenient, and most women who commented on this 
did not receive all three injections at the pharmacy.   
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“When you call the pharmacy not everyone knows what you are calling 
for.” (19 year old, 6-12 months using injection, 2 injections at pharmacy) 
“The pharmacy had no idea about it the first time, the person who knew 
about it wasn’t in. A real lack of communication.” (21 year old, 2-3 
years using injection, 1 injection at pharmacy) 
“Problems getting appointment at the pharmacy – seemed to be 
confusion regarding making appointments and mixed messages from staff 
and lead pharmacist.” (33 year old, 6 months using injection, 2 
injections at pharmacy) 
A small number of participants who completed questionnaires also expressed 
concerns about the ability of the pharmacist to give the drug. They commented on 
the anxiety of the pharmacist, and their apparent lack of familiarity with the 
injection.  
“The two times I attended, the pharmacist was very, very nervous… she 
was very doubtful of herself. She asked me where on the stomach I 
normally get the injection and just seemed nervous at all times, shaky 
hands etc.” (27 year old, 1-2 years using injection, 2 injections at 
pharmacy) 
However, participants who chose to highlight this did not find it off putting enough 
to stop using the service. One person said “I have had the injection many many times 
before, so the above didn’t phase me too much, as I know what to do and what to 
expect already.” This was a participant in whom the pharmacist attempted the 
injection four times at one visit. However she explicitly states that the reason she did 
not receive three injections at the pharmacy was not because of this.   
A high number of participants also commented on the lack of convenience of 
attending the pharmacy. They were unable to find a time that suited them to come in 
where the trained pharmacist was working. This was more evident in the chain 
pharmacies, where one of the trained providers might only be available a few days a 
week. In addition this availability changed from week to week, so participants were 
not able to get an idea of when they could attend in advance. The independent 
pharmacies usually had the trained provider there for most of the working hours of 
the pharmacy and were therefore more flexible for attendance. After the problem of 
staff who were not aware of the project wrongly advising participants when they 
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called, difficulties of access and opening hours were the next most commonly 
mentioned comments.  
“Wasn’t as convenient as expected due to pharmacy opening hours and 
having to make appointment and check that they had the depot in stock” 
(43 year old, 2-3 years using injection, 3 injections at pharmacy) 
“I thought the opening hours would be better, as I work 9-5 and 
[pharmacy] is opening later, its closer to my home and easy to get to. But 
it turns out there was only one trained pharmacist, who was only in this 
pharmacy part time, and only seemed to work at the same times I work 9-
5. So the times didn’t suit me better than going anywhere else.” (27 year 
old, 1-2 years using injection, 2 injections at pharmacy) 
The variety of comments made by participants reflects their mixed experiences. 
Anecdotally it seemed to the research team that two pharmacies were extremely 
reliable, two or three were generally reliable but participants could encounter some 
problems, and the rest were either rarely or never used.  
5.5 Results: community pharmacy involvement 
As has been documented in Chapter 4, we ended up starting the project with 11 
pharmacies. Four were independent pharmacies, three were from smaller chains, and 
four were from a large national chain. Unfortunately two pharmacies withdrew 
during the project, one after their first injection, and one before any participants 
attended them. One independent pharmacist went on long-term sick leave, and one 
pharmacist from a small chain pharmacy left the practice, and none of his colleagues 
wished to participate. Another two pharmacists left whilst the research was 
continuing, one was replaced by a colleague who wanted to participate, and the other 
was not. After approximately eight months a further pharmacist was recruited, from a 
small chain which already had one participating pharmacist. This pharmacist also left 
the pharmacy after giving two injections.  
There was a large variety in the popularity of the pharmacists and the number of 




Table 5-5 Pharmacy activity 










Pharmacy 1 6 9 Throughout 2 
Pharmacy 2  2 4 Throughout 2 
Pharmacy 3  0 0 Throughout 4 
Pharmacy 4  0 0 Pharmacist left before 
any injections given 
1 
Small chains 
Pharmacy 5  1 1 Pharmacist left after 
giving one injection 
1 
Pharmacy 6  0 0 One pharmacist left six 
months in, another 
pharmacist was trained 
2 
Pharmacy 7  0 0 Pharmacist joined after 8 




Pharmacy 8  7 13 Throughout 1 
Large chain 
Pharmacy 9  2 3 Throughout 1 
Pharmacy 10  8 14 Throughout 2 
Pharmacy 11 1 2 Pharmacist left after 1 
year 
1 
Pharmacy 12  2 2 Throughout 1* 
* The pharmacist from pharmacy 11 delivered no injections, the trained pharmacist 
from pharmacy 12 delivered the injections at pharmacy 11.  
 
5.6 Results: pharmacist interviews 
In order to get an idea of the pharmacist experience, each pharmacist was invited to 
participate in a recorded, one-to-one semi-structured interview. Interviews were 
conducted with pharmacists from all of the above pharmacies except for pharmacies 
4 and 5, where the trained pharmacists left early in the project. One was not able to 
be contacted and the other declined to be interviewed. Interviews were conducted 
with two pharmacists from Pharmacy 1, three pharmacists from Pharmacy 3, two 
pharmacists from Pharmacy 11 and one pharmacist from all the others. The 
pharmacist interviewed from Pharmacy 6 was the replacement for the pharmacist 
who left the project, who declined to be trained. Interviews took place after the 
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project had been running for approximately 18 months. The number of injections 
pharmacists had given prior to interviewing ranged from zero to five. Pharmacists 
ranged in experience from just over three years to over 30 years.  
5.6.1 Pharmacies as a way to improve access 
All pharmacists felt that providing contraceptive services in the pharmacy was a way 
to improve access to them. They felt strongly that the pharmacy was easy for 
participants to get to and conveniently located for people. This was for a variety of 
reasons; almost all interviewees mentioned increased opening hours, the number of 
pharmacists available and the quicker appointments. They compared this to general 
practitioners and sexual health clinics, which they felt would be harder to get to, due 
to their central location and the difficulty of getting appointments. The flexibility of 
the pharmacy was also mentioned as an advantage. Pharmacists saw their service as 
convenient for women to attend and providing fewer barriers to attending than 
settings where other healthcare practitioners are based.  
A number of pharmacists also talked about the unique relationship that pharmacists 
had with people attending in deprived communities. There was a perception that 
there was a greater familiarity than a GP would have.  
“In community pharmacy, some people are in here every day. So they 
know me better than they know their GP. So they might feel confident to 
come here as well.” [Pharmacist from chain pharmacy, no injections 
given] 
A number mentioned dispensing EHC, and the idea that people were comfortable 
attending for this, and pharmacists were happy dispensing it. They felt that this was a 
useful service. Pharmacists felt that they were well placed to give advice to women, 
and that the pharmacist was an appropriate place for women to go for contraceptive 
advice. There was a perception among some pharmacists that people came to the 
pharmacy before going to other services, a pharmacy was a “first port of call”, and so 
it was particularly appropriate if pharmacists could offer more services.  
Pharmacists also saw themselves as contributing to the healthcare of the population 
in a way that “freed up” other services such as doctors. There was a view that 
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enabling contraception from the pharmacy would mean that GPs had greater 
availability “to actually deal with emergencies”. Pharmacists appointments were seen 
as more appropriate for routine contraception than a GP appointment, so providing 
this service would help the general healthcare system, which almost all pharmacists 
perceived as being under severe pressure.  Another advantage mentioned by one 
pharmacist was that people might not be registered with a GP, and attending the 
pharmacist meant they could still access contraception. This pharmacist discussed 
how full the GP practices around his pharmacy were, and that he knew his customers 
were having difficulty registering when they moved into the area. This particular 
pharmacist had close links with the sexual health centre and used it to refer people he 
saw: “we’ve got your cards here, we always give them that option as well you 
know”.   
Most pharmacists did not perceive the movement of pharmacists and the covering of 
holidays to be a problem. They felt that this would be easily manageable in most 
cases and would not prove difficult for participants in the research. Although they 
did acknowledge that if they weren’t available for a prolonged period “you’re going 
to have to find somewhere else so it’s not going to work that way”, generally, even 
when questioned specifically, they felt that neither movement of pharmacists or 
pharmacist absence would interrupt service delivery unduly.  
5.6.2 Thoughts about expanded roles 
Generally pharmacists showed an enthusiastic willingness to expand their role. 
About half of pharmacists interviewed didn’t see any downside to taking on the 
ability to administer the contraceptive injection. They saw it as an interesting 
addition to their current skill set, and a refreshing change from dispensing 
medication. Some pharmacists however made the point that the expanded pharmacist 
role was not necessarily optional, and that there was pressure from managers to 
constantly develop new skills, perhaps beyond what they had time to do, in order that 
the pharmacy could offer an increasing amount of services. “We don’t have a choice 
really.” This was mentioned by pharmacists working in chains only, the independent 
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pharmacists appeared to feel in control of the decision to participate, and had done so 
because they felt it was a good fit for their pharmacy.  
There was a perception among chain pharmacists that expansion of roles needed to 
be matched by sufficient time and staffing to enable this.  
I think it’s great, but I just don’t think that we’re being given enough 
time to actively, and proactively take part in these roles. And being given 
the support. [Chain pharmacist, no injections given] 
Most chain pharmacists mentioned that they would be happy to continue delivering 
contraceptive injections, but that it was much easier to offer the service when there 
was a second pharmacist in the branch, and no additional cover had been made 
available to assist with research participation.  There was a general consensus among 
chain pharmacists, particularly when offering the contraceptive injection long term 
was being discussed, that more support would need to be offered at a managerial 
level in the form of additional pharmacy cover, in order to enable reliable service 
delivery.  
5.6.3 Feelings about contraceptive injections 
A factor that the research team had not anticipated was the level of anxiety 
pharmacists felt about delivering the contraceptive injection. This was in part due to 
the fact that it was an injection and meant “breaking the skin”; a number of 
pharmacists talked about the anxiety this caused them. However anxiety was also 
attributed to the fact that they were giving contraception, a field in which the stakes 
were very high. 
“if I don’t do it well, and she gets pregnant… that would be soooo… 
[shocked face] …so that was my major scare, yeah” [chain pharmacist, 
13 injections given] 
A number of pharmacists that were trained to give flu injections compared their 
anxiety to first learning to deliver that service. All found giving the contraceptive 
injection more stressful than the flu injection, although a number stated that this was 
probably due to unfamiliarity. The interviews were conducted in the early months of 
the research when most participants had given only a few injections.  
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Many pharmacists mentioned the importance of contraception to women and that 
they felt therefore that it was extremely important to get it right. For some 
pharmacists the fact that the research was about contraception had been part of the 
appeal. Through their delivery of EHC a number of pharmacists were aware of the 
number of women not using regular contraception and therefore felt like they wanted 
to contribute to this unmet need through offering the contraceptive injection.  
“It’s frustrating as well when people come, and they’ve forgotten their 
pill or whatever, and we can’t supply it… and I just think there’s so much 
more we could do.” [chain pharmacist, 3 injections given] 
5.7 Discussion 
The number of participants who received all three injections at the community 
pharmacy ended up being just over a tenth. Approximately a third of injections for 
participants were delivered in the community pharmacy setting. This was 
considerably less than we had anticipated. The number of withdrawals was also 
extremely high, with over half of the participants withdrawing before the end of the 
research, the majority after the first injection. Although numbers are too small to 
draw real conclusions, most withdrawals were from participants who had received 
their first injection at a clinic rather than a pharmacy. The high number of 
withdrawals does not therefore seem to indicate a negative pharmacy experience. 
However, some attempted to receive an injection at the pharmacy and were not 
successful, and ended up attending a clinic. This could be for a variety of reasons, as 
will be discussed, but as the comments in 5.4 highlight, participants had problems 
accessing the pharmacy service, citing lack of information among the pharmacy staff 
about when and how it was offered. If participants met barriers attending the 
pharmacy they seemed more likely to withdraw from the research and carry on 
attending the clinic as they were used to doing. The most common reason for 
withdrawing from the research given was that participants preferred to attend a 
clinic. Although there is little literature on this subject, when attendees of a sexual 
health clinic in England were offered a choice concerning various aspects of 
obtaining EHC, they demonstrated a preference for a doctor or a nurse (Seston et al., 
2007). The pharmacists themselves did not see pharmacy access being a problem and 
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many highlighted the ease of access to a pharmacy as making things more 
straightforward. This was not always borne out by either our numerical data or 
participants’ comments.  
Six participants also discontinued the research because they did not like the side 
effects experienced on DMPA-SC. This was usually a lump at the injection site, 
although two women who had been amenorrhoeic on DMPA-IM found they had 
some bleeding on DMPA-SC and discontinued for this reason. Unacceptable side 
effects is a reason women discontinue all contraception, including the contraceptive 
injection (Moreau et al., 2007). Our own research in Chapter 3 demonstrated that the 
main reasons participants discontinued the contraceptive injection were irregular 
bleeding, weight gain and acne (Heller and Cameron, 2016).  However the burden 
that side effects cause may be weighed by women against the inconvenience of 
attending clinic, and so it is possible that a more straightforward experience might 
have led to participants continuing with research, despite some ongoing side effects. 
The participants who received all three injections at the pharmacy tended to be those 
who were recruited later in the project. All except one were participant number 35 or 
higher. This may reflect the time that it took to establish the service in the 
pharmacies, and for the staff to become comfortable delivering it. Various factors 
make successful change more likely in health services. Grol et al divided theories 
into aspects relating to individual, aspects relating to social context and aspects 
relating to organisation and economic context (Grol and Wensing, 2004). In the 
scope of an exploratory pilot project we had restricted abilities to affect aspects like 
the existing pharmacy culture, and only limited economic incentives to offer. As time 
progressed and more participants attended successfully for their injections, the 
attitudinal contexts probably did shift towards a service change, which may be why 
the project was more successful in later stages, with more injections delivered in 
pharmacy and lower withdrawals. However the high number of withdrawals and the 
number of people who did not successfully receive their injection at the pharmacy 
was due at least in part to specific challenges encountered by this research. These 
challenges are explored here.  
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5.8 Discussion: challenges encountered  
5.8.1 Recruitment 
The first difficulty was recruitment: this was largely a consequence of the 
recruitment site. Recruitment initially took place at a large urban sexual health 
centre. However following the conception of the research there was a concerted 
effort by the centre’s lead clinicians to move routine contraception appointments, 
such as the contraceptive injection, away from specialist sexual health centres and 
into primary care. A triage system redirected these patients, giving priority instead to 
patients with symptoms of sexually transmitted infections, and those requiring 
emergency contraception or long-acting reversible contraception. This heavily 
reduced participants available for recruitment. A number of steps were taken to try 
and overcome this problem. The first step was to inform reception staff taking phone 
calls from patients that I would see any patient requesting a contraceptive injection. 
This strategy had reasonable success, and most participants were recruited through 
this pathway.  
Recruitment was initially expanded to include peripheral clinics associated with the 
sexual health centre; these were located in areas of higher social deprivation and 
operated on a booked appointment system rather than a walk-in system. However 
although these clinics saw a high number of appropriate patients, the recruitment rate 
was low in this population. Peripheral clinics were already conveniently located for 
patients to attend: this was the reason behind their inception. Attending their 
community pharmacy did therefore not offer them the advantage that it might offer 
those who had to travel to receive their injection. Many patients had been attending 
clinics for years and knew the staff well, and confided to research staff that this was 
a reason they wished to continue attending clinic. This strategy did not therefore 
increase recruitment rates. 
A second attempt to increase recruitment looked at recruiting participants from 
primary care. By the time the research had started it was clear that some pharmacists 
were finding it more challenging than others, for a variety of reasons demonstrated in 
pharmacist interviews.  In addition, some pharmacists were more popular with 
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participants. Three GP centres were therefore chosen that were located near 
pharmacies that were successfully delivering injections. The GPs and practice 
managers were contacted with information about the project, and invited to 
participate. Two practices agreed. I attended each practice to explain to the medical 
team about the research. Bright attractive posters and leaflets were designed, 
approved by the ethics committee that had originally reviewed the project, and 
located in the patient waiting room and nursing rooms. These encouraged patients to 
get in contact with the research team if they were interested in participating. Practice 
nurses were also encouraged to speak to patients that they saw for contraceptive 
injections. Despite an enthusiastic response from the healthcare professionals 
involved, no participants were recruited via this method.  
In the end the decision was made to cap recruitment for the project at 50 participants, 
though the original target had been 100. By the time 50 participants were recruited, 
the timescale for recruitment had already been longer than anticipated. It was also 
clear that there were a number of problems with the research, and it was not 
necessary to recruit another 50 participants to demonstrate this.  
5.8.2 Unavailability of Sayana Press® 
Approximately three months after recruitment of the first participant, and after 
recruitment of 25 participants, Sayana Press® (Pfizer®), the only licensed product for 
delivery of the subcutaneous contraceptive injection, became globally unavailable. It 
was not possible to order it from anywhere and supplies to give to patients 
participating in the research quickly ran out. Throughout the shortage Pfizer® was 
unable to anticipate when supplies of the drug would become available: the shortage 
lasted approximately five months. As a consequence all participants already recruited 
were unable to attend the pharmacy for one injection, and some were unable to 
attend for two injections. Instead they attended the clinic and were seen by the 
research team, and given the DMPA-IM that they had previously received.  
During this time some good will appeared to be lost with participants. Many that had 
anticipated attending the community pharmacy but instead attended their regular 
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clinic withdrew from the project. During the time that Sayana Press® was unavailable 
17 participants withdrew from the project.  
We cannot say with certainty that the reason that these 17 participants withdrew was 
the unavailability of Sayana Press®. The questionnaire asking about reasons for 
withdrawal was designed before the study commenced, and the option of 
withdrawing due to unavailability of the contraceptive was not included. The 
majority of patients who withdrew during this time period cited preferring to attend 
clinic as the reason for their withdrawal. They declined the option of being notified 
when Sayana Press® was back in stock so that they could continue to receive 
injections at the pharmacy at a later date. Other participants received an injection 
from the clinic during the period of unavailability and then subsequently returned to 
the pharmacy. However it seems likely that the unavailability made the experience 
less attractive to participants, and it certainly made it less straightforward.   
5.8.3 Licensing of Sayana Press® for self-injection 
In September 2015 Sayana Press® was licensed in the UK for self-injection (Faculty 
of Sexual and Reproductive Healthcare, 2015a). The main sexual health centre from 
where recruitment took place began offering this service in July of 2016. This had a 
small impact on our study, as three participants left the study preferring to learn self-
injection rather than continue attending the pharmacy. As evidence outlined in 
chapter 2 suggests, the main perceived advantages in attending the pharmacy are 
access and convenience of attending. It is therefore unsurprising that self-injection at 
a time and place of their own choosing offers patients another level of convenience 
that they are keen to take advantage of. The available literature on self-injection 
highlights the convenience of this method (Kim et al., 2017; Beasley et al., 2014; 
Cameron et al., 2012b). 
5.8.4 Working with community pharmacies 
Working with community pharmacies was challenging in ways that were not 
anticipated when the project started. Some pharmacists working for commercial 
chains took months to be able to deliver the contraceptive injection. This was not the 
case for any independent pharmacists. Pharmacies did not have protocols for practice 
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in the context of research, and all pharmacists except one were new to clinical 
research. Each commercial chain had forms that needed to be signed by differing 
levels of management before the pharmacists could deliver injections, and senior 
staff were unsure which of their own protocols applied to pharmacists involved in 
research. In addition pharmacists have a number of pressures that inevitably 
impacted the time available for them to spend on this research, particularly as they 
were not offered any extra time or financial compensation. The time taken for each 
pharmacist to receive full approval from each level of management delayed progress 
and consequently a number of participants that anticipated receiving their injection at 
a chain pharmacy needed to attend a clinic instead. This break in anticipated service 
delivery may be another explanation for the high withdrawal rate seen.  
The number of people working in each pharmacy meant that the full staff was not 
always aware that the service was being offered. Participants attempting to make 
their appointment were informed on more than one occasion that this service was not 
available. This misinformation generated some frustration, as demonstrated in the 
participant comments. Attempts to rectify these communication difficulties were 
made by repeated site visits and contact with the pharmacy, but a high degree of staff 
turnover meant that many staff remained unaware of their pharmacy’s participation. 
When asked, pharmacists involved felt confident that all staff in the pharmacy were 
aware of the service, and declined further visits or meetings, but this picture did not 
match patient’s comments. Dissemination of information is a challenge in large 
pharmacy chains and would be an important aspect of the feasibility of the research 
being expanded or repeated. It is likely that the uncertainty was a consequence of this 
being a small research project rather than a service offered generally, but our 
experience demonstrates the difficulty of bringing about service change, particularly 
within large services employing many staff members. Grol and Wensing highlight 
the importance of the social context in which any change is planned. The existing 
culture, the opinion of key people and the observed behaviour of role models all 
contribute to change being more or less likely to happen (Grol and Wensing, 2004). 
Although we did not collect any evidence from other groups, it does not seem as if 
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other staff at the pharmacy felt part of the service delivery , and were not invested in 
its successful implementation.  
A further unexpected challenge was the number of times that pharmacists moved 
between pharmacies. Pharmacists who had been trained to give the subcutaneous 
injection could at any time be sent to work in a different pharmacy not listed as 
participating. Pharmacists had no control over this and found out only a week in 
advance. Participants had been instructed (on the pharmacists’ advice) to phone up 
the week before their injection was due. However the pharmacist might only be 
working at the relevant pharmacy one or two days a week. As one key advantage 
potentially offered by the pharmacy was better opening hours, this was a 
considerable disadvantage. Participants who contacted pharmacies but were unable 
to arrange appointments at a time when a pharmacist was available often contacted 
the research team to ask for a clinic appointment, as they were anxious about putting 
themselves at risk of unplanned pregnancy.  The pharmacists themselves did not see 
this as problematic. Even when explicitly asked, they felt that moving between 
pharmacies would be a surmountable problem that would not impact on the research. 
This discrepancy between the access anticipated by the pharmacist and the 
participant experience was conspicuous. Chapter 2’s literature review demonstrated 
that, although there is often marked enthusiasm by pharmacists about role expansion, 
there is limited evidence that sexual and reproductive healthcare services will be 
delivered as comprehensively in pharmacies as in traditional healthcare settings. This 
differential was clearly evident in this aspect of our research.  
Some of the challenges of working with community pharmacists on research projects 
have been explored elsewhere. Pharmacists often receive minimal or no training on 
conducting healthcare research, and they have commercial pressures in addition to 
those of service delivery, not found elsewhere in the NHS (Black et al., 2009). The 
pressures experienced by pharmacists were particularly apparent in comments made 
by pharmacists working within a chain. Only these pharmacists raised concerns 
about managerial support and cover if the service was to expand. Working within a 
pharmacy corporate structure carries further challenges, and can often mean rapid 
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turnover in staff involved, necessitating adjustments and changes on the research 
team’s part (Weinberger et al., 2002). A high staff turnover meant that our original 
plan – to train a number of pharmacists at the beginning of the research – was not the 
best approach, leaving us with fewer trained pharmacists than we had originally 
planned. In addition the comments from patients and pharmacists indicating their 
anxiety suggests that further training would have been useful for those that remained 
in the research. Although we emphasised that the pharmacists could contact the team 
if they wanted further training, this option was only taken up by one pharmacist, who 
received additional supervision at her pharmacy. The anxiety displayed is 
particularly relevant in the context of proposed expansion of healthcare services to 
community pharmacies, and the potential resources this may require. Suggestions for 
alternative approaches to training pharmacists in order to increase their confidence 
are discussed below. It should however be noted that, although some participants 
commented on pharmacist anxiety, none offered this as a reason for withdrawal from 
the research. 
The response of participants and pharmacists, particularly in chain pharmacies, 
suggests that any contraceptive service offered would have a greater chance of 
success if the majority of pharmacists in most pharmacies offered the service. The 
confusion of some staff and the sporadic nature of the injections given seem to have 
had a significant influence on the experience of both participants and pharmacists. In 
particular the lack of awareness about the project by pharmacy staff influenced 
women’s access, and increased access was the main hope for initiating the research. 
If offering the contraceptive injection at the pharmacy became routine then it is 
likely awareness would spread and both pharmacists and pharmacy staff would 
become more comfortable with the concept.  
The influenza vaccination is a good example of an injection delivered successfully 
by UK pharmacies, both as part of the NHS and privately (Orrell et al., 2015; Brown 
et al., 2012).  Some patients will even pay for a vaccination at the pharmacy that they 
would be eligible to receive at no cost (Anderson and Thornley, 2014). Evidence 
indicates that pharmacy vaccination results in vaccination for those who would not 
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otherwise receive it; this is potentially due to better accessibility and convenience. 
The Isle of Wight introduced a program in 2010-2011 expanding influenza 
vaccinations to include community pharmacies. 1597/2207 (72.3%) of patients who 
received the vaccination at a pharmacy answered a satisfaction questionnaire, and 
98% (n=1540) indicated that they would use the pharmacy service again. 6.8% 
(n=207) indicated that they would not have been vaccinated if not for the pharmacy 
service (Warner et al., 2013). Patient questionnaires completed by 898 patients in 
Grampian, Scotland, as part of a pharmacy influenza vaccination scheme in 2002, 
demonstrated similar views, with 37% (n=335) stating that they would not have 
received an influenza vaccine if it had not been offered at the pharmacy (Hind and 
Downie, 2006). Investigation of pharmacy vaccination in Wales in 2012/13 showed 
that 30.8% of patients vaccinated at pharmacy (350/1136) had not been vaccinated 
the previous year. When questioned 26.7% of under-65s indicated that they would 
not have been vaccinated if they had not been at the pharmacy that day (Evans et al., 
2013). By contrast however a 2015 survey of 7154 pharmacy customers, 63% 
(n=4480) of whom were eligible to receive an NHS vaccine, noted that 51% 
(n=3620) preferred to receive vaccinations at their GP surgery, with 12% (n=834) 
preferring the pharmacy (Tan et al., 2015).  
Pharmacists are usually paid a small amount for delivering influenza vaccinations: in 
Scotland the pharmacy is reimbursed for the cost of the vaccination by the Scottish 
Government (The Scottish Government: Pharmacy & Medicines Division, 2013) and 
private patients pay a fee of around £10 (Boots.com, 2016). Although pharmacists 
were paid a fee of £20 in our research this was not sufficient to remove barriers to 
smooth service delivery. If the service were offered routinely this fee would be 
unlikely to be sustainable. A key difference between our pilot project and influenza 
vaccination is that high-level management within pharmacies instigated influenza 
vaccination, and a number of systems were concurrently put in place to ensure that 
vaccinations could be delivered to customers. The barriers that participants discussed 
tended to be service delivery barriers, and minimising these might make future 
research more successful, as I will go on to discuss.  
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5.9 Suggestions for future research 
The small-scale nature of this research resulted in specific challenges around service 
delivery that may well be present in future pilot studies. However it would not be 
either good practice or cost effective to instigate large changes in service delivery on 
equivocal evidence such as we produced. Repeating the project but addressing some 
of the training and communication needs identified by pharmacists and staff working 
in pharmacy might generate more positive findings. The comments about “shaky 
hands” and multiple attempts being needed to give injections suggests that the 
training was not adequate for pharmacist confidence, even if it was deemed adequate 
for competence. A rolling programme of training for pharmacists to attend prior to 
giving an injection might alleviate anxiety and increase confidence. This style of 
training would also enable pharmacists joining the service to gain skills as others left, 
maintaining a larger pool of proficient pharmacists. Ideally future research would 
include adequate funding to enable pharmacists to attend training in their paid 
working hours by providing relief pharmacist cover.  
In our research only one pharmacist from each pharmacy wished to develop the 
necessary skill. If more financial support was available, perhaps with remunerated 
time and more extensive training, more pharmacists might wish to be involved. 
Training every pharmacist working at pharmacies involved in service delivery would 
be an excellent approach, as this would remove the barrier of limited trained 
pharmacist availability that frustrated some participants. However the chain 
pharmacies had a large number of pharmacists who could potentially work in each 
pharmacy, and therefore training them all might prove challenging.  A potential 
solution would be to make delivering the contraceptive injection a core pharmacist 
skill, as influenza vaccination now is (Orrell et al., 2015; Brown et al., 2012). Such a 
significant change in pharmacy services would need managerial input, as well as the 
support of local public health authorities, and this might be difficult to achieve 
without compelling research to demonstrate its efficacy and acceptability. 
Nevertheless, enthusiastic support at a managerial level would be considerably more 
likely to lead to new service implementation (Grol and Wensing, 2004).  
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Our research demonstrates the importance of involving all staff at the pharmacy, not 
just the trained pharmacists delivering the injection. Training and information 
sessions held with all staff likely to be in contact with participants would minimise 
the chance of inaccurate information being conveyed. Ensuring that the majority of 
pharmacists in participating pharmacies are adequately trained, and that all staff 
members know about the service, might be achieved by conducting future studies 
using either just independent pharmacies, or pharmacists from one chain only. This 
approach would enable limited financial resources (which would be most usefully 
spent on staff to train pharmacists and compensating pharmacists for training time) to 
be targeted effectively. However, doing so would lose the advantage of greater 
flexibility for participants about where they attended, which some identified as a 
positive. Running the research again without the global unavailability of the product 
would also be likely to positively influence the participant experience.   
Ultimately the licensing in the UK of Sayana Press® for self-administered injection 
will impact substantially on the utility of further exploring pharmacy administration. 
The main concern that patients cite when discussing receiving healthcare in the 
community pharmacy setting is lack of privacy, with resulting anxiety about 
confidentiality (Saramunee et al., 2014; Lambeth Lewisham and Southwark Health 
Action Zone, 2002; Anderson et al., 2004).  The primary advantages are cited as 
convenience and speed and ease of access (Barlassina, 2015; Greene et al., 2006). 
Giving patients the option to self-administer in the privacy of their own homes at a 
time that suits them may therefore confer greater advantages than attending a 
pharmacy (Kim et al., 2017; Beasley et al., 2014; Cameron et al., 2012b). However 
some people may continue to prefer receiving their injection from a healthcare 
professional, and there is potential to further explore pharmacy delivery, adapting 
our research as outlined above.  
5.10 Summary and conclusion 
This was a pilot study to assess the feasibility and acceptability of patients receiving 
their contraceptive injection at the community pharmacy. Our study failed to show 
either feasibility or acceptability to participants, as reflected in the high withdrawal 
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rate. This may be due to some particular challenges encountered throughout the 
research, as outlined in my discussion.  
The most robust way to investigate women receiving their contraceptive injection 
from the pharmacy would be to conduct an RCT where participants were randomised 
to either current care (injections at a sexual health clinic or a GP) or injections 
received from a pharmacy. For greatest utility this would be powered to identify a 
difference not just in continuity rates, but also, and more importantly, in unplanned 
pregnancy rates. Normally a pilot project such as we conducted would assess 
feasibility issues concerned with an RCT, as well as identifying any barriers prior to 
conducting it. Any RCT, particularly one large enough to detect a difference in 
unplanned pregnancy rates, would require significant resources. Due to the change in 
licensing for self-injection, and the problems in feasibility that we have identified 
through our pilot trial, it would not be sensible to allocate resources to an RCT at this 
time. Further pilot studies are instead merited, using the lessons learnt from our 
research, that aim to overcome to some of the difficulties we encountered with 
training and staff. Indeed, despite the potential for delivering contraception in the 
community pharmacy as outlined in chapter 2, any contraceptive service from 
pharmacies needs to be comprehensively piloted, ensuring that limited public 
resources are spent in the most useful and effective ways possible. 
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Chapter 6 Postpartum contraception: a 
missed opportunity to prevent 
unintended pregnancy and short 
inter-pregnancy intervals 
6.1 Introduction 
Chapter 1 outlined the unmet need for contraception, and set out the case for 
expanding current service delivery. Doing so has the potential to increase 
contraceptive uptake and offer women better protection against unplanned 
pregnancy, particularly if use of the most effective LARC methods was increased. 
Chapters 2-5 examined delivery of contraception from the community pharmacy. 
This would represent novel service delivery but unfortunately chapter 5 presented the 
difficulties our research encountered, and I concluded that delivering the 
contraceptive injection at the community pharmacy presents considerable access 
challenges for recipients and is not resource efficient. 
As discussed in chapter 1, a key opportunity for contraceptive intervention currently 
gaining attention in the UK is the immediate postpartum period. Systematic reviews 
consistently show immediate postpartum contraception to be safe, acceptable and 
cost-effective (Lopez et al., 2015; Washington et al., 2015; Prager and McCoy, 2015; 
Goldthwaite and Shaw, 2015). Sexual health strategies from Scotland, England and 
Wales all encourage delivery of contraceptive services from maternity settings and 
agree that access to postnatal contraception should be a public health priority (The 
Scottish Government, 2011; The Scottish Government, 2015; Department of Health, 
2013; Welsh Assembly Government, 2010). The development of a best practice 
paper by the Royal College of Obstetricians and Gynaecologists in 2015 entitled 
‘best practice in postpartum family planning’ provided further impetus for clinicians, 
policy developers and public health strategists to recognise the importance of the 
postpartum period as an opportunity for women to plan their future pregnancies 
(Royal College of Obstetricians and Gynaecologists, 2015).  In Scotland, the 2015 
update to the Sexual Health and Blood Borne Virus Framework increased its 
emphasis on postpartum contraception, recommending that all NHS Boards in 
  
 104
Scotland include antenatal counselling about contraception, and provide patients in 
maternity services with their preferred choice of contraception, or a bridging method, 
prior to discharge following delivery (The Scottish Government, 2015). Finally, at 
the beginning of 2017, the Faculty of Sexual and Reproductive Health’s guidelines to 
contraception after pregnancy recommend that effective contraception should be 
initiated as soon as possible after childbirth, that maternity services should ensure all 
women have access to a full range of contraceptives, including LARC, and that 
intrauterine contraception and the contraceptive implant can be inserted immediately 
after vaginal or caesarean delivery (Faculty of Sexual and Reproductive Healthcare, 
2017).   
Until these guidelines, UK guidance about postpartum contraception has lacked 
specificity. The clinical guideline from NICE (the National Institute of Health and 
Care Excellence) about postnatal care up to eight weeks after birth says only that 
“methods and timing of resumption of contraception should be discussed within the 
first week of birth”, and that healthcare professionals should provide proactive 
assistance to women who may have difficulty accessing contraceptive care (National 
Institute for Health and Care Excellence (NICE), 2006). There is no explanation of 
who may have difficulty accessing care, or what such proactive assistance might 
entail, and no attempt to standardise discussion. As of January 2017 this guideline is 
currently being updated (National Institute for Health and Care Excellence (NICE), 
2017).  
It is unsurprising that NICE guidance offers little clarity about what postpartum 
contraception counselling should comprise, as generally there is a paucity of 
evidence about strategies that lead to an improved uptake. Two Cochrane reviews 
have examined interventions; the first in 2012 investigated education about 
postpartum contraceptive use from RCTs, looking at 12 trials comprising 4145 
women (Lopez et al., 2012). The authors of the review note the considerable 
heterogeneity in the contraception counselling described. Four studies provided a 
single counselling session about contraception to one arm of the trial, and then 
examined the contraception uptake at a later date. Two showed that counselling 
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(structured or informal) meant the experimental group were more likely to be using 
contraception than the control group (Saeed et al., 2008; Torres et al., 2014). 
However, two other trials showed that neither a one minute script about LARC nor 
counselling, video and written material appeared to make a difference to the 
intervention group in use of the contraceptive investigated (Tang et al., 2014; Gilliam 
et al., 2004). It is particularly challenging to conduct RCTs in this area, as 
standardising the intervention is both complex to achieve and difficult to measure. 
The authors of the review note this difficulty, and suggest that the quality of the 
evidence could be improved by better reporting of the training providers received, 
ways of measuring adherence to the protocol and way of measuring recipients 
knowledge and understanding. They also note the lack of an objective outcome 
measure in most trials, such as a pregnancy test or structured questionnaire (Lopez et 
al., 2012).  
An attempt is made to address some of these challenges with a 2014 Cochrane 
review of non-randomised studies to improve postpartum contraception use. The 
authors point out that educational interventions may not be suitable for RCTs, 
particularly as blinding is unlikely to be feasible, and funding for large RCTs may be 
harder to obtain. As with the RCTs discussed, most studies examined an educational 
intervention, where messages were given about healthy birth spacing and postpartum 
contraception, sexual health, lactational amenorrhoea or a combination of all three. 
The 2014 review examined six studies and 5143 women. Although all studies 
showed some association of an educational intervention with contraception use, only 
two showed fewer pregnancies in the treatment group. In these interventions, 
counselling at various times postpartum did appear to mean people receiving the 
intervention were more likely than comparison groups to be using a modern or 
effective method of contraception (Hardy et al., 1998; Lee et al., 2011). When a 
contraceptive method (the IUD) was actually made accessible to women, in addition 
to contraceptive counselling, women in the intervention group were more likely to be 
using it. Women in the intervention group were not more likely to be using other 
methods of contraception, suggesting that access to a method may make at least as 
much difference to women as education about it (Foreit et al., 1993).  
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The Cochrane reviews demonstrate the difficulties inherent in assessing a complex 
and multifactorial health intervention. Engin-Üstün et al examined the effect of 
providing counselling to 143 women in the immediate postpartum period. They 
noted that after counselling, 33% of women (n=47) had decided to use intra-uterine 
contraception. At a telephone interview at least five months later however, only 10% 
(n=14) were using this method. Although initially this might indicate the counselling 
was not successful, this intervention is not designed to either investigate or report 
barriers in place for these women getting IUC. Without this knowledge it is difficult 
to assess the use of the counselling as an isolated intervention, particularly as there 
are clear documented barriers to accessing IUC postpartum (Ogburn et al., 2005; 
Potter et al., 2016; Zerden et al., 2015; Harney et al., 2017). 
Until the 2017 guideline there was no clear guidance about when information about 
postpartum contraception should be offered and when the contraception itself should 
be offered. Although only a very limited amount of research has been done with 
women themselves about what they want, what is available demonstrates only the 
need to tailor counselling to individual women. Available evidence shows a wide 
variety of opinions about what counselling should be offered and when, with women 
as likely to criticise providers for not providing information about the most effective 
methods as to feel that they were being coerced into using them (Murphy and British 
Pregnancy Advisory Service, 2014; Yee and Simon, 2011a; Yee and Simon, 2011b).  
Further research, both qualitative and quantitative, on women’s feelings about 
discussion of contraception at various points in the antenatal and postnatal course is 
needed. This should be linked with birth spacing and unplanned pregnancy as 
objective measures, as well as the acceptability of differently timed interventions.  
6.1.1 Summary 
There is some weak evidence that educational or counselling style interventions 
designed to improve uptake of postpartum contraception may result in adoption of 
more effective methods in the postpartum period, though length of follow-up in the 
literature is often short term. There is weaker evidence that such interventions lead to 
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fewer unplanned pregnancies. The literature provides little consensus about what 
postpartum women prefer.  
6.2 Justification for the methodologies 
At the time and location this research was carried out postpartum contraception 
consisted of a brief discussion with patients by the midwife discharging the patient. 
Evidence from this population indicates that contraceptive information given was 
basic, giving it was not a priority, and midwives felt ill equipped to deal with any 
discussion (McCance and Cameron, 2014). However before developing any 
intervention to alter services we wanted to assess whether any change was necessary. 
Short inter-pregnancy intervals are an independent risk factor for intrauterine growth 
restriction, preterm birth and neonatal death (Smith et al., 2003). A WHO Technical 
Consultation assessed all available evidence and determined that this risk was 
present in both resource-rich and resource-poor countries, and recommends a birth to 
pregnancy interval of two years (World Health Organisation, 2006). The first part of 
this research used maternity records to examine what percentage of women 
delivering in our maternity unit had conceived their baby within a year of a previous 
birth. We also examined records from women attending the termination of pregnancy 
service to see what percentage had conceived the pregnancy within a year of a 
previous birth. This evidence can be used to help assess the unmet need for 
contraception among this population.  
As there is a lack of evidence about what women want, we also designed a self-
administered questionnaire for our postpartum population, asking about plans for 
future pregnancies, contraceptive counselling already received, and whether they 
would take up the option of immediate LARC if available to them. This was 
distributed on maternity wards in the immediate post-partum period.  
In the context of expanding sexual healthcare beyond current service delivery 
models, the research described in this chapter seeks to examine both the need and the 
patient willingness to expand service delivery of contraception to include the 
postpartum period.  
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6.3 Postpartum contraception: a missed opportunity 
to prevent unintended pregnancy and short inter-
pregnancy intervals 
Published in full: Heller R, Cameron ST, Briggs R, Forson, N, Glasier A. 
Postpartum contraception: a missed opportunity to prevent unintended pregnancy 
and short inter-pregnancy intervals. Journal of Family Planning and Reproductive 
Health Care 2016 42(2):93-8. Published with permission of the editor and co-
authors.  
6.3.1 Introduction 
The World Health Organization (WHO) recommends that birth to pregnancy 
intervals be at least two years in order to optimise maternal and infant outcomes 
across both resource poor and resource rich countries (World Health Organisation, 
2006). Data from the United Kingdom (UK) has shown that women with intervals 
between births of less than 12 months are at increased risk of obstetric complications, 
premature birth and neonatal death, even after the potentially confounding effect of 
maternal obstetric history has been taken into account (Smith et al., 2003). It is 
therefore essential that in the postpartum period there are as few barriers as possible 
to accessing effective contraception, particularly long-acting reversible contraceptive 
(LARC) methods such as intrauterine contraception and the contraceptive implant 
since these are the most effective at preventing pregnancy (Winner et al., 2012; 
Trussell, 2011).  
Guidelines from the National Institute for Health and Care Excellence (NICE) state 
that method and timing of contraception should be discussed in the first week 
postpartum, although provide no guidance about the content of this discussion 
(National Institute for Health and Care Excellence (NICE), 2006). The Faculty of 
Sexual & Reproductive Healthcare guidelines advise that time should be found in 
both the antenatal and postnatal period to discuss all forms of contraception (Faculty 
of Sexual and Reproductive Healthcare, 2009a). However, a large Internet survey of 
UK mothers found widespread dissatisfaction with the timing and quality of 
contraceptive advice received postnatally (British Pregnancy Advisory Service, 
2012; McCance and Cameron, 2014). Although traditionally contraception is 
discussed at the six week GP visit, fertility may have returned by this time for 
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women who are not exclusively breast feeding (Jackson and Glasier, 2011). There is 
evidence that 35-57% of mothers resume intercourse within six weeks postpartum 
(Connolly et al., 2005; Murphy and British Pregnancy Advisory Service, 2014) and 
that attendance for additional visits required to insert an intrauterine method or 
implant is poor at this time (Ogburn et al., 2005). Caring for a young baby, as well as 
fatigue and adapting to a period of change may make attendance particularly 
challenging. At delivery however, the mother is already in a health care setting with 
access to trained health professionals. Provision of implants and intrauterine 
contraception from the maternity service after childbirth could be convenient for 
women as they are already in a health care setting with skilled providers available. 
Although some maternity services in the UK currently provide contraceptive 
implants for some women before discharge home (Vanthuyne et al., 2014; Smith and 
McLellan, 2014), this is not universal across UK maternity services. 
The Royal Infirmary of Edinburgh (RIE) is the main delivery unit for women in NHS 
Lothian (Edinburgh and the surrounding region), a district which had more than 9000 
births in the year ending 31st March 2013 (NHS Scotland Information Services 
Division, 2014b). In NHS Lothian in 2013, there were 2314 induced abortions (NHS 
Scotland Information Services Division, 2014a). The RIE and the Chalmers Centre 
for Sexual and Reproductive Healthcare are the main providers of abortion in NHS 
Lothian.  The aim of this study was to determine what proportion of women 
attending the abortion service had given birth in the preceding 12 months, and what 
proportion of women giving birth in NHS Lothian had given birth following a birth 
to pregnancy interval of 12 months or less. We also wished to determine views of 
postpartum mothers on future contraception and in particular on the theoretical 
acceptability of provision of intrauterine contraception and implants in the immediate 
postpartum period.  
6.3.2 Methods 
We examined the computerised database for women presenting for abortion at RIE 
and Chalmers Centre, Edinburgh between 1st September 2013 and 28th February 
2014 to determine if women had given birth in the preceding year.   All women 
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attending the abortion service have a routine ultrasound for gestational dating, and so 
we calculated the inter-pregnancy interval from the date of last childbirth to the 
estimated date of conception of the index pregnancy (abortion request). The date of 
conception was assumed to be two weeks after the last menstrual period (using the 
ultrasound gestational age). 
We used the regional maternity computer database (Trak) to identify women who 
gave birth during the same study period in the region. We then gathered further data 
on anyone with an inter-pregnancy interval of 12 months or less i.e. a previous birth 
within 21 months (we assumed a gestation of nine months for the index pregnancy 
and added 12 months for an inter-birth interval to give 21 months). This method may 
underestimate the number of inter-pregnancy intervals less than twelve months, as it 
does not take account of shorter gestations associated with preterm birth. (For 
reference, in 2012/13 the percentage of babies born under 37 weeks was 5.3%, 476 
out of a total of 9050 births (NHS Scotland Information Services Division, 2014b).) 
Demographic data collected on women from abortion and maternity cohorts included 
age, parity and deprivation scores based upon postcode area of residence. Due to the 
different ways that the services managed data, women presenting for abortion were 
assigned deprivation scores (DEPCAT) based on 2001 census data about their 
postcode at the time of presentation (Carstairs and Morris, 1991; McLoone and 
Boddy, 1994), but for maternity patients the deprivation measure assigned was the 
Scottish Index of Multiple Deprivation (SIMD) spread into population-weighted 
categories of roughly equal quintiles (The Scottish Government, 2012a; NHS 
Scotland Information Services Division, 2010). 
An anonymous self-administered survey asking women their views on postnatal 
contraception and contraceptive intentions was conducted between 3/10/13 and 
31/1/14 on postnatal wards and the Lothian Birth Centre (low risk delivery unit) in 
the RIE. Specifically, women were asked whether they would be likely to use a 
contraceptive implant or intrauterine contraception if these methods were available in 
the immediate postpartum period, before discharge from the maternity service.  
Questionnaires were distributed by a research midwife. Women who spoke little 
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English and who were without an interpreter or who had had poor pregnancy 
outcomes (e.g. still birth) were not given a questionnaire. The questionnaire 
consisted mainly of a series of simple tick box answers or a Likert scale (very likely 
to very unlikely) to indicate level of agreement with a range of statements on 
contraception. The questionnaire also provided free space for any comments women 
wished to make. Women were asked to place completed questionnaires in a closed 
box on the ward.  
The local Quality Improvement Team for obstetrics & gynaecology approved both 
projects. The scientific officer of the local ethics committee reviewed the project 
proposal and confirmed that ethical approval was not required. 
6.3.2.1 Statistics 
The questionnaires were coded and the data was entered into Microsoft Excel. 
Statistical analysis was conducted using IBM Statistical Package for Social Sciences 
(SPSS) software Version 18 (SPSS Inc. Chicago, Il, USA). Descriptive statistics 
were performed for demographics and groups were compared by Chi squared test of 
significance. Statistical significance was taken as a P value of <0.05.  
6.3.3 Results 
6.3.3.1 Women presenting for abortion within one year of childbirth 
Over the study period, 1179 women attended requesting abortion. Of these, 75 had 
given birth within the year preceding conception of this index pregnancy (6.4%). 
Considering only the parous women (n= 563) who attended the clinic, 13.3% of 
women had given birth within the year preceding the index conception. The average 
gestation at the time of presentation for abortion was 52 days. The average number 
of days between childbirth and the start of the index pregnancy as determined by 
ultrasound was 193 (just over 6 months), with a minimum of 51 days (just over 7 
weeks). The average age of women who had given birth in the previous year was 26 
(17 to 37 years).  29.3% of women (n=22) who attended for abortion within a year of 
giving birth were aged 30 or older. Table 6.1 demonstrates their demographics and 
compares them to the demographics of all women presenting to the same abortion 
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service during this period. Women who had given birth within twelve months were 
more likely to be deprived (p=0.016) and to be aged 20-34 (p=0.021).  
Table 6-1 Demographics of women attending for abortion who had given birth within 12 months of 
conception of index pregnancy compared with demographics of all women attending for abortion 
September 2013-February 2014 
  Women who 
have given 
birth within 1 
year  





Total number 75 1179 
Deprivation Category* (p=0.016) 
1-2 (affluent) 14 (18.7%) 193 (16.4%) 
3-5 (intermediate) 44 (58.7%) 820 (69.6%) 
6-7 (most deprived) 17 (22.7%) 146 (12.6%) 
Unknown 0 20 (1.7%) 
Age/ yrs (p=0.021) 
<20 8 (10.6%)  221 (18.7%) 
20-24 24 (32%) 362 (30.7%) 
25-29 21 (28%) 266 (22.6%) 
30-34 17 (22.7%) 161 (13.7%) 
35-39 5 (6.7%) 106 (9.0%) 
40 and over 0 61 (5.2%) 
Unknown 0 2 (0.2%) 
* (McLoone and Boddy, 1994) 
 
6.3.3.2 Women giving birth who previously delivered within one year of 
pregnancy 
4713 women gave birth in the region over the time period. 332 women had given 
birth within the preceding 21 months, (representing a birth to pregnancy interval of 
less than a year), representing 7.0% of the total births. When considering only the 
2393 parous women, the percentage was 13.9%. The average time between births of 
this cohort was 17 months with the shortest period being 9 and a half months 
between births (in this case the index birth was significantly preterm). 108 women 
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(4.5% of parous women) had a birth to birth interval of 15 months or less, 
representing conception within 6 months of childbirth.  
The average age of the women with a birth to pregnancy interval of 12 months or 
less was 29 years (see table 6.2).  53.6% (n=178) were aged 30 years or older. Table 
6.2 demonstrates the deprivation and ages of women in both categories. There was a 
statistically significant difference in the characteristics of women with short birth to 
pregnancy interval and the general population of women giving birth. Women who 
had given birth within 12 months of their previous birth were more likely to come 
from areas of deprivation  (P=0.002) and tended to be younger (P=0.020).  
Table 6-2 Demographics of women giving birth who had given birth within the preceding 21 
months compared with demographics of all women giving birth September 2013-February 2014 
  Women who have 
also given birth 
within 12 months  
 N = (%) 
All women giving 
birth 
 N= (%)  
 
 332 4713 
SIMD Quintile* (p=0.002)  
4-5 (affluent) 107 (32.2%) 1927 (40.9%) 
3 (intermediate) 79 (23.8%) 912 (19.4%) 
1-2 (deprived) 137 (41.3%) 1715 (36.4%) 
Unknown 9 (2.7%) 159 (3.4%) 
Age (p=0.020) 
<20 10 (3.0%) 190 (4.0%) 
20-24 61 (18.4%) 633 (13.4%) 
25-29 83 (25%) 1165 (24.7%) 
30-34 105 (31.6%) 1554 (33.0%) 
35-39 64 (19.3%) 927 (19.7%) 
40 and over 9 (2.7%) 244 (5.2%) 
* (The Scottish Government, 2012b) 
 
6.3.3.3 Questionnaires 
A total of 300 questionnaires were handed out to a total of 318 postpartum women, 
present in the maternity wards over the study period, representing a distribution rate 
of 95%. The completion rate was 83%: 250 completed.  The reasons why 18 women 
did not receive a questionnaire included inability to speak English and poor 
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pregnancy outcome. These judgments were made through discussion with the 
midwives looking after the women on the ward. Women may have also been absent 
from the ward when researchers were distributing questionnaires. 
Of those completing the questionnaires, 49% (n=121) had given birth before. The 
average age was 30, with an age range from 16 to 47.  20% of women were from 
DEPCAT categories 1-2 (affluent), 65.6% were from categories 3-5 (moderate 
deprivation) and 8% were from categories 6-7 (severely deprived). 6.4% did not 
provide their postcode.  Of the 242 women (97%) who answered the question about 
whether or not they could recall ever having a discussion antenatally with a health 
care provider about future contraception, 73 women (30 %) indicated that they had 
discussed contraception during the pregnancy. Of this group, 56 women (77%) had 
found the discussion helpful. 
237 women (96.7% of 245 women) stated that they were not planning a baby in the 
next year.  Table 3 shows which methods of contraception women intended using. 
Only 32 women (12.8%) were planning on using the contraceptive implant or 
intrauterine contraception and 27 (10.8%) were planning male or female sterilisation. 
35.2% of women (88) indicated that they did not know what contraception they 
would be using postnatally. 4% (n=10) women indicated that contraception was not 
necessary for them. The most popular method that women were planning to use was 
condoms (see table 6.3).  
 
Table 6-3 Intentions for contraceptive use 
 n= 250 (*%) 
Don’t know 88 (35.2%) 
Condoms  71 (28.4%) 
Progestogen only pill 28 (11.2%) 
Combined oral contraceptive pill 24 (9.6%) 
Progestogen only implant 16 (6.4%) 
Intrauterine contraception**   16 (6.4%) 
Progestogen only injectable 13 (5.2%) 
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Male sterilisation 14 (5.6%) 
Contraception not necessary 10 (4%) 
Female sterilisation 10 (4%) 
Lactational amenorrhoea 7 (2.8%) 
Combined contraceptive patch or ring  2 (0.8%) 
Question not answered 5 (2%) 
* Numbers add up to more than 100% as some respondents ticked 
more than one answer 
**Intrauterine contraception includes both the copper intrauterine 
device and Levonorgestrel releasing intrauterine system 
 
Of 239 women who answered the question about whether they would choose an 
intrauterine method if it could be inserted prior to leaving the hospital, 78 (32.6%) 
described themselves as “very likely” or “quite likely” to choose this. Of 241 women 
answering the same question about the likelihood of choosing the contraceptive 
implant if it could be fitted before leaving the hospital, 74 (30.7%) said they would 
be “very likely” or “quite likely” to choose this.  Combining the numbers of women 
likely to choose either intrauterine methods or implants gives a total of 107 
respondents (42.8%) who stated they would opt for one of these methods if insertion 
were available before leaving hospital. The difference in planned use of implant and 
intrauterine method and ‘theoretical’ use of the method if it was immediately 
available was statistically significantly (p<0.0001).   Only 12 women (4.8%) who 
completed questionnaires were aged 20 or under and six (50%) indicated that they 
would be very likely or quite likely to choose a contraceptive implant if available 
before discharge home.  
6.3.4 Discussion 
Almost 1 in 13 women in our population presenting for abortion or giving birth have 
conceived within a year of giving birth. Of women who already have children, over 
one in eight requesting an abortion or giving birth conceived again within one year of 
their previous birth. Yet the survey suggests that the vast majority of postnatal 
women do not plan on having another pregnancy within the next year. Does this 
suggest that we are failing to meet the contraceptive need of women postpartum? It 
may well do.  Most women had not discussed ongoing contraception during the 
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pregnancy with a health professional and most were unsure about what method they 
would use. Although one in 10 were considering intrauterine contraception or 
implants, almost one in two women indicated that they would ‘ in theory’ choose 
these methods if they could be provided before they left hospital. This interesting 
finding may reflect the convenience of this option, or the removal of important 
barriers that would otherwise deter them from choosing this method.  Immediate 
postpartum provision of these methods could therefore be an important strategy to 
prevent unintended pregnancies for women in the same way that immediate uptake 
of LARC post-abortion reduces a woman’s risk of having another abortion in the 
next two years (Cameron et al., 2012a). There is also evidence that uptake of 
contraceptive implants in the early postpartum period reduces the risk of another 
pregnancy in young women in the next 12 months (Tocce et al., 2012b; Lewis et al., 
2010).  Although there has been some concern about the impact of early initiation of 
progestogen on breastfeeding, the available evidence is consistently reassuring and 
shows no adverse effects on lactation or infant growth (Cameron, 2014). 
Women who attended for an abortion within a year of giving birth were more likely 
to be from areas of deprivation as were women who gave birth to a baby that had 
been conceived within one year of childbirth. Nevertheless, both women who gave 
birth after a short inter-pregnancy interval and those attending for an abortion were 
from a wide age range and all socio-economic groups, suggesting that all women, not 
only those from vulnerable groups (who are often the focus of targeted, contraceptive 
interventions) (Lewis et al., 2010; Wilson et al., 2011; Wilson et al., 2013; Lopez et 
al., 2012; Stevens-Simon et al., 2001) could benefit from immediate access to 
implants and intrauterine contraception postpartum.  
Although a significant proportion of women expressed a desire for immediate 
intrauterine contraception, this service is not usually available in the UK, with 
insertion usually taking place after four weeks postpartum (Faculty of Sexual and 
Reproductive Healthcare, 2009b). There is however reasonable evidence from low 
and middle-income countries that post-placental insertion of intrauterine 
contraception (within 10 minutes of placental expulsion) is safe and effective (Kapp 
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and Curtis, 2009; Grimes et al., 2010; Chen et al., 2009; Lara et al., 1989), although 
expulsion rates of between 7 and 25% have been reported (Kapp and Curtis, 2009; 
Grimes et al., 2010; Chen et al., 2009; Mwalwanda and Black, 2013). Insertion 
immediately postpartum may also be easier since the cervix is dilated. Small studies 
also show that insertion at elective caesarean section may be a particularly beneficial 
option, with low expulsion rates of 0-4% (Lara et al., 1989; Chi et al., 1986; Levi et 
al., 2012). 
A major limitation of our study is that the survey asked women about what they 
would theoretically choose: i.e. they are open to the idea in theory, but this is not the 
same as evidence of acceptability. Addressing the question of whether women would 
choose LARC immediately post-partum and whether this would result in fewer 
unintended pregnancies and fewer short inter-pregnancy intervals will need further 
research. In addition, this study is unable to determine what proportion of the 
pregnancies following a short inter-pregnancy interval was intentional. Any 
intervention to improve uptake of LARC postpartum would ideally therefore contain 
an educative component which makes clear the risks of short inter-pregnancy 
intervals, as well as providing the means to prevent them. Finally, although our 
research was conducted in one of the largest maternity services and abortion services 
in the UK, our findings cannot be assumed to reflect others throughout the UK. 
6.3.4.1 Conclusions 
This study shows that short inter-pregnancy intervals are not uncommon, However 
our survey data suggests that a significant proportion of women might be open to 
choosing one of the most effective methods of contraception (intrauterine 
contraception or the implant) in the immediate postpartum period, if this option was 
available. Provision and uptake of these methods at this time could in theory prevent 
more unintended pregnancies that currently end in abortion, miscarriage, ectopic 
pregnancies or short inter-pregnancy intervals.  This would have important health 
benefits for women, their children and their future opportunities.  Research is 
therefore necessary to progress strategies to provide LARC in the immediate 
postpartum period and to evaluate the acceptability and effectiveness of such 
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strategies. This will necessitate both training of healthcare providers in maternity 
services to counsel and provide LARC to women postpartum, and funding to provide 
this service.  
~ End of published paper ~ 
6.4 Conclusion 
The paper presented here demonstrates clearly that in our patient population there is 
both a need and a willingness to expand contraceptive care to include the postpartum 
period. Short inter-pregnancy intervals leading to both termination and birth are 
clearly present in this population, and span all maternal ages and socioeconomic 
groups, in keeping with larger data examining inter-pregnancy intervals in Scotland 
(Smith et al., 2003). However, in isolation this data is not sufficient evidence of an 
unmet need for contraception in this population. It is plausible that women either 
choose to space their pregnancies with full knowledge of the inherent risks, or would 
prefer to risk unplanned pregnancy than to receive contraception in this period.  
Our survey suggests that this is not the case, particularly given the high number of 
women who say they are not planning a pregnancy in the next year following a birth. 
This evidence is in keeping with the theory that the immediate postpartum period is a 
time when women may be particularly motivated to avoid unplanned pregnancy 
(Cameron, 2014). The number of women who say that they would be likely to 
choose insertion of LARC immediately post-partum if it was available further 
emphasises this motivation. The enthusiasm for this option points clearly towards a 
further intervention to explore, namely routinely offering LARC in the immediate 
postpartum period. One option to make LARC available to postpartum women with 
as few barriers as possible will be explored in chapter 7.  
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Chapter 7 Intrauterine contraception inserted 
at caesarean section  
7.1 Introduction  
Chapter 6 introduced the need to improve contraception delivery in the immediate 
postpartum period. One in 13 women requesting termination had conceived the 
pregnancy within one year of childbirth and one in 13 women who gave birth had 
conceived within one year of childbirth. 32.6% of women would like an intrauterine 
device inserted in the immediate postpartum period (Heller et al., 2016).  
Long acting reversible contraception (LARC) methods such as the copper 
intrauterine device (Cu-IUD) and levonorgestrel intrauterine system (LNG-IUS), and 
the subdermal implant are known to be the most effective methods of preventing 
unintended pregnancy (Winner et al., 2012; Trussell, 2011). The prevalence of use of 
intrauterine contraception (IUC) in the UK is 8-9% (Cea Soriano et al., 2014a; Lader, 
2009), and in 23.2 per 1000 women in Scotland (NHS Scotland Information Services 
Division, 2016b). Traditionally women choosing IUC postpartum may require 
several visits with a healthcare provider before insertion (Lunniss et al., 2016). Each 
visit may represent a significant barrier for women who are likely to be recovering 
from childbirth (particularly after a caesarean section) and caring for a new baby, and 
additional visits have been identified by women themselves as a reason they do not 
receive postpartum LARC after choosing it (Zerden et al., 2015). 
Inserting IUC at the time of caesarean section is not new, with studies showing 
efficacy dating back to the 1970s and 1980s (Newton et al., 1977; Ruiz-velasco et al., 
1982; Chi et al., 1984). However the practice is now gaining increasing attention 
from obstetricians and gynaecologists as a straightforward and efficient way to 
provide obstetric patients with immediate effective contraception (Blumenthal and 
Goldthwaite, 2015). In this chapter I will initially examine the evidence for the 
insertion of IUC at the time of caesarean section. I will then detail and appraise 
research conducted with our patient population in Edinburgh investigating making 




(A modified version of this chapter has been published in Acta Obstetricia et 
Gynecologica Scandinavica, under the title ‘Routine provision of intrauterine 
contraception at elective cesarean in a national public health service: a service 
evaluation.’ September 2017.) 
7.2 Literature review 
In order to examine the current evidence on this subject, a literature search was 
conducted in Medline. Search terms were intrauterine device OR intrauterine device, 
copper OR intrauterine device, medicated AND caesarean section (keyword) or 
caesarean section (exploded). The search was limited to humans and articles in 
English. 93 articles were retrieved. After review by title and abstract, 30 articles were 
found to be relevant, including 6 reviews of the literature, 4 of which were from the 
last five years. References of these four reviews were also examined for papers but 
no additional literature was found. Papers were included if they were research, or 
reviews of research, about the insertion of intrauterine contraception at the time of 
caesarean section.  
Studies from the 1980s and 1990s showed that insertion at caesarean section was 
safe and associated with low complication rates (Liu et al., 1983; Chi et al., 1984; 
Chi et al., 1986; Zhou and Chi, 1991; Xu et al., 1992). These studies investigated 
devices used in China that were intended to be permanent, so their utility with regard 
to modern devices used in the United Kingdom is limited. Celen et al undertook an 
observational study in Turkey in 2004, inserting copper IUDs in 235 women within 
ten minutes of placental expulsion. 26% of these were in women who had a 
caesarean section; total number was not given but would have been 61-2. Expulsion 
rate was 12.3% by twelve months (total data), and continuation rate was 76.3% at six 
months, with a follow up rate of 78% (Celen et al., 2004). A much smaller 
observational study was undertaken in 2005 in South Africa, looking at the Mirena® 
LNG-IUS (levonorgestrel-releasing intra-uterine system) inserted at caesarean 
section in 33 women. Information was not given on expulsion or removal rates but 
20 patients still had a device in situ at six months (Puzey, 2005). In 2007 Celen’s 
team in Turkey undertook further research, examining 245 women who had copper 
  
 121
IUDs inserted at caesarean section within ten minutes of placental removal. There 
was one case of unplanned pregnancy (0.4%), and the cumulative expulsion rate at 
six months was 17.6%. Continuation rates at six months were 62% (Celen et al., 
2011). 
A study of 1317 women who had a copper IUD inserted after delivery of the placenta 
after either vaginal delivery or at caesarean section was undertaken by Shukla et al in 
India. 653 had insertion during caesarean section. The cumulative expulsion rate was 
10.1%, but the paper does not differentiate between expulsion rate for vaginal and 
caesarean deliveries, and this is based on a follow up rate of only 11.2%. 
Continuation rates at six months are also not given, and it is therefore difficult to 
draw conclusions about long or even medium term effects from this study, despite 
large numbers (Shukla and Qureshi, 2012). Follow up was more successful in a pilot 
study undertaken with 90 patients in Chapel Hill, USA, each of whom had a copper 
IUD inserted at the time of caesarean section. 47% of women were successfully 
contacted at six months by telephone, when no expulsions or removal were reported. 
However 26% of women who returned for follow up and had no visible threads did 
not return for their ultrasound to confirm location: expulsion cannot be ruled out 
among this patient population (Levi et al., 2012).   
Extensive follow up was carried out by Elsedeek et al on 143 women who had either 
a copper IUD (n=63) or an LNG-IUS (n=80) during caesarean section. Women were 
seen weekly for six weeks, monthly for a year and then every three months, an 
ultrasound was performed at every visit and women answered a questionnaire. No 
expulsions were seen over five years in the LNG-IUS group, and four in the IUD 
group (6.3%). Removal rates were very low: 7.9% (n=5) in the IUD group and 3.8% 
(n=3) in the LNG-IUS group. Total continuation rates are not given. The ultrasounds 
performed gives useful data that is not available from other studies. After placement 
during caesarean delivery, in 65% of women (using both copper IUD and LNG-IUS) 
the device appeared to be abnormally placed on ultrasound performed at six weeks. 
A copper IUD was more likely to ‘self-correct’, but the efficacy of an LNG-IUS 
device did not appear to be affected by its position within the uterus – this is to be 
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expected given that its method of action does not work primarily by its mechanics, 
but by its hormonal effect (Faculty of Sexual and Reproductive Healthcare, 2015b). 
Unusually, in this study a failure rate of 6.3% (n=4) was seen in the IUD group 
(Elsedeek, 2015). 
Dias et al performed ultrasounds on 91 postpartum patients in Sri Lanka, 31 of whom 
had had a post-placental IUD insertion at caesarean section. Ultrasounds were 
performed prior to hospital discharge and at six weeks following delivery. Measuring 
the distance between the lower end of the IUD and the internal os on ultrasound at 
discharge was found to be moderately accurate in predicting IUD retention, but 
expulsion rates in this study (22.4% after vaginal delivery and 25.8% after caesarean 
section) were higher than rates quoted in other studies. This study also found that 
mode of delivery had no impact on IUD retention (Dias et al., 2015). The fact that 
mode of delivery did not influence the expulsion rate of the IUD was also noted by 
Sucak et al in Turkey. They compared expulsion rates for 51 women who underwent 
an elective caesarean, 47 women who underwent a caesarean during active labour, 
and 62 women who had a vaginal delivery. There was no significant difference in 
either expulsion rates at six weeks, or cumulative expulsion rates at 12 months 
follow up (Sucak et al., 2015). This study is of particular interest, as there is little 
literature examining women who have undergone a caesarean during active labour.  
A further study on a subset of Elsedeek’s population looks specifically at bleeding in 
the puerperium between 80 controls (no device inserted at caesarean), 75 women 
who had a copper IUD inserted at caesarean and 65 women who had an LNG-IUS 
inserted at caesarean. Women who had an LNG-IUS inserted had a significantly 
shorter and lighter puerperium compared to the other two groups (20.2±7.7 days), 
and women with a copper IUD had heavier menstrual periods once menses returned 
compared to the control group, but this difference was not significant (Elsedeek, 
2012). 
A case controlled study in Pakistan examined three groups of women: 50 who had a 
copper IUD inserted at caesarean section, 50 who had a caesarean without an IUD, 
and 50 who had an IUD inserted 3 months following a vaginal delivery or abortion. 
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There was no significance difference in length of hospital stay or heavy lochia 
between the two caesarean groups, and no difference in willingness to continue with 
IUD at one week, six weeks or six months between the caesarean and interval 
insertion groups (Bhutta et al., 2011).  
An RCT (randomised controlled trial) produces the highest level of evidence to 
compare two different options for patients.  There have been five RCTs randomising 
women to insertion at the time of caesarean section versus insertion six to eight 
weeks later. In 2014 Whitaker et al in Chicago, USA randomised 42 women to 
receive an LNG-IUS at the time of caesarean section or four to eight weeks later. Use 
of the LNG-IUS was higher in the group who had it inserted during caesarean section 
(60% vs. 41%), but not significantly so. Expulsion was significantly more common 
in these women (20% vs. 0%).  The number needed in each group to assess a 
significant difference in LNG-IUS continuation rates was calculated to be 46, but the 
trial was stopped early due to lack of recruitment (Whitaker et al., 2014). Lester et al 
conducted a small RCT in Uganda with 68 women undergoing caesarean delivery, 
34 receiving an IUD during their caesarean and 34 receiving it six weeks afterwards. 
The primary outcome was use of the IUD at six months post-delivery, and use in the 
caesarean insertion group was 79% versus 47% in the delayed insertion group, a 
difference that was statistically significant. Of note, only approximately 53% (n=18) 
of women in the delayed insertion group received an IUD (Lester et al., 2015). 
As a development of their earlier pilot in 2012 (Levi et al., 2012), Levi et al 
conducted an RCT in New York, USA, randomising 112 women to insertion of an 
IUD at the time of caesarean or six or more weeks later. Follow up at six months 
showed continuing use of IUD by 83% of women randomised to insertion during 
caesarean compared to 64% of women randomised to insertion six or more weeks 
later, with a 95% confidence interval of 1.02 – 1.66. Satisfaction was also high in 
both groups (92% and 100% respectively) (Levi et al., 2015). A small RCT in 
Australia examining just the LNG-IUS randomised 48 women to LNG-IUS (n=23) 
insertion at the time of caesarean versus six weeks postpartum (n=23). This study 
took satisfaction rates as its primary endpoint, and noted no significant difference in 
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satisfaction rates between the two groups at six weeks, three months or six months. 
Four women in the interval insertion group withdrew prior to receiving an LNG-IUS 
but, in contrast to Lester et al, the remaining 82% of women in the delayed cohort 
attended for a six week visit (Braniff et al., 2015). Each of the RCTs mentioned uses 
small numbers only, and follows women up for a relatively short amount of time – 
six months or a year. As the WHO recommends a birth-to-pregnancy interval of two 
years (World Health Organisation, 2006) follow up of this length is therefore 
inadequate to determine whether post-caesarean insertion of IUC leads to successful 
birth spacing. Numbers in RCTs are also small, perhaps due to the difficulties of 
recruitment described in Whitaker et al. (Whitaker et al., 2014). 
There is a very small amount of literature looking at modifying techniques or devices 
to improve patient outcomes with insertion of IUC at caesarean section. A small pilot 
in Los Angeles, USA looked at tying additional suture material to strings of the 
copper IUD in just seven women, in at attempt to ensure the threads were always 
visible for removal. All women involved had threads visible at the os after six weeks 
(Nelson et al., 2009). 
A number of systematic reviews have assessed the insertion of intrauterine 
contraception in the immediate postpartum period, though none have focused 
specifically on provision at caesarean section. A Cochrane review is recognised as 
being one of the most rigorous assessments of literature on a medical subject. In 
2015 a Cochrane review examined intrauterine devices in the postpartum period, 
investigating insertion after all types of delivery, using only RCTs. This was an 
update of a previous Cochrane review on the same subject (Grimes et al., 2010). Of 
trials that have a full report of data available, the ones used by the Cochrane review 
are the ones mentioned in this chapter ((Whitaker et al., 2014; Lester et al., 2015; 
Levi et al., 2015)), other than Braniff et al, which was published after the literature 
search for the review had concluded. The authors of the review found that evidence 
was limited due to small sample sizes and limited reporting – particularly in older 
studies. However, the conclusion was that the benefit of providing effective 
contraception immediately after delivery may outweigh the disadvantages, namely 
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increased expulsion risk (Lopez et al., 2015). As expulsion risk appears to only be 
increased after a vaginal delivery, and not a caesarean section (Lopez et al., 2015; 
Sucak et al., 2015), this Cochrane review presents an especially compelling case for 
insertion of intrauterine contraception at the time of caesarean section.  
The most recent evaluation, by Goldthwaite and Shaw in 2015, concludes that the 
use of highly effective contraception immediately postpartum protects against short 
inter-pregnancy intervals and unintended pregnancy. They highlight the fact that 
women in the delayed insertion arm of studies often fail to receive effective 
contraception, and are therefore ultimately less likely to use effective methods 
(Goldthwaite and Shaw, 2015). Similar conclusions have been reached by other 
systematic literature reviews (Sonalkar and Kapp, 2015; Mwalwanda and Black, 
2013; Kapp and Curtis, 2009), and this body of evidence is reflected in the recent 
UK guidelines about contraception after pregnancy (Faculty of Sexual and 
Reproductive Healthcare, 2017).  
7.2.1 Summary 
There is good evidence that insertion of IUC at caesarean is safe, convenient and 
acceptable, and has high continuation rates. However, this data comes mainly from 
low-income countries and the United States. There is no data from the UK or from 
Europe. With a caesarean section rate of 30% in the UK in 2014/5, there is the 
potential to offer IUC at caesarean to a significant proportion of women. We 
therefore decided to conduct research with our own patient population, offering 
insertion of IUC at caesarean section.  
7.3 Justification for the methodology 
Although there have been relatively few, the evidence from RCTs, the highest level 
of scientific evidence, is that women who have intrauterine contraception inserted in 
the immediate postpartum period, including at caesarean section, are more likely to 
be using it six to 12 months later. This has been the conclusion of two Cochrane 
reviews and multiple other reviews of the literature. We therefore decided not to 
instigate a randomised controlled trial in our clinical setting, particularly given 
documented difficulties of recruitment (Whitaker et al., 2014). Instead we chose to 
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examine the practicality and feasibility of making insertion of IUC at caesarean 
section routine practice in a non-fee paying healthcare system. In systems where 
contraception is available only for a charge, availability of free devices within a 
research setting can alter the findings of who chooses a device and who attends for 
follow-up. The devices in the study by Levi et al were paid for by TEVA, a 
pharmaceutical company, and this may have influenced women’s choice of device 
(Levi et al., 2015). In the United Kingdom all contraception is available free of 
charge.  
Research conducted with our population outlined in chapter 6 demonstrates both the 
short inter-pregnancy intervals present and a willingness among postpartum women 
to consider immediate postpartum contraception (Heller et al., 2016). By routinely 
offering IUC at the time of caesarean section we were able to gather data on how 
many women took up this offer, knowing that the only determinant of their choice 
was timing. In addition by collecting data on routine procedure we were able to 
examine barriers to instigating this practice as part of a real-life healthcare setting.  
NHS Lothian began a series of pilot initiatives in 2013 to improve the uptake of 
postpartum contraception. This involved the introduction of antenatal contraceptive 
counselling by midwives and provision of contraception to women living in one area 
of the region from the maternity service after delivery (Cameron et al., 2017). As 
part of this initiative this study aimed to investigate the feasibility of routinely 
offering all women within this region who were undergoing an elective caesarean 
section the opportunity to have IUC insertion at this time, and to assess uptake, 
complications, continuation rates and acceptability. 
7.4 Methods 
7.4.1 Training materials 
A training package and video were developed that included the technique of insertion 
of IUC at caesarean section, medical eligibility criteria for contraceptive use (Faculty 
of Sexual and Reproductive Healthcare, 2016), contraindications to IUC postpartum, 
and what post-procedure counselling with women should include. We also produced 
checklists that obstetricians could use for counselling women about IUC, detailing 
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the risks, benefits and possible side effects and written information for women about 
what to expect after IUC insertion and what follow-up was necessary. All of these 
materials were presented to consultants and obstetric trainees working at the two 
maternity hospitals in the region (approximately 35 doctors). Consultants underwent 
one individual training session and registrars observed the video as part of their 
ongoing training. Ongoing peer-supervision in theatre was encouraged and adopted 
until all staff were trained, this took approximately four months. Obstetricians were 
instructed that following delivery of placenta the IUC should be removed from its 
inserter and placed at the fundus through the uterine incision. They were instructed to 
use artery forceps to guide the threads of the device towards the cervix, and through 
the cervix if possible.  Threads of the device were not cut. The uterus, sheath and 
skin were then sutured as per the obstetrician’s normal practice. In addition, training 
on contraception and information about IUC insertion at caesarean was also provided 
to hospital midwives.  
From the 22nd June 2015, information about all types of postpartum contraception 
was included with routine information sent to women scheduled for an elective 
caesarean section three to four weeks before their scheduled caesarean date. They 
also received a letter explaining that if they wished to use an IUC postnatally they 
might be able to have it inserted during their caesarean section. Women were invited 
to discuss this option with their obstetrician in advance of delivery. This was in 
addition to the routine antenatal contraceptive counselling that some women in the 
region at that time received with a midwife at 22 weeks (Cameron et al., 2017). The 
telephone numbers of the evaluation team were included so that women could 
contact the team if they had any unanswered questions about IUC at caesarean. 
When women were consented for their delivery on the day of caesarean section those 
who had made the prior decision to have IUC also gave written consent for insertion 
of IUC.  
Following delivery all women who had elective caesareans were routinely reviewed 
by obstetricians. Both obstetric and midwifery staff provided verbal and written 
information about the device that was inserted and what to expect in coming weeks. 
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All women who had IUC fitted were identified by the evaluation team using 
electronic maternity records (TRAK). These women were contacted and offered a six 
week IUC thread check at their local hospital or sexual health centre with the 
evaluation team, consisting of myself and a research nurse. At this visit women had 
the opportunity to ask any further questions about IUC. They underwent a speculum 
to look for the threads of the IUC and trim them if necessary. If no threads were 
seen, an ultrasound scan was conducted to ensure the device was in situ. A partial 
expulsion was diagnosed if the stem of the device was seen on clinical speculum 
examination or if an ultrasound scan revealed the device to be in the cervical canal. 
Women were also asked how satisfied they were with having IUC inserted at the 
time of caesarean. Women were then contacted by phone or text at three, six and 12 
months to determine continuation rates, and satisfaction with IUC as a method of 
contraception. Our primary outcome measures were uptake of IUC and 
complications by six weeks. Secondary outcomes were continuation and satisfaction 
with IUC at 12 months.  
In addition to the information gathered at follow-up, the regional hospital database 
was reviewed for each woman in order to ensure that data on any complications was 
accurate. For all women who were lost to follow up both the regional hospital 
database and the local sexual health database were examined, to gain any further 
information about the presence or removal of IUC, and any further pregnancies. 
Sample size was not determined on an a priori hypothesis. Data continues to be 
collected and I report here data from those women who have completed 12 months 
follow up.   
The local Quality Improvement Teams for women’s services and sexual and 
reproductive health approved the project. The scientific officer of the local ethics 
committee reviewed the project proposal and confirmed that ethical approval was not 
required as this was a health service evaluation project. 
7.4.2 Analysis 




During the time period (13th July 2015 to 2nd March 2016) 877 women were 
scheduled for caesarean section, and were sent information about having IUC 
inserted at delivery. 120 women chose this option (13.7%). Demographics of women 
who chose IUC are detailed in table 7-1.  
Table 7-1 Demographics of women who chose IUC 
Age median (range) 33 (21-41) years 
BMI (body mass index) at 
booking: median (range) 
26.25 (17.0 – 49.7) 
kg/m2 
Parity 
0 9     (7.5%) 
1 80   (66.6%) 
2 26   (21.6%) 
3 2      (1.7%) 
4 2      (1.7%) 
4+ 1      (0.8%) 
SIMD (Scottish index of maternal deprivation) (The 
Scottish Government, 2012a) 
SMID 5 (affluent) 33   (27.5%) 
4 22   (18.3%) 
3 20   (16.6%) 
2 24    (20.0%) 
1 (deprived) 21    (17.5%) 
 
114 devices were inserted at the time of caesarean, 100 LNG-IUS and 14 Cu-IUD. 
Two women changed their minds and four devices could not be inserted due to 
postpartum haemorrhage. All of the latter four women attended the local sexual 
health service for subsequent insertion of IUC  (n=3) or insertion of a subdermal 
contraceptive implant. (n=1). 103 women attended for a six week follow up 
appointment, and a further nine were contacted at this time by phone. The percentage 




Figure 7-1 Percentage of women with information available at follow up 
 
7.5.1 Outcomes and complications 
Outcomes of IUC insertion are detailed in figure 7-2. 100/114 women who had IUC 
inserted at caesarean (88.5%) attended for a follow up check at six weeks. A further 
three women who had not had a device inserted came for insertion at six weeks. 14 
women attended earlier than six weeks due to noticing long threads or threads 





























and the device was removed and a new IUC replaced. All others had the threads 
trimmed to 2cm from the os.  
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There were ten expulsions, seven by six weeks following insertion, one at seven 
weeks, one at 14 weeks and one at 28 weeks. This includes five partial expulsions 
(the stem of the device was seen in the cervical canal). All complete expulsions were 
noticed by women except in one case (details below). Of the ten expulsions, six 
women were fitted with a replacement IUC. In four cases, IUCs were removed 
accidentally by women. Two happened before women were seen for their six week 
thread check, when their threads had not been trimmed. Two others were pulled out 
with tampons. One woman had her device replaced.  
There was one case of endometritis diagnosed at the six week check (pain plus E. 
coli infection confirmed on high vaginal swab). This was treated with oral antibiotics 
and the device was left in situ. Another device was removed at two days post 
insertion due to an initial suspicion of endometritis, but microbiological investigation 
was negative, and the woman was subsequently diagnosed with pyelonephritis. (A 
further device was inserted eight months later.) 
Of complications that occurred, complications that had occurred by six weeks 
included six expulsions (three partial and one complete), two accidental removals 
and one case of endometritis. There were three removals before six weeks, one for 
suspected infection and two at patient request.  
Of 97 women who attended believing they had an IUC in situ, threads were visible in 
49 cases (50%). Ultrasound confirmed intra-uterine placement in all but two women 
with missing threads. One woman was noted to have an intra cervical device, this 
was removed and alternative contraception started; this is counted in our data as a 
partial expulsion. Another woman had no device seen on ultrasound. Unfortunately 
despite multiple efforts she did not attend for abdominal x-ray. She did attend clinic 
six months after insertion with an unplanned pregnancy for a termination. Six 
women did not attend the six week thread check but were followed up by telephone 
and either reported that they could feel threads or had attended their GP (general 
practitioner) for a confirmation that the IUC threads were visible.  Of four women 
that could not have an IUC inserted at caesarean, three of them attended for IUC 
insertion at six weeks.  
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7.5.2 Continuation and satisfaction rates 
Continuation rates are detailed in table 7.2. Percentages are detailed both from the 
total number of devices planned, using intention to treat and assuming that everyone 
lost to follow up is no longer using IUC for contraception, and as a percentage of 
number of women contacted. At 12 months 93 women were contactable, and 
information about a further six was gained from clinical databases, making a follow 
up rate of 82.5%. As a proportion of all 117 women who got the device fitted either 
at caesarean (n=114) or afterwards (n=3), 71.8% were known to have a device in situ 
at 12 months (n=84) 
 
Table 7-2 Continued use of intrauterine contraception 











Number of women 
contacted/information 
available 
120 112 109 105 99 
Using IUC 114 111* 96 91 84** 
Continuation rates as 
percentage of those 
with known status 
95% 99% 88% 87% 85% 
Continuation rates as 
percentage of 120 
planned insertions 
95% 91% 80% 76% 70% 
*114 devices inserted at caesarean, 3 removals, 7 expulsions, 4 replacements, 
3 new insertions 
**72 still in situ, 6 expulsions replaced, 2 removals replaced, 1 accidental 
removal replaced, 3 new insertions 
 
There have been 15 removals out of 117 devices inserted (12.8%). 14 removals were 
of devices inserted at caesarean, one of a device inserted ten weeks postpartum.  
Removals have been from two days after insertion to 27 weeks, all were LNG-IUS 
devices. Reasons for removal included disliking bleeding patterns (n=5), headache 
(n=1), disliking a foreign body in the uterus (n=1),) recurrent thrush (n=1), pain 
during intercourse (n=1), postpartum haemorrhage (n=1), not liking the method 
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(n=1), believing the method affected milk production (n=1) and wanting to conceive 
again (n=1, 10 months in situ). One removal was due to placement concerns. An 
ultrasonographer reported the IUC to be embedded in the myometrium, but it was 
removed easily and replaced. One woman whose device was removed due to an 
infection concern had IUC subsequently replaced. All removals were straightforward 
outpatient procedures, including in three cases where threads were not visible. Of 
note, one woman who chose to have her LNG-IUS removed and commenced a less 
effective method (the combined hormonal contraceptive patch) had an unintended 
pregnancy two months later.   
After one year, 82 women still using the device were asked about their satisfaction 
with the device. 92.7% of them were ‘very’ or ‘fairly’ happy with the IUC (n=76). 
Further satisfaction rates are detailed in table 7.3.  
Table 7-3 Satisfaction rates 
Satisfaction with insertion taking place at the time of caesarean section (n=114) 
(asked at 6 week follow up) 
Number of women asked  98 
Very happy 74 (76%) 
Fairly happy  21(21%) 
Neither/nor 3 (3%) 
Fairly unhappy 0 
Very unhappy 0 
Satisfaction with intrauterine contraception device 









Number of women with IUC 
in situ 
111* 96 91 84 
Number of women asked 
(=n) 
99  92 89 82 
Very happy 42 (42%) 67 (72%) 61 (69%) 64 (78%) 
Fairly happy 43 (43%) 21 (23%) 22 (25%) 12 (15%) 
Neither/nor 14 (14%) 4 (4%) 4 (4%) 5 (6%) 
Fairly unhappy 0 0 0 1 (1%) 
Very unhappy 0 0 2 (2%) 1 (1%) 
*Including those who had had a device expelled or removed, and reinserted 





7.6.1 Main findings 
Routinely offering insertion of IUC at the time of elective caesarean section was 
popular amongst women, with just over one in seven women choosing this option, 
the majority opting for an LNG-IUS. In addition, the study confirmed the low 
complication rate associated with insertion of IUC at this time and an expulsion rate 
in keeping with that of insertion of IUC in women who are not postpartum (Faculty 
of Sexual and Reproductive Healthcare, 2015b). Furthermore, satisfaction rates 
amongst women with IUC insertion at caesarean were high, and satisfaction and 
continuation with the method remained high by twelve months post insertion. 
7.6.2 Strengths and Limitations 
To our knowledge this is the first study from Western Europe to evaluate insertion of 
IUC at the time of elective caesarean section, routinely offered in a public health 
setting. Our loss to follow up was low, and reviewing regional databases minimised 
the risk of missing any serious complications associated with IUC insertion. In 
addition there is little existing data in the literature regarding women’s acceptability 
of IUC insertion at this time. It is a significant strength of our research that we 
examined routine insertion of IUC in a setting where all contraception is free. A 
number of other studies have made IUC free for the purposes of research, in a setting 
where it would normally be an extra cost for patients. However in this NHS 
population, cost is not an incentive to choice of contraceptive method, so removing 
the barrier of attending a clinic at a later date in the postpartum period may have a 
proportionately greater impact on women’s choice of IUC at caesarean.  
This was an evaluation of a new service and so the findings are likely to represent 
uptake of IUC in similar public maternity settings. Our study is limited though, by 
the fact that this service evaluation relates to a single region. The percentage of 
women choosing IUC and the satisfaction rates may differ in other populations. We 
have limited data on removals, as only a small number of women have had their 
device removed. It is however reassuring that removal was straightforward in those 
women who requested it. 
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7.6.3 Discussion of results 
As has been argued elsewhere, the main advantage of insertion of IUC at caesarean 
section is the advantage it confers for uptake and continuity (Blumenthal and 
Goldthwaite, 2015).  In addition the procedure is convenient both for women and 
health services, and avoids a potentially more difficult vaginal insertion (in some 
cases through a cervical os that has never dilated) weeks later. This is particularly 
relevant given the evidence that the risk of uterine perforation is increased in the first 
36 weeks postpartum, with breastfeeding at time of insertion associated with a 
sixfold increased risk (Heinemann et al., 2015). The number of women choosing 
IUC as postpartum contraception was considerably higher than was previously found 
in a similar maternity population, when insertion at caesarean section was not 
routinely available (Heller et al., 2016).  
Expulsion rates in our study were low, and when it did occur it was recognized in all 
but one case, and most women chose to have another device inserted. A potential 
challenge with IUC insertion at caesarean is that a significant proportion of women 
will not have visible threads at six weeks. In our study this was half of all cases. This 
indicates that an important component of making insertion of IUC at caesarean 
routine practice is a system ensuring rapid access to ultrasound scans to confirm that 
the IUC is in situ. This could be either at a hospital or clinic or by direct referral to 
sexual health centers that have ultrasound capabilities. A small number of women in 
our study presented with very long threads, but trimming the threads can be easily 
managed by any healthcare practitioner who is competent to conduct a cervical 
smear.  
Insertion of IUC at caesarean section is a relatively straightforward procedure. 
Obstetricians are skilled operators and insertion of the IUC at caesarean is not 
complicated. Indeed it is less complicated than female sterilisation at the time of 
caesarean, and could in fact be offered to women as an alternative to this practice, 
particularly as sterilisation is a permanent procedure. Training of obstetricians was 
straightforward and required a small number of dedicated trainers only (the 
evaluation team). Training for midwives to ensure a basic knowledge about IUC and 
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dispel any myths was also required, although some of this could be delivered online 
or in video format rather than face to face teaching sessions (Cameron et al., 2017).   
Robust processes need to be in place in order for appropriate follow up post IUC 
insertion to succeed and so close working partnerships between maternity, sexual 
health services and GPs are important to make routine insertion of IUC at caesarean 
achievable and successful.  
7.7 Conclusion 
Chapter 6 set out the unmet need for contraception among the postpartum 
population, as shown by short inter-pregnancy intervals. Questionnaires conducted 
with patients suggest that these short intervals were not by choice, and the same 
questionnaires captured the openness of patients to considering immediate 
postpartum contraception. Chapter 7 outlines a practical, straightforward and viable 
approach to improving postpartum contraception for patients.  
As demonstrated by the literature review in 7.2, there is robust evidence that 
insertion of IUC at caesarean section is safe and carries a low complication rate. 
Randomised controlled trials demonstrate that continuation rates of IUC at six 
months are significantly higher in women randomised to insertion at the time of 
caesarean section (Lester et al., 2015; Levi et al., 2015; Braniff et al., 2015). Most 
RCTs are not powered to detect a difference in unplanned pregnancy rates or short 
inter-pregnancy intervals, however continuation rates of the most effective methods 
of contraception (Trussell, 2011) can act as a reasonable proxy for pregnancy rates in 
the absence of other data. Our complication rate was consistent with the existing 
evidence base, as was our continuation rate.  
Set against the evidential background, our research aimed to investigate the 
feasibility of offering and delivering this service in a public health system, as well as 
its acceptability to patients. Over a period of six months, approximately one in seven 
women undergoing a caesarean section chose the option of IUC insertion. This was a 
new service, and it may be that this number rises as word and use of the service 
spreads.  Already the popularity demonstrates the feasibility and acceptability of this 
service to patients, as does the high continuity and low withdrawal rates seen in this 
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research. As immediate postpartum contraception also marks a culture change, it 
would also be useful to conduct some qualitative research, both with patients and 
staff, to gain a richer understanding of how participants feel about this change. In 
addition, we would like to continue to follow patients up for as long as five years, to 
capture information on their pregnancy spacing and on removals of devices inserted 
at caesarean. Longer-term information is currently scarce about this practice. Both 
aspects are possible areas for future research.  
7.7.1 Summary 
Routine provision of IUC at caesarean section is feasible with a simple training 
package for maternity staff. It is both safe, with low complication rates, and highly 
acceptable to women, with good uptake and good continuation rates. Any increase in 
LARC in the postpartum setting has the potential to prevent unintended pregnancy 
and enable women to achieve healthy inter-pregnancy intervals. This option should 





Chapter 8 Conclusions, Clinical Implications 
and Directions for Future Research  
8.1 Introduction 
This chapter will examine the research contained in this thesis in the context of 
expanding sexual healthcare provision. The successes and challenges of different 
aspects of research will be considered. 
8.2 Expanding contraception uptake to prevent 
unplanned pregnancy 
In Chapter 1 I introduced the idea of preventing unplanned pregnancy through 
avoiding one of three antecedents: non-use of contraception, incorrect or inconsistent 
use of contraception and contraceptive failure. This thesis describes research to 
address the first two of these precursors. Chapters 4 and 5 describe our pilot project 
examining users of the contraceptive injection receiving their injection from 
pharmacy. Although this does not in itself increase uptake, the survey described in 
chapter 3 suggests that if this was a feasible option, current non-users of 
contraception and users of less effective methods than the injection might be 
interested in this service (Heller et al., 2016). By increasing the convenience of the 
injection, both non-users and users of methods where inconsistent use is more likely 
(condoms and oral contraceptive pills) might be more likely to use this effective 
method. However, the pathway that is explored in chapters 4 and 5 of this thesis did 
not prove to be a feasible option for patients. The high level of withdrawals and the 
number of participants that chose to continue to visit the clinic even with the option 
of pharmacy attendance suggests that this was not an attractive option for many 
people. 
As discussed in chapters 6 and 7, provision of contraception at childbirth is an ideal 
time to offer postpartum women, who may be unsure about what contraceptive 
methods they can use, (Murphy and British Pregnancy Advisory Service, 2014) the 
most effective methods. Since the start of my research fellowship, a great deal more 
evidence has been published supporting this idea. Research consistently 




form of the most effective LARC methods, is acceptable to women, straightforward 
for clinicians, and cost-effective. Notably, receiving LARC post-pregnancy leads to 
longer inter-pregnancy intervals (Harney et al., 2017). Women are much more likely 
to receive LARC if they are offered it in the immediate postpartum period, whether 
that means an IUD at the time of delivery (Lester et al., 2015; Levi et al., 2015; 
Foreit et al., 1993), or a contraceptive implant inserted immediately postpartum 
(Tocce et al., 2012b). The publication of a Best Practice Paper in Postpartum Family 
Planning by the Royal College of Obstetricians in 2015 (Royal College of 
Obstetricians and Gynaecologists, 2015), and the guidance on Contraception after 
Pregnancy from the Faculty of Sexual and Reproductive Health in 2017 (Faculty of 
Sexual and Reproductive Healthcare, 2017) are beginning to alter the landscape of 
postpartum contraception significantly.  
It is easy to identify why immediate postpartum contraception has gained increasing 
attention not only from clinicians but also from government and legislators (The 
Scottish Government, 2015; Kramer, 2017). What evidence there is shows that 
postpartum women in the United Kingdom lack information about postpartum 
fertility and when to start a contraceptive method (Murphy and British Pregnancy 
Advisory Service, 2014). Prior to the new guidelines neither postpartum midwives 
(McCance and Cameron, 2014) nor GPs at the postpartum check (Lunniss et al., 
2016) prioritised contraceptive advice. As a result postpartum women may end up 
being non-users of contraception, and at high risk of unplanned pregnancy. An 
intervention at the time of delivery offers the opportunity for women to receive any 
contraceptive method. Interval postpartum insertion (four to six weeks after birth) of 
intrauterine contraception in particular may require additional visits (Lunniss et al., 
2016), which are a reason women do not receive IUC (Zerden et al., 2015). All 
LARC methods require insertion by someone who has been trained, a fact that can 
sometimes be a barrier to improving uptake (Kavanaugh et al., 2013).  However 
maternity staff are likely to have many of the requisite basic skills such as pelvic 
examination and familiarity with inserting devices such as scalp electrodes through 
the cervix. Fostering interest and inclination in maternity HCPs to undertake some 
brief additional training would enable women to be provided with all methods, 




Healthcare, 2017). In this way fertile women who might be non-users, or users of 
less effective methods, can have access to the methods with the least risk of incorrect 
or inconsistent use, and therefore the best chance at avoiding unplanned pregnancy.  
Chapter 6 showed that when asked only a small number of women were planning on 
using LARC in the postpartum period. However a much greater number were open to 
immediate insertion, with almost one in three saying that they would use intrauterine 
contraception if it could be fitted immediately (Heller et al., 2016). Most women 
questioned were planning on using condoms or pills, in keeping with the popular 
methods in the United Kingdom (Cea Soriano et al., 2014a; Lader, 2009). However, 
among modern contraceptive methods, these methods are most likely to be 
associated with unplanned pregnancy, due to their higher risk of inconsistent and/or 
imperfect use (Jones et al., 2002; Rasch, 2002).  Increasing postpartum uptake of 
LARC would therefore also address the problem of unplanned pregnancy by 
reducing pregnancies associated with inconsistent and imperfect use of 
contraception. Chapter 7 demonstrates the feasibility and acceptability of a 
straightforward way to offer LARC at delivery for women delivering by caesarean 
section.  
8.3 The crucial nature of convenience 
In my research examining the feasibility of participants receiving the contraceptive 
injection at the community pharmacy, participants’ comments emphasise difficulties 
of access. Barriers to attending the pharmacy included lack of information when 
contacting the pharmacy and limited availability of the pharmacist trained to provide 
the service.  Those patients who did comment positively on the pharmacy all 
mentioned convenience and ease as being a significant part of why the experience 
was a good one, with comments such as “easy and positive experience”, “flexible 
with times” and “so much more convenient than visiting the nurse”. Chapter 3 
outlines a questionnaire conducted in the sexual health clinic, which demonstrates 
the anticipation that pharmacy attendance would be more convenient, with better 





What patients were looking for was a more convenient experience, where obtaining 
contraception fitted seamlessly into their daily lives. The extra work involved in 
contacting the pharmacy more than once and negotiating appointments during 
limited opening hours clearly impacted upon participants, and it seems likely that 
this is partly responsible for the high numbers of participants who left the study. The 
importance of convenience is echoed in the literature asking women about 
advantages of pharmacy access. In a survey of 811 American women about 
pharmacy access to contraception, 85% believed they would benefit from convenient 
hours of pharmacies, 84% from convenient locations, 82% from saved time, and 
74% from the absence of the need for a clinician appointment (Landau et al., 2006).  
In a survey of 651 American women seeking abortion services, 514 expressed 
support for over-the-counter access to contraception. The most commonly cited 
reason was convenience, given as a reason by 76% (Grindlay et al., 2014). Focus 
groups with young women and women of colour, again in the United States, 
emphasise once more that convenience is the most important perceived advantage of 
over-the-counter access, with one participant stating that to get hormonal 
contraception from a pharmacy would make it “almost as convenient as a condom” 
(Baum et al., 2016). 
For some participants in the research described in chapters 4 and 5, the experience of 
making an appointment with the pharmacist with limited availability did not come 
close to the experience of buying condoms from a pharmacy, and therefore their 
involvement fell short of offering the advantages of convenience both anticipated by 
participants and in the literature. The contraceptive injection does not feature 
prominently in research looking at method failure leading to unplanned pregnancy 
(Schünmann and Glasier, 2006; Rasch, 2002; Jones et al., 2002). However this is 
likely to be because of its relative unpopularity rather than its efficacy, in 2008 it was 
the method for just 2.4% of contraceptive users (Cea Soriano et al., 2014a). It is 
clearly evident that if patients are unable to attend their injection provider in a timely 
fashion, they will be at risk of unplanned pregnancy.  
Rather than replicating a current contraceptive service delivery method in the 




effective to concentrate on over-the-counter access for contraception. The evidence 
for this is detailed in Chapter 2, however there is very little evidence assessing the 
acceptability of this idea among a UK public. In addition, over-the-counter access is 
likely to be available only for short-acting methods like the pill, the patch, and 
possibly the vaginal ring (though this last method is not popular in the UK) (Lader, 
2009). All of the existing literature about the acceptability of contraception OTC 
focuses on the pill, patch and ring, which is unsurprising as both the contraceptive 
implant and intrauterine contraception need trained providers to insert. Making less 
effective methods available at pharmacy might therefore work to reduce the uptake 
of LARC, as women may attend pharmacies as their primary place to receive 
contraception. OTC access to contraception would need to be accompanied by close 
partnership links between pharmacy and sexual health clinics, and pharmacists must 
be aware of comparative effectiveness rates of LARC methods. The research 
described in Clement and Mansour, where pharmacists received intensive education 
about all emergency contraception options including the copper IUD, and a rapid 
access referral pathway was established for pharmacists, is an ideal model to 
consider here (Clement and Mansour, 2014). 
Self-administration of the contraceptive injection clearly offers the most convenient 
way for patients to access this particular method, and it is to be welcomed that the 
SC-DMPA used in our study is now licensed for self-injection (Faculty of Sexual 
and Reproductive Healthcare, 2015a). The available evidence is that self-
administration is feasible and straightforward for patients, with high satisfaction 
rates, although of note no study has to date shown that it improves continuation rates 
compared to receiving an injection by a healthcare professional (Prabhakaran and 
Sweet, 2012; Cameron et al., 2012b; Beasley et al., 2014; Cover et al., 2017). 
Offering patients insertion of intrauterine contraception at the time of caesarean 
section presented them with a clear advantage in terms of convenience. Evidence 
shows that women who want a LARC method fitted in the weeks after giving birth 
may need to attend two visits with a healthcare practitioner, in addition to the routine 
six-week check, in order to get intrauterine contraception fitted (Lunniss et al., 




as 50% (Ogburn et al., 2005), and women identify extra visits as a barrier to 
insertion, even when they have decided that they would like to use a LARC method 
(Zerden et al., 2015). By contrast, almost all the women in the study described in 
Chapter 7 did attend for the check of their IUC inserted at caesarean section, 
suggesting that women may prioritise a check up for an existing method of 
contraception differently to a visit to start a new method.  
RCTs looking at insertion of IUC at caesarean section demonstrate that women who 
are randomised to receive IUC at the time of caesarean are more likely to receive it 
than those who are randomised to receive it at a follow up visit (Lester et al., 2015; 
Levi et al., 2015; Braniff et al., 2015). Unsurprisingly, a recent analysis of women 
who plan to use LARC after delivery has demonstrated that those who do not receive 
LARC are more likely to have short inter-pregnancy intervals (Harney et al., 2017). 
In addition a very large cohort study of 61,448 women in six European countries 
examining IUC insertion found that both breastfeeding at the time of insertion and an 
interval of ≤36 weeks since last delivery were independently associated with an 
increased risk of uterine perforation (Heinemann et al., 2015). There are no 
documented perforations when IUC is inserted at caesarean section. Immediate 
postpartum IUC may therefore not only be more convenient, it may carry fewer 
risks.  
The high continuation and satisfaction rates described in chapter 7 lend weight to the 
idea that opportunistic delivery of contraception at the time of childbirth works 
equally as well as the well-documented opportunistic delivery of contraception at the 
time of termination of pregnancy (Goodman et al., 2008; Rose and Lawton, 2012; 
Cameron et al., 2012a; Church et al., 2010; Royal College of Obstetricians and 
Gynaecologists, 2011). Although these areas have traditionally been viewed 
differently for contraception provision, with the advent of new guidelines that 
comprehensively address delivery of contraception after pregnancy, whether the 
outcome of the pregnancy is childbirth, abortion, miscarriage or ectopic pregnancy, 
the medical norms around contraception are beginning to change (Faculty of Sexual 




8.4 Ideas for future research 
The new guidelines on contraception delivery after pregnancy identify all 
pregnancies as a time to discuss contraception, regardless of outcome.  This includes 
miscarriage and ectopic pregnancy. Evidence from Scotland shows the percentage of 
unintended pregnancies was almost the same for women at the miscarriage clinic as 
at the antenatal clinic (11.9% versus 7.7% respectively) (Lakha and Glasier, 2006). 
Data from the Natsal-3 survey in 2010-2012 demonstrates that of women whose 
pregnancy ended in miscarriage, 35.3% were planned pregnancies, 31.1% were 
ambivalent and 33.6% were unplanned pregnancies (Wellings et al., 2013). These 
figures would suggest that women experiencing miscarriage are at an equal if not 
higher risk of the pregnancy being unintended as women having a live birth. They 
are therefore a cohort in whom opportunistic contraception would be appropriate.  
Although some clinicians might assume that after a miscarriage women would want 
to become pregnant again quickly, there is no data about how many women go on to 
have an unplanned pregnancy that then ends in abortion after a miscarriage. Given 
the high number of unplanned pregnancies ending in miscarriage the number is likely 
to be substantial. These could be avoided if effective contraception was started after 
miscarriage for those women who wanted it. However there is essentially no 
literature about the feasibility, acceptability or effectiveness of offering women 
contraception at the time of miscarriage (Faculty of Sexual and Reproductive 
Healthcare, 2017). This is a rich area for further research, both qualitative and 
quantitative. Qualitative research with midwives in maternity care revealed that some 
felt their poor knowledge of contraception was a barrier to contraceptive discussions 
(McCance and Cameron, 2014). Similar research could be usefully conducted in 
miscarriage services, to identify perceived barriers and opportunities, as well as with 
women who have experienced miscarriage, in order to identify ways to bring up 
contraception at a sensitive time. 
The period after an ectopic pregnancy may be perceived as an easier time to 
introduce the idea of contraception to women, as the clinical advice is to delay 
pregnancy for three months (Faculty of Sexual and Reproductive Healthcare, 2017). 




after ectopic pregnancy in order to avoid future unplanned pregnancies, and therefore 
a similar opportunity to learn more. 
There is evidence that insertion of IUC after a vaginal birth offers many of the 
advantages of convenience, time saving, cost-effectiveness and attractiveness to 
patients as insertion of IUC at caesarean section, even taking into account that the 
expulsion rate is higher (Chen et al., 2009; Kapp and Curtis, 2009; Chen et al., 2010; 
Mwalwanda and Black, 2013; Lopez et al., 2015; Washington et al., 2015; 
Goldthwaite and Shaw, 2015; Eggebroten et al., 2017). To date there has been no 
research with a UK patient population examining this practice, although an 
observational study is now beginning in Edinburgh (Wellbeing of Women, 2016). 
An RCT examining this practice, large enough to detect a difference in unplanned 
pregnancy rates or short inter-pregnancy intervals, would give the highest level of 
evidence about this exciting possibility.  
One of the reasons that participants withdrew from our research investigating 
contraceptive injections at the community pharmacy was that they preferred self-
injection. To date there has been one RCT examining self-injection of DMPA 
compared to clinic use, with 86 women randomised to self-injection and 46 to clinic 
administration. There was no significant difference in continuation rates at the end of 
one year (p=0.47) (Beasley et al., 2014).  The study was not powered to investigate 
pregnancy rates. The percentage of women experiencing an unintended pregnancy in 
the first year of using Depo-Provera® is 6% with typical use (Trussell, 2011). This 
rate might be lower in women who are self-injecting and are therefore at less risk of 
missing injections. Any RCT powered for a difference in unplanned pregnancy rates 
would therefore have to be very large. However a larger trial could more robustly 
confirm or refute any significant difference in continuation rates. The existing RCT 
(Beasley et al., 2014) also took place in the United States, so repeating this trial in 
the United Kingdom would be a useful way to determine whether UK women 
respond differently to the availability of self-injection. A recent systematic review 
found only this RCT, a pilot cohort study from Scotland and a prospective cohort 
study examining a combined injection of DMPA and estradiol.  It concludes that 




either clinic or self-administration (Kim et al., 2017). More research, looking at 
ideally unplanned pregnancy, but if not then at continuation rates and patient 
satisfaction would be a very useful addition to the literature. Self-administration is 
likely to be resource saving for the National Health Service and therefore any 
research would benefit from a cost-effectiveness analysis too.  
8.5 Final thoughts 
Novel service models can offer patients improved access contraception. Those which 
present the most straightforward and convenient ways of delivery are the most likely 
to be successful in enabling patients to either begin contraception, or to begin using a 
method with less risk of imperfect use. The post-pregnancy period is gaining 
momentum both globally and in the United Kingdom as an ideal time to offer 
contraception, and LARC methods have the best evidence for preventing unplanned 
pregnancy and increasing inter-pregnancy intervals.  
Before any new service models are adopted and funded a rigorous examination of the 
literature will enable targeted and well-designed research trials to investigate service 
delivery. Definitive research should then be conducted, ideally using RCTs, although 
this is not always practical in the field of contraception. Similarly endpoints of 
unplanned pregnancy rates, whilst providing the most useful data, may be difficult 
when examining what is still a rare event. Nonetheless, rigorous research is our best 
approach to understanding how to best deliver contraception. Improved uptake of the 
most effective contraceptive methods offers the best chance at avoiding unplanned 
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Appendix 1: Questionnaires administered in 
research described in this thesis 
1. Questionnaire administered to patients in Chapter 3: Depo at the pharmacy 
2. Questionnaire administered to patients exiting the project described in 
Chapter 5: Exit Questionnaire  





Depo-provera contraception at the pharmacy 
 
Depo-provera (‘the jag’) is a kind of contraception that is given every 3 months by an 
injection. At the moment this injection is into the muscle, and needs to be given by a 
doctor or nurse, which means visiting a clinic or your GP every 3 months. We now 
have a new kind of the jag which is an injection just under the skin, and this is the 
kind of injection a pharmacist can give.  
 
We are doing a survey to find out what women think about this. Your answers are 
completely confidential and nobody in the clinic will know what you have ticked. We 
would be very grateful if you could take 5 minutes to fill in this quick questionnaire. 
Thank you.   
 
 
1. What contraception are you using at the moment? 
¨ Combined pill   ¨ Diaphragm 
¨ Progesterone only pill  ¨ Withdrawal 
¨ Condoms   ¨ IUD/IUS (coil/Mirena) 
¨ Not using any     
¨ Nexplanon (contraceptive implant/the rod) 
¨ Natural family planning/timing your cycle 
¨ Trying for a pregnancy 
¨ Contraception not necessary for me 
¨ I am currently using the depo injection (please go to question 7) 
 
2. Have you ever used the 3 monthly depo injection? 








4. Have you ever considered 
using the depo injection? 
¨ Yes (go to question 5) 
¨ No (go to question 6) 
3. What was your reason for 
stopping it? (Please tick all 
that apply) 
 
¨ Having to see a doctor or nurse 
every 3 months 
¨ Painful injection 
¨ Weight gain 
¨ Acne 
¨ Periods stopping 
¨ Irregular bleeding 
¨ Mood swings 
¨ Headaches 
¨ Wanting to get pregnant 
¨ Wanting something longer 
acting 
¨ Wanted a hormone free method 
¨ Other (please let us know) 
____________________ 
(Please go to question 6) 
 
5. What was your reason for 
deciding not to use it? 
¨ Having to see a doctor or 
nurse every 3 months 
¨ Fear of needles/injections 
¨ Worry about weight gain 
¨ Worry about bone health 
¨ Don’t want a method 
where your periods stop 
¨ Delay in return to fertility 
¨ Prefer something longer 
acting 
¨ Other people put me off 
¨ Other (please let us know) 
____________________ 
(Please go to question 6) 
_ 
6. If you are NOT using depo, would you consider using it if you 
could get an injection under your skin given at your local 
pharmacy? 
Yes (go to question 9)  ¨  No (go to question 10)    ¨  
 
7. If you are a current user of the depo jag, how long have you been 
using it? 
 
o I am getting my first injection today 
o Less than a year 
o 1 to 3 years 
o More than 3 years 
 
8. If you are a current user of the depo jag, would you be interested 
in getting a jag under the skin at the pharmacy? 
 




















Thank you very much for filling in this questionnaire. Please hand it 
back to the receptionists. We are very grateful for your help with our 
research. 
10. Why would this not be a good 
option for you? (Please tick 
as many as you like) 
 
¨ Prefer to see a nurse or 
doctor every 12 weeks 
¨ Better opening hours here 
¨ Easier to get here 
¨ Prefer an injection into the 
muscle to under the skin 
¨ Would never consider using 
depo 
¨ Want a hormone free method 
¨ Other (please let us know) 
9. Why would this be a good 
option for you? (Please tick as 
many as you like) 
 
¨ Better opening hours at 
pharmacy 
¨ Easier to get there 
¨ Closer to my house 
¨ Quicker appointment 
¨ Prefer an injection under the skin 
to into the muscle 
¨ Other (please let us know)  
 
Exit questionnaire 
Version 1 6/6/14 
Thank you for participating in our research into women receiving their contraceptive 
injection at the pharmacy. We would be grateful if you could answer some questions 
now the project is over. 
Name:________________________________________________ 
 
Why are you completing this exit questionnaire? 
o The project is finished 
o I left the project early 
 
How many times did you attend the pharmacist for your contraceptive injection? 
o 1  o 3 
o 2 
 
What did you find to be the benefits of attending the pharmacy? (Tick all that apply) 
o Better opening hours 
o Nearer to me 
o Easier to get to a pharmacy 
o Flexibility of attending different pharmacists 
o Shorter waiting time 
o Quicker appointment 
o Can do other things at the same time in the pharmacy 
o Don’t think there will be any real benefit 
o Other (please say) 
 
 
And if you had to pick one as being the best thing about it, what was it? (Pick just one) 
o Better opening hours 
o Nearer to me 
o Easier to get to a pharmacy 
o Flexibility of attending different pharmacists 
o Shorter waiting time 
o Quicker appointment 
o Could do other things at the same time in the pharmacy 
o Don’t think there was any real benefit 
o Other (please say) 
 
 
What was the worst thing about attending the pharmacy? 
o Wasn’t able to discuss any problems I had with the method 
o Feel more comfortable seeing a nurse or doctor than a pharmacist 
o Wasn’t able to discuss other medical problems 
o Better opening hours at doctors/sexual health clinic 
o Doctors/sexual health clinic is nearer to me 
o Easier to get to GP/clinic 
o There was a longer waiting time at the pharmacy 
o There was a longer appointment at the pharmacy 
o Can do other things at the same time in the sexual health clinic  
o No downside to attending the pharmacy 
o Other (please say) 
 
 
If you had to pick one thing that was the worst, what would it be? (Pick just one) 
o Wasn’t able to discuss any problems I had with the method 
o Feel more comfortable seeing a nurse or doctor than a pharmacist 
o Wasn’t able to discuss other medical problems 
Exit questionnaire 
Version 1 6/6/14 
o Better opening hours at doctors/sexual health clinic 
o Doctors/sexual health clinic is nearer to me 
o Easier to get to GP/clinic 
o There was a longer waiting time at the pharmacy 
o There was a longer appointment at the pharmacy 
o Can do other things at the same time in the sexual health clinic  
o No downside to attending the pharmacy 
o Other (please say) 
 
If you left the project early without getting all 3 injections at the pharmacy, please can 
you tell us why? 
 
Can you tell us anything else that you think we should know about what being in this 
research project was like? We will keep everything you say confidential from the 
pharmacy team. 
  

































































r	 Very	likely	 	 r	 Quite	likely	 	 r	 Neither/nor	
r	 Quite	unlikely	 	 r	 Very	unlikely	
(b)	If	you	could	choose	to	have	the	implant	inserted	into	your	arm	before	you	go	home	how	likely	would	
you	be	to	choose	this	(please	tick	box	next	to	statement	that	corresponds	most	to	how	you	feel)	
r	 Very	likely	 	 r	 Quite	likely	 	 r	 Neither/nor	
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The feasibility of contraceptive injections at the community pharmacy
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ABSTRACT
Purpose: The progestogen-only intramuscular injectable Depo-ProveraVR (depot medroxyprogester-
one acetate) is an effective contraceptive method, but users need to attend a clinic every 12–13
weeks for a repeat injection from a doctor/nurse. This limits convenience of the method and may
affect continuation rates. We conducted a pilot study to examine the feasibility and acceptability of
users receiving the subcutaneous form of the contraception injection from pharmacists in the com-
munity pharmacy setting.
Materials and methods: Existing users of Depo-ProveraVR , who wished to switch to the subcutane-
ous preparation with the same active ingredient (Sayana PressVR ) were invited to attend 1 of 11
community pharmacies for up to three repeat injections, given by a pharmacist. Evaluation con-
sisted of (i) self-administered questionnaires of women and (ii) interviews with participating phar-
macists, at study exit on their respective experiences.
Results: Global unavailability of the product during the study adversely affected recruitment and
retention. 50 women were recruited. Only 48 injections were delivered at the pharmacy out of a
possible 150 (34%). About 26 participants received no injections at the pharmacy and only seven
(14%) participants received all three injections at the pharmacy. Participants reported mixed experi-
ences, with some welcoming the intervention but others experiencing difficulty with pharmacist
availability. Pharmacists were enthusiastic about this expansion of their role, and did not view their
availability as a barrier to service delivery.
Conclusions: Delivery of the subcutaneous contraceptive injectable from a community pharmacy
may be feasible but availability of sufficient numbers of pharmacists trained in this technique is
necessary for a robust model of service delivery.
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Community pharmacists are located within patients’ com-
munities, of particular relevance for those living in areas of
deprivation or rural settings [1]. In the interest of improving
access to health care and also cost savings, there has been
increasing attention on the ability of the community phar-
macy to deliver health care, and sexual health care has
been a particular focus [2,3]. One possible area of sexual
health care that community pharmacists could become
involved in is the delivery of contraception. Two small stud-
ies in the United States have demonstrated the feasibility
of community pharmacists administering the subcutaneous
contraceptive injection [4,5]. However, the feasibility and
acceptability of this approach in a UK setting has not been
addressed, crucially in a setting where all contraception
and health care delivery is free.
The contraceptive injection is a reliable method of
contraception, when users are able to receive regular doses
in a timely fashion [6]. The methods available for use in the
United Kingdom are both depot medroxyprogesterone
acetate in the intra-muscular version (150mg DMPA-IM
given every 12 weeks, Depo-ProveraVR ) and the more
recently licensed subcutaneous version (104mg DMPA-SC
given every 13 weeks, Sayana PressVR ). The subcutaneous
version was developed to be as straightforward to adminis-
ter as possible, with a view to self-administration, but at
the time this project was conceived both versions of inject-
able contraception were only licensed for administration by
health care professionals in the United Kingdom.
Despite its popularity, discontinuation rates of the injec-
tion are reported to be as high as 42.3% at 12 months
[7,8]. Although the primary reason women give for discon-
tinuation is side effects [9,10], the inconvenience of having
to attend a clinic regularly may be a contributory factor.
Due to the regular visits needed, compared to other LARC
(long acting reversible contraception) methods which last
for years after insertion (three years for the subdermal
implant and 5 or 10 years for intrauterine methods) or
short-acting methods where patients may be provided with
one year’s supply at a single visit [11], using the contracep-
tive injection entails more visits to a clinician than any
other method. Research within a specialised contraceptive
service in Scotland indicated that the option to receive
injections from a community pharmacy might improve
uptake of this method. In a survey of women attending the
contraceptive service, 31% of those respondents who iden-
tified as non-users of the injectable indicated that
they would be potentially interested in using this method
if they could receive injections from the community
pharmacy [12].
We therefore conducted a pilot study in Edinburgh,
Scotland to examine the feasibility and acceptability of
CONTACT Rebecca Heller rebecca.heller@ed.ac.uk Trainee in Community Sexual & Reproductive Health, Chalmers Centre, 2A Chalmers Street,
Edinburgh, EH3 9ES, Edinburgh, UK
 2017 The European Society of Contraception and Reproductive Health







































users of the contraceptive injectable receiving repeat sub-
cutaneous injections of DMPA-SC from pharmacists in the
community pharmacy setting.
Methods
Selection and description of participants
A total of 11 pharmacies throughout Edinburgh and the
surrounding area were identified as suitable for participa-
tion, based on a number of factors, including: established
links with the research team, a high proportion of contra-
ceptive injectable users in close proximity to the pharmacy
and convenient location of pharmacy such as a shopping
centre. Pharmacists underwent training in emergency resus-
citation and anaphylaxis, as well as training in giving sub-
cutaneous injections, with supervised injections on
simulated models until they felt competent. All pharmacists
were provided with a DVD demonstrating the injection
technique to watch before each injection. A patient group
direction, which is a document allowing certain health care
professionals to administer medications to specific groups
without a prescription, was created to be used in this
research.
Women were recruited from a large integrated sexual
and reproductive health service in the centre of Edinburgh,
and from peripheral clinics staffed by this centre. All
women who attended who were aged 16–45 and had been
using the contraceptive injection for at least six months
were given information about the study and offered
participation.
Technical information
Women wanting to participate received their first DMPA-SC
injection with the research team at a clinic. Participants
were asked to contact their chosen participating pharmacist
one week before their next injection was due to arrange an
appointment to receive this. If women encountered difficul-
ties getting a pharmacist appointment they could contact
the research team and attend the clinic.
Upon completion of each injection, sent information to
the research team and a payment of £20 per injection plus
the cost of one Sayana PressVR injection (£6.90) was paid to
the pharmacy for participation in the research.
Participants were followed up by phone call or text mes-
sage after their injection was due. Data was collected about
any problems encountered, and whether they were happy
to attend a pharmacy for their next injection. After one
year of injections comprising an initial injection at clinic fol-
lowed by three injections at the pharmacy, participants
were invited to attend the research team for their fifth
injection and to complete a questionnaire about their
experience. This was also offered to any withdrawing par-
ticipants who had received at least one injection at a phar-
macy. The questionnaire asked about the disadvantages
and advantages of attending the community pharmacy,
and contained free text boxes for participants to discuss
their experience.
Each participating pharmacist was invited to participate
in a recorded, semi-structured interview. Interviews were
recorded, transcribed and analysed. Pharmacists discussed
barriers to delivering the service, and their perspective of
the role of the pharmacist in sexual and reproductive
health care.
Approximately three months after recruitment of the
first participant, and after recruitment of participant num-
ber 25, Sayana PressVR , the only brand of subcutaneous
contraceptive injectable, became globally unavailable, a
shortage lasting five months. The impact will be examined
in the discussion.
Pharmacists were approached in July 2014 and recruit-
ment began 1 October 2014. The last patient was recruited
in March 2016 and the final injection was given in
November 2016.
Ethical approval was granted by the National Research
Ethics Service Committee East Midlands – Leicester 01 on
15th July 2014 (REC reference 14/EM/1058).
Results
Demographics
About 78 women were approached for study participation
and 50 were recruited, with an age range of 17-48.
Demographics and reproductive history of participants are
shown in Table 1.
Participant flow
Twenty-six participants (52%) received no injections at the
pharmacy, for a variety of reasons (see Table 2). Forty-eight
injections were received at a pharmacy out of a possible
150. Figure 1 demonstrates where participants received
their injections. A total of 26 participants (54%) chose not
to continue with the study after one or two injections.
Three participants were lost to follow-up over the course of
the study.
Continuation and satisfaction
During the period DMPA-SC was unavailable 17 participants
withdrew from the research. At the end of the project there
were 21 participants remaining; seven received all three
injections at the pharmacy, eight received two injections at
Table 1. Demographics of participants
Age median (range) 28 (17–48) years







Previous termination of pregnancy (TOP)
0 40 (80%)
1 10 (20%)
SIMD (Scottish index of maternal deprivation) [13]




1 (deprived) 3 (6%)













































the pharmacy, two had received one, and four participants
stayed in the project but did not manage to receive any
injections at the pharmacy. Of the 50 women recruited, 24
received at least one injection at a community pharmacy.
Seven received one injection, 10 received two injections
and seven received three injections. 22 women completed
an exit questionnaire. This was 44% of participants, 92% of
those who had experienced the intervention. Results are
detailed in Tables 3 and 4. Details from the free text com-
ments reflect participants’ mixed experiences.
Some participants found the service excellent, and
thought it should be available as a routine service. 11 par-
ticipants had nothing but positive comments.
Very easy and positive experience! Pharmacist great (32-year-
old, six months using depo, three injections at pharmacy)
Some women had a more difficult experience, with
problems focusing on a few themes. Seven women com-
mented that when they phoned the pharmacy to make an
appointment, staff who answered the phone did not know
about the service and were unsure how to advise them.
This difficulty was reported by women using larger, chain
pharmacists, and was more marked at the beginning of the
project, but continued throughout the research.
Participants found this frustrating and inconvenient, and
most women who commented on this did not receive all
three injections at the pharmacy.
Three women also expressed concerns about the abil-
ity of the pharmacist to give the drug. They commented
on the anxiety of the pharmacist, and their apparent lack
of familiarity with the injection. This anxiety was men-
tioned by pharmacists themselves in interviews. One
woman said ‘I have had the injection many many times
before, so the above didn’t phase me too much, as I
know what to do and what to expect already.’ This was
a participant in whom the pharmacist attempted the
injection four times. She explicitly states that the reason
she did not receive three injections at the pharmacy was
not because of this.
A high number of participants also commented on the
challenge of attending when a trained pharmacist was
working. This was more evident in chain pharmacies, where
a trained provider might only be available a few days a
week.
Working with community pharmacies
There was a considerable variety in the popularity of phar-
macies and the number of injections each pharmacy gave.
This was due in part to the movement of pharmacists.
Some left the project and were replaced with pharmacists
who wanted to continue participating, but others were not
replaced. This movement is detailed in Table 5.
Table 2. Timings and reasons for patient withdrawals.
Withdrew before first injection at pharmacy due (n¼ 3)
Left area 1
Changed contraceptive method 1
Unacceptable side effects DMPA-SC 1
Withdrew after first injection at pharmacy due/given (n¼ 19)
First injection received at pharmacy (n¼ 4) First injection received at clinic (n¼ 15)
Left area 0 0
Prefer to attend clinic 1 6
Discontinued contraceptive injection 1 2
Outwith protocol due to age 0 2
Unacceptable side effects with DMPA-SC 0 4
Prefer self-injection 2 1
Withdrew after second injection at pharmacy due/given (n¼ 4)
Second injection received at pharmacy (n¼ 1) Second injection received at clinic (n¼ 3)
Prefer to attend clinic 0 1
Discontinued contraceptive injection 1 1
Unacceptable side effects with DMPA-SC 0 1
Figure 1. Outcomes and withdrawals.






































Table 3. advantages of attending community pharmacy.
What did you find to be the benefits of attending the pharmacy? (Respondents could tick as many as they
wished)
22 questionnaires completed
Better opening hours 10
Nearer to me 13
Easier to get to a pharmacy 15
Flexibility of attending different pharmacists 6
Shorter waiting time 11
Quicker appointment 14
Can do other things at the same time 7
Other (write in space):
Not registered with a GP so very helpful 1
What one thing was the best thing about attending the pharmacy? (Respondents asked to select one but three
selected more than one) (n¼ 22)
Better opening hours 5
Nearer to me 4
Easier to get to a pharmacy 5
Flexibility of attending different pharmacies 2
Shorter waiting time 2
Quicker appointment 5
Could do other things at the same time 2
Table 4. Disadvantages of attending the community pharmacy.
What was the worst thing about attending the pharmacy? (Patients could tick as many as they wished)
22 questionnaires completed
Wasn’t able to discuss problems I had with the method 1
Feel more comfortable seeing a nurse or doctor 1
Wasn’t able to discuss other medical problems 1
Better opening hours at doctors/sexual health clinic 1
Doctors/sexual health clinic is nearer to me 1
Easier to get to GP/sexual health clinic 1
Longer waiting time at the pharmacy 2
Longer appointment at the pharmacy 1
Can do other things at the same time in the sexual health clinic 1
No downside to attending the pharmacy 10
Other: the pharmacist wasn’t there every day 1
Other: I thought the opening hours would be better 1
Other: the injection was painful 2
If you had to select one thing that was the worst thing about attending the pharmacy what would it be?
(Respondents asked to select one) (n¼ 22)
Wasn’t able to discuss problems I had with the method 1
Feel more comfortable seeing a nurse or doctor 2
Wasn’t able to discuss other medical problems 2
Better opening hours at doctors/sexual health clinic 1
Doctors/sexual health clinic is nearer to me 1
Easier to get to GP/sexual health clinic 1
Longer waiting time at the pharmacy 1
Longer appointment at the pharmacy 0
Can do other things at the same time in the sexual health clinic 1
No downside to attending the pharmacy 9
Other: the injection was painful 1
Table 5. Pharmacy activity.
Number of patients seen Number of injections given Length of participation Number of pharmacists trained
Independent pharmacies
Pharmacy 1 6 9 Throughout 2
Pharmacy 2 2 4 Throughout 2
Pharmacy 3 0 0 Throughout 4




Pharmacy 5 1 1 Pharmacist left after giving
one injection
1
Pharmacy 6 0 0 One pharmacist left six months
in, another pharmacist was
trained
2




Pharmacy 8 7 13 Throughout 1
Large chain
Pharmacy 9 2 3 Throughout 1
Pharmacy 10 8 14 Throughout 2
Pharmacy 11 1 2 Pharmacist left after 1 year 1
Pharmacy 12 2 2 Throughout 1a
aThe pharmacist from pharmacy 11 delivered no injections, the trained pharmacist from pharmacy 12 delivered the injections at pharmacy 11.







































Interviews were conducted with pharmacists from all but
two pharmacies. Pharmacists ranged in experience from
just over three years to over 30 years. All pharmacists felt
that providing contraceptive services in the pharmacy was
a way to improve access for women, as they were conveni-
ently located for people, with better opening hours and
quicker appointments than general practitioners or sexual
health clinics. They saw themselves as a ‘first port of call’
and indicated that their contribution to public health care
enabled ‘freeing up’ of doctors. There was a view that pro-
viding contraception from the pharmacy would result in GP
availability ‘to actually deal with emergencies’, which would
help the health care system, which all pharmacists per-
ceived as being under severe pressure.
Most pharmacists did not perceive the movement of
pharmacists or maintaining the service during holiday leave
to be a problem. Although they did acknowledge that if
they weren’t available for a prolonged period: ‘you’re going
to have to find somewhere else so it’s not going to work
that way’, generally, even when questioned specifically,
they felt that neither movement of pharmacists or pharma-
cist absence would interrupt the service delivery and would
not prove difficult for participants in the research.
Generally pharmacists were enthusiastic and willing to
expand their role. About half of pharmacists interviewed
were wholly pleased to develop the ability to administer
the contraceptive injection. Some chain pharmacists felt
they were not given a choice about role expansion, with
pressure from managers to constantly develop new skills so
the pharmacy could increase services offered. ‘We don’t
have a choice really.’ All chain pharmacists agreed that
more managerial support would be necessary to enable
long-term delivery of this service.
A factor that the research team had not anticipated was
the anxiety which pharmacists felt about delivering the
contraceptive injection. Pharmacists stated that this was
because administration involved ‘breaking the skin’.
However, the fact that they were giving contraception also
meant the stakes were very high. The importance of contra-
ception to women meant it was crucial to get it right.
Pharmacists felt that the pharmacy was an appropriate
place for women to receive contraceptive services and
advice. For some pharmacists the fact that the research
centred around contraception had been part of the appeal.
Through their delivery of emergency hormonal contracep-
tion pharmacists were aware of the unmet need for contra-
ception and wanted to help meet it: ‘I just think there’s so
much more we could do.’
Discussion
Findings and interpretation
As the high number of withdrawals and some patient com-
ments indicate, this research met a number of challenges.
The primary one was the global unavailability of Sayana
PressVR . During this unavailability all patients who had
already been recruited were unable to attend the pharmacy
for one injection, and some for two injections. Instead they
were seen by the research team, and given DMPA-IM.
During this time a significant amount of good will was lost
with patients. Many that had anticipated attending the
community pharmacy but were not able to, withdrew from
the project. We cannot say whether the reason that these
17 patients withdrew was definitely the unavailability of
Sayana PressVR . The questionnaire asking participants about
reasons for withdrawals was designed and approved by the
board of ethics before the study commenced, and the pos-
sibility of withdrawing due to unavailability of the contra-
ceptive was not anticipated. The majority of patients who
withdrew during this time period cited preferring to attend
clinic as the reason for their withdrawal. They declined the
option of being notified when Sayana PressVR was back in
stock so that they could continue to receive injections at
the pharmacy once this option was available to them.
However it seems likely that this difficulty made the experi-
ence less attractive to participants.
In addition, a number discontinued due to side effects.
This is a common reason to discontinue all contraception,
including the contraceptive injection [7]. In addition, in
September 2015 Sayana PressVR was licensed in the UK for
self-injection [14]. The centre from where recruitment took
place began offering this service in July of 2016. Three par-
ticipants withdrew to learn self-injection rather than con-
tinue attending the pharmacy.
Working with community pharmacies presented other
challenges. Some pharmacists working for commercial
chains took months to be able to deliver the contraceptive
injection. This was not the case for any independent phar-
macists. Pharmacies did not have any protocols or proce-
dures for practice in the context of research, and all
pharmacists except one were new to clinical research. Each
commercial chain had forms that needed to be signed by
differing levels of management to enable pharmacists to
use the patient group direction. In addition pharmacists
involved had a number of pressures that inevitably
impacted the resources available for them to spend on this
research, particularly as they were not given any extra time
or financial compensation. The time taken for each pharma-
cist to receive full approval from each level of management
delayed progress and consequently a number of partici-
pants that anticipated receiving their injection at a chain
pharmacy needed to attend a clinic instead. This break in
anticipated service delivery may be another explanation for
the high withdrawal rate seen. This frustration was reflected
in the participant comments, and may be a further explan-
ation for the high withdrawal rate seen.
A further unexpected challenge was the number of
times that trained pharmacists were moved to different
pharmacies. The participating pharmacist might only be
working at the relevant pharmacy one or two days a week.
As a consequence, a number of patients ended up contact-
ing the research team to ask for a clinic appointment, as
they were anxious about not receiving their injection in
time, and putting themselves at risk of unplanned
pregnancy.
The number of people working in each pharmacy meant
that the full staff was not always aware that the service
was being offered, or potentially offered. Participants
attempting to make their appointment were informed on
more than one occasion that this service was not offered.
This was discouraging and generated some discontent, as
is demonstrated in the participant comments. Attempts to
rectify this were made by repeated site visits by






































investigators, but a high degree of staff turnover meant
that many staff remained unaware of their pharmacy’s par-
ticipation. When asked, pharmacists involved felt confident
that all staff in the pharmacy were aware of the service,
and declined further visits or meetings, but this picture did
not match patient’s comments. Dissemination of informa-
tion is a challenge in large pharmacy chains and is an
important aspect of the feasibility of the research being
expanded. It is likely that the uncertainty was a conse-
quence of this being a small research project rather than a
service offered generally, but demonstrates the difficulty of
bringing about service change, particularly within large
pharmacies employing many pharmacists.
Strengths and weaknesses of the study
A strength of this study is that very limited research has
been carried out into patients receiving contraception
injections at the community pharmacy. Those that do have
concentrated on using a single pharmacy, or involved
many but found that by far the majority of injections were
given at a very small number of pharmacies [4,5,15]. Our
results replicate this finding, as the majority of participants
also attended three pharmacies in the study.
The weaknesses of the study are the small sample size
and the high number of withdrawals. Withdrawals were for
a number of reasons but the global unavailability of the
injection being used was almost certainly a contributory
factor. The training and the way the research was set-up
did not adequately cover the amount of pharmacist move-
ment within the study. These aspects could be minimised
in further studies.
Differences in results and conclusions in relation to
other studies
Little has been published on this subject. Picardo et al.
conducted the only randomised controlled trial, where 50
women were randomised to receive contraceptive injec-
tions either at their clinic or at a nearby pharmacy.
Women were less likely to return to the pharmacy than
the clinic for both their second and third injection,
although there was no reported difference in satisfaction
with location or convenience. Our findings were in keep-
ing with this, with more injections being given in the
clinic than at a pharmacy [4]. Monastersky et al. partnered
27 pharmacists with 19 clinics, offering 69 women 143
contraceptive injections. There is no information on dis-
continuation or withdrawal rates so it is difficult to com-
pare our results, but clinicians involved concluded, as we
did, that the programme would benefit from all local
pharmacies carrying the service [5]. Ferreira et al exam-
ined women who had received three-monthly injections at
the pharmacy compared to women who had received six-
monthly injections at the pharmacy, with alternate three-
month injections being given at a location closer to
home, including pharmacies. Women who received this
service were more likely to continue with the method,
and less likely to become pregnant [15]. Some of the diffi-
culties we experienced in working with pharmacists, not-
ably their lack of experience in clinical research, have also
been documented in the literature [16].
Relevance of the findings: implications for clinicians
and policy makers
In the future, the licensing of Sayana PressVR for self-admin-
istered injection [14] is likely to impact significantly upon
the utility of exploring pharmacy administration. The main
concern that women cite when discussing receiving health
care in the community pharmacy setting is lack of privacy,
with resulting anxiety about confidentiality [17–19]. The
main advantages are cited as convenience and speed and
ease of access [20,21]. Giving patients the ability to self-
administer in the privacy of their own homes at a time that
suits them would confer more advantages in these areas
than attending a pharmacy does, as evidence on self-injec-
tion suggests [22–24].
It may be that there are small numbers of women who
do not wish to self-inject, and the pharmacy could offer
this resource. The response of participants and pharmacists,
particularly in chain pharmacies, suggests that any contra-
ceptive service offered would have a greater chance of suc-
cess if the service was offered by the majority of
pharmacists in all pharmacies. The confusion of some staff
and the sporadic nature of the injections seems to have
had a negative impact on the experience of patients. In
particular the limited pharmacist availability hindered
access, and increased access to this method was the ration-
ale for initiating the research. If offering the contraceptive
injection at the pharmacy became routine then it is pos-
sible awareness would spread and both pharmacists and
pharmacy staff would become more comfortable with the
concept. The influenza vaccination is a good example of an
injection delivered successfully by pharmacies [25,26]. A
key difference seems to be that this was instigated by
high-level management within pharmacies, and a number
of systems were put in place to ensure that vaccinations
could be delivered to customers.
Unanswered questions and future research
It is difficult to know to what extent the problems encoun-
tered are a result of specific systems in place. It is possible
that repeating the project but addressing some of the
training needs identified by pharmacists and staff working
in pharmacy could generate a more successful response.
The comments about ‘shaky hands’ and multiple attempts
being needed to give injections suggests that the training
was not adequate for pharmacist confidence, even if it was
deemed adequate for competence. A rolling programme of
training for pharmacists to attend prior to giving an injec-
tion might alleviate some of these anxieties. Ideally future
research would provide adequate funding to enable phar-
macists to attend further training in their paid working
hours, for example by providing relief pharmacist cover. An
alternative option would be for a research student or nurse
to attend each pharmacist prior to each injection to repeat
the procedure and answer any questions. Our approach
was to provide an open line of communication that the
pharmacists could use if they wanted further training. This
option was only taken up by one pharmacist who had add-
itional supervision and training at their pharmacy. However,
if the research were to be repeated, routinely offering add-
itional training, at least in the early stages, might increase
pharmacist confidence. It should however be noted here






































that, although some participants commented on pharma-
cist anxiety, none offered this as a reason for withdrawal
from the research.
When we invited the pharmacists to participate, only
one pharmacist from each pharmacy wished to develop the
skill, but this might be different if more financial support
had been available or more in-depth training. Training
every pharmacist working at each pharmacy involved in
service delivery could be a useful approach in further stud-
ies, as this would negate the problem of advertised open-
ing hours being so different to trained pharmacist
availability. However, the largest chain pharmacies had a
very large number of pharmacists who could work in each
pharmacy, and therefore this would be very challenging
unless delivering the contraceptive injection became a core
pharmacist skill, as influenza vaccination has now done
[26,27]. Such a change in pharmacy services would need
managerial input, as well as the support of local public
health authorities, and this might be difficult to achieve
without compelling research to demonstrate its efficacy
and acceptability. Nevertheless, enthusiastic support at a
managerial level would be considerably more likely to lead
to new service implementation [28].
Ultimately a randomised controlled trial, where patients
are randomised to receive injections either from the phar-
macy or from a clinic or GP, would be the most robust way
to assess injections received, continuity rates and patient
experiences.
Conclusions
Delivery of the subcutaneous contraceptive injectable from
a community pharmacy may be feasible but availability of
sufficient numbers of pharmacists trained in this technique
is necessary for a robust model of service delivery.
Funding
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Abstract
Introduction. We conducted a prospective health service evaluation to assess
the feasibility and acceptability of routinely offering insertion of intrau-
terine contraception at cesarean section in a maternity setting in the UK.
Material and methods. One month before scheduled cesarean section, women
were sent information about postpartum contraception including the option of
insertion of an intrauterine contraception at cesarean. Women choosing
intrauterine contraception (copper intrauterine device or levonorgestrel
intrauterine system) were followed up in person at six weeks, and telephone
contact was made at three, six and 12 months postpartum. Our main outcome
measures were uptake of intrauterine contraception and complications by six
weeks. Secondary outcomes were continuation and satisfaction with
intrauterine contraception at 12 months. Results. 120/877 women opted to
have intrauterine contraception (13.7%), of which 114 were fitted. By six
weeks, there were seven expulsions (6.1%). The expulsion rate by one year was
8.8%. There were no cases of uterine perforations and one case of infection
(0.8%). Follow-up rates were 82.5% at 12 months, and continuation rates with
intrauterine contraception at 12 months were 84.8% of those contacted. At
12 months, 92.7% of respondents asked were either ‘very’ or ‘fairly’ happy
with their intrauterine contraception. Conclusions. Routine provision of
intrauterine contraception at elective cesarean for women in a public maternity
service is feasible and acceptable to women. It is associated with good uptake
and good continuation rates for the first year. This could be an important
strategy to increase use of intrauterine contraception and prevent short inter-
pregnancy intervals and unintended pregnancies.
Abbreviations: IUC, intrauterine contraception; LARC, long–acting reversible
contraception; LNG-IUS, levonorgestrel intrauterine system; NHS, National
Health Service.
Introduction
There is growing recognition of the need to improve
uptake of contraception in the immediate postpartum
period. Up to 50% of women have resumed sexual activ-
ity by six weeks postpartum and ovulation may occur as
early as three weeks postpartum in non breast-feeding
women (1). A UK study reported that one in 13 women
requesting termination had conceived the pregnancy
within one year of childbirth (2), and one in 13 women
who gave birth had conceived within one year of child-
birth. An interpregnancy interval of less than 12 months
increases the risk of complications, including preterm
birth, stillbirth and neonatal death (3).
Long-acting reversible contraception (LARC) methods
such as the copper intrauterine device (Cu-IUD) and
levonorgestrel intrauterine system (LNG-IUS), and the
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subdermal implant are known to be the most effective
methods of preventing unintended pregnancy (4). The
prevalence of use of intrauterine contraception (IUC) in
the UK is approximately 8.7% (5). Traditionally, women
choosing IUC postpartum may require several visits with
a healthcare provider before insertion (6). Each visit may
represent a significant barrier for women who are likely
to be recovering from childbirth (particularly after a
cesarean section) and caring for a new baby. There is
good evidence that insertion of IUC at cesarean is safe,
convenient and acceptable, and has high continuation
rates (7–18). However, this information comes mainly
from low-income countries and the USA. This practice
has not been widely reported in Europe, and there are no
data from the UK. With a cesarean section rate of 30% in
Scotland (19) and 27% in England (20) in 2015/2016,
there is the potential to offer IUC at cesarean to a signifi-
cant proportion of women. In the UK, maternity care
and sexual healthcare, including all contraception, is free
of charge, delivered through the National Health Service
(NHS).
NHS Lothian (Edinburgh and the surrounding region,
Scotland) began a series of pilot initiatives in 2013 to
improve the uptake of postpartum contraception. This
involved the introduction of antenatal contraceptive
counseling by midwives and provision of contraception
to women living in one area of the region from the
maternity service after delivery (21). This current study
aimed to investigate the feasibility of routinely offering all
women within this region who were undergoing an elec-
tive cesarean section the opportunity to have IUC inser-
tion at this time, and to assess uptake, complications,
continuation rates and acceptability.
Material and methods
A training package and video were developed that
included the technique of insertion of IUC at cesarean
section, medical eligibility criteria for contraceptive use
(22), contraindications to IUC postpartum, and what
post-procedure counseling with women should include.
The team also produced checklists that obstetricians could
use for counseling women about IUC, detailing the risks,
benefits and possible side effects, and written information
to give to women about what to expect after IUC inser-
tion and what follow up was necessary. This material was
presented to all consultants and obstetric trainees working
at the two maternity hospitals in the region (approxi-
mately 35 doctors). Consultants underwent one individual
training session and registrars observed the video as part
of their ongoing training. Ongoing peer supervision in
theater was encouraged and adopted until all obstetricians
were trained; this took approximately four months.
Obstetricians were instructed that following delivery of
the placenta, the IUC should be removed from its inserter
and placed at the fundus through the uterine incision.
They were instructed to use artery forceps to guide the
threads of the device towards the cervix, and through
the cervix if possible. Threads of the device were not cut.
The uterus, sheath and skin were then sutured as per the
obstetrician’s normal practice. In addition, training on
contraception and information about IUC insertion at
cesarean was also provided to hospital midwives.
From the 22 June 2015, information about all types of
postpartum contraception was included with the routine
information on an elective cesarean section that was sent
to women three to four weeks before their scheduled
cesarean date. This included a letter stating that if women
wished to use IUC for contraception postnatally, they
might be able to choose to have it inserted during their
cesarean section. Women were invited to discuss this
option with their obstetrician in advance of delivery. This
was in addition to the routine antenatal contraceptive
counseling that some women in the region received at
that time from a midwife at 22 weeks (21). The telephone
numbers of the evaluation team were included so that
women could contact the evaluation team if they had any
unanswered questions about IUC at cesarean. When
women gave consent for their delivery on the day of
cesarean section, those who had made the prior decision
to have IUC also gave written consent for insertion of
IUC.
Following delivery all women who had elective cesare-
ans were reviewed by obstetricians. Both obstetric and
midwifery staff provided verbal and written information
about the device that was inserted and what to expect in
coming weeks. All women who had IUC fitted were iden-
tified by the evaluation team using electronic maternity
records (TRAK). These women were contacted and
offered a six-week IUC thread check at their local hospital
or sexual health center with the evaluation team (A.J., a
research nurse, and R.H., a research fellow who is an
obstetric and gynecology trainee). At this visit, women
had the opportunity to answer any further questions
Key Message
Short interpregnancy intervals are associated with
poorer obstetric outcomes, so providing effective con-
traception immediately postpartum is an essential
part of healthcare. Routinely offering women under-
going cesarean section, intrauterine contraception
provides a safe solution with high satisfaction and
continuity rates one year later.
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about IUC. They underwent a speculum (RH) to look for
the threads of the IUC and trim them if necessary. If no
threads were seen, an ultrasound scan was conducted to
ensure the device was in situ. A partial expulsion was
diagnosed if the stem of the device was seen on clinical
speculum examination, or if an ultrasound scan revealed
the device to be in the cervical canal. (A complete expul-
sion was diagnosed if the woman reported the device as
expelled, or if no threads were seen, no device was visible
on ultrasound, and no device was visible on abdominal
x-ray.) Women were also asked how satisfied they were
with having the IUC inserted at cesarean.
Women were then contacted by phone or text at three,
six and 12 months to determine continuation rates and
satisfaction with the IUC as a method of contraception.
Our main outcome measures were uptake of IUC and
complications by six weeks. Secondary outcomes were
continuation and satisfaction with IUC at 12 months.
In addition to the information gathered at follow up,
the regional hospital database was reviewed for each
woman to ensure that data on any complications was
accurate. For all women who were lost to follow up, both
the regional hospital database and the local sexual health
database were examined to obtain any further informa-
tion about the presence or removal of IUC, as well as any
further pregnancies. Sample size was not determined
based on an a priori hypothesis; we continue to collect
data on women that undergo this procedure. We report
here data from those women who have completed
12 months follow up.
Ethical approval
The local Quality Improvement Teams for women’s ser-
vices and sexual and reproductive health approved the
project. The scientific officer of the local ethics committee
reviewed the project proposal and confirmed that ethical
approval was not required as this was a health service
evaluation project.
Results
Between 13 July 2015 and 2 March 2016, 877 women
were scheduled for cesarean section and were sent infor-
mation about having IUC inserted at delivery. In all, 120
women chose this option (13.7%). Demographics of
women who chose IUC are detailed in Table 1.
A total of 114 devices were inserted at the time of
cesarean, 100 LNG-IUS and 14 Cu-IUD. Two women
changed their minds. Four IUC could not be inserted due
to postpartum hemorrhage; of these, the women were
known to have attended the local sexual health service for
subsequent insertion of IUC (n = 3) or insertion of a
subdermal contraceptive implant (n = 1) (Figure 2). In
all, 103 women attended the six-week follow up, and a
further nine were contacted at this time by phone. The
percentage of women with information available at each
interval is detailed in Figure 1.
Outcomes of IUC insertion are detailed in Figure 2. Of
the 114 women who had IUC inserted at cesarean
(88.5%), 100 attended for a follow up at six weeks. A fur-
ther three women who had not had a device inserted
came for insertion at six weeks. Fourteen women
attended earlier than six weeks due to noticing long
threads or threads external to the vagina. One of these
women was found to have a partial expulsion and the
device was removed and a new IUC replaced. All others
had the threads trimmed to 2 cm from the os.
There were 10 expulsions, seven by six weeks following
insertion, one at seven weeks, one at 14 weeks, and one
at 28 weeks. One of the early expulsions was unnoticed
but was presumed to be before six weeks, as no device
was seen at the six-week scan (details below). The 10
expulsions included five partial expulsions. Four Cu-IUDs
were expelled and six LNG-IUSs. All complete expulsions
were noticed by women except in one case. Of the 10
expulsions, six women were fitted with a replacement
IUC. In four cases, IUCs were removed accidentally by
women. Two happened before women were seen for their
six-week thread check, when their threads had not been
trimmed. Two others were pulled out with tampons. One
woman had her device replaced.
There was one case of endometritis diagnosed at the
six-week check (pain plus Escherichia coli infection con-
firmed on high vaginal swab); this was treated with oral
antibiotics and the device was left in situ. Another device
was removed at two days post-insertion due to an initial
suspicion of endometritis, but microbiological investiga-
tion was negative, and the woman was subsequently
Table 1. Demographics.
Age, median (range) 33 (21–41) years
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1 (deprived) 21 (17.5%)
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diagnosed with pyelonephritis (a further device was
inserted eight months later).
Complications that had occurred by six weeks included
seven expulsions (three partial and four complete), two
accidental removals and one case of endometritis. There
were three removals by six weeks, one for suspected infec-
tion and two at patient request.
Of 97 women who attended believing they had an IUC
in situ, threads were visible in 49 cases (50%). Ultrasound
confirmed intrauterine placement in all but two women
with missing threads. One woman was noted to have an
intracervical device, this was removed and alternative
contraception started; this is counted in our data as a
partial expulsion. Another woman had no device as seen
on ultrasound. Unfortunately, despite multiple efforts she
did not attend for abdominal x-ray. She did attend clinic
six months after insertion with an unplanned pregnancy
for a termination, and was considered to have a unrecog-
nized complete expulsion. Six women did not attend the
six-week thread check but were followed up by telephone
and either reported that they could feel threads or had
attended their general practitioner for a confirmation that
the IUC threads were visible. Of the four women who
could not have an IUC inserted at cesarean, three of them
attended for IUC insertion at six weeks.
Continuation rates are detailed in Table 2. Percentages
are detailed both from the total number of devices
planned, using intention-to-treat and assuming that
everyone lost to follow up is no longer using IUC for
contraception, and as a percentage of number of women
contacted. At 12 months, 93 women were contactable,
and information about a further six was gained from the
clinical databases, a follow up rate of 82.5%. As a propor-
tion of all 117 women who had the device fitted either at
cesarean (n =114) or afterwards (n = 3), 71.8% were
known to have a device in situ at 12 months (n = 84).
Of 117 devices inserted, 15 have been removed
(12.8%); 14 removals were of devices inserted at cesarean
and one of a device inserted 10 weeks postpartum.
Removals have been from two days after insertion to
27 weeks, all were LNG-IUS devices. Reasons for removal
included disliking bleeding patterns (n = 5), headache
(n = 1), disliking a foreign body in the uterus (n = 1),
recurrent thrush (n = 1), pain during intercourse (n = 1),
postpartum hemorrhage (n = 1), not liking the method
(n = 1), believing the method affected milk production
(n = 1) and wanting to conceive again (n = 1, 10 months
in situ). One removal was due to placement concerns. An
ultrasonographer reported the IUC to be embedded in
the myometrium, but it was removed easily and replaced.
One woman whose device was removed due to an infec-
tion concern subsequently had the IUC replaced. All
removals were straightforward outpatient procedures,
including three cases where threads were not visible. Of
note, one woman who chose to have her LNG-IUS
removed and commenced a less effective method (the
combined hormonal contraceptive patch) had an unin-
tended pregnancy two months later.
After one year, 82 women still using the device were
asked about their satisfaction with the device; 92.7% of
them were ‘very’ or ‘fairly’ happy with the IUC (n = 76).
Further satisfaction rates are detailed in Table 3.
Figure 1. Percentage of women with information available at follow
up.
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Discussion
Routinely offering insertion of IUC at the time of elective
cesarean section was popular among women, with more
than one in eight women in this cohort choosing this
option, the majority opting for an LNG-IUS. In addition,
the study confirmed the low complication rate associated
with insertion of IUC at this time and an expulsion rate
in keeping with that of insertion of IUC in women who
are not postpartum (24). Furthermore, satisfaction rates
among women with IUC insertion at cesarean were high,
and satisfaction and continuation with the method
remained high at 12 months post-insertion.
To our knowledge this is the first paper from Western
Europe to evaluate insertion of IUC at the time of elec-
tive cesarean section, routinely offered in a public health
setting. Our loss to follow up was low, and reviewing
regional databases minimized the risk of missing any seri-
ous complications associated with IUC insertion. In addi-
tion, there are few existing data in the literature regarding
women’s acceptability of IUC insertion at this time. It is
a significant strength of our paper that we examined rou-
tine insertion of IUC in a setting where all contraception
is free. A number of other studies have made IUC free
for the purposes of research, in a setting where this would
normally entail an extra cost for patients. However, in
this NHS population, cost is not an incentive to chose a
contraceptive method, so removing the barrier of attend-
ing a clinic at a later date in the postpartum period may
have a proportionately greater impact on women’s choice
of IUC at cesarean.
This was an evaluation of a new service and so the
findings are likely to represent uptake of IUC in similar
public maternity settings. Our study is limited, however,
Figure 2. Outcomes of participants.
Table 2. Continued use of intrauterine contraception (IUC).
n = 120 At cesarean section 6 weeks 3 months 6 months 12 months
Number of women contacted/information available 120 112 109 105 99
Using IUC 114 111a 96 91 84b
Continuation rates as percentage of those with known status 95% 99% 88% 87% 85%
Continuation rates as percentage of 120 planned insertions 95% 93% 80% 76% 70%
a114 devices inserted at cesarean, 3 removals, 7 expulsions, 4 replacements, 3 new insertions.
b72 still in situ, 6 expulsions replaced, 2 removals replaced, 1 accidental removal replaced, 3 new insertions.
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by the fact that this service evaluation relates to a single
region. The percentage of women choosing IUC and the
satisfaction rates may differ in other populations. We
have limited data on removals, as only a small number of
women have had their device removed. It is reassuring
that removal was straightforward in those women who
requested it.
As has been argued elsewhere, the main advantage of
insertion of IUC at cesarean section is the benefit it con-
fers in terms of uptake and continuity (25). In addition,
the procedure is convenient for both women and health
services, and avoids a potentially more difficult insertion
through a possibly narrow os weeks later. This is particu-
larly relevant given the evidence that the risk of uterine
perforation is increased in the first 36 weeks postpartum,
with breastfeeding at time of insertion associated with a
sixfold increased risk (26). The number of women choos-
ing IUC was considerably higher than was previously
found in a similar maternity population, when insertion
at cesarean section was not routinely available (2).
Expulsion rates in our study were low, and when
expulsion did occur, it was recognized in all but one case,
and most these women chose to have another device
inserted. A potential challenge with IUC insertion at
cesarean is that a significant proportion of women will
not have visible threads at six weeks. In our study this
was half of all cases. This indicates that an important
component of making insertion of IUC at cesarean rou-
tine practice is a system ensuring rapid access to ultra-
sound scans to confirm that the IUC is in situ. This
could be either at a hospital or clinic or by direct referral
to sexual health centers that have ultrasound capabilities.
A small number of women in our study presented with
very long threads, but trimming the threads can be easily
managed by any healthcare practitioner who is competent
to conduct a cervical smear.
Insertion of IUC at cesarean section is a relatively
straightforward procedure. Obstetricians are skilled opera-
tors and insertion of the IUC at cesarean is not compli-
cated. Indeed, it is more straightforward than female
sterilization at the time of cesarean, and could in fact be
offered to women as an alternative to this practice, partic-
ularly as sterilization is a permanent procedure. Training
of obstetricians was easy and required a small number of
dedicated trainers only (the evaluation team). Training
for midwives to ensure a basic knowledge about IUC and
dispel any myths was also required, although some of this
could be delivered online or in video format rather than
in face-to-face teaching sessions (21).
Robust processes need to be in place for appropriate
follow up post IUC insertion to succeed; thus a close
working partnership between maternity, sexual health ser-
vices and general practitioners is important to make rou-
tine insertion of IUC at cesarean achievable and
successful.
Conclusion
Routine provision of IUC at cesarean section is feasible
with a simple training package for maternity staff. It is
both safe, with low complication rates, and highly accept-
able to women, with good uptake and good continuation
rates. Any increase in LARC in the postpartum setting
has the potential to prevent unintended pregnancy and
Table 3. Satisfaction rates.
Satisfaction with insertion taking place at the time of cesarean section (n = 114) (asked at six-week follow up)
Number of women asked 98
Very happy 74 (76%)
Fairly happy 21 (21%)











Satisfaction with intrauterine contraception device
Number of women with intrauterine contraception in situ 111a 96 91 84
Number of women asked 99 92 89 82
Very happy 42 (42%) 67 (72%) 61 (69%) 64 (78%)
Fairly happy 43 (43%) 21 (23%) 22 (25%) 12 (15%)
Neither happy nor unhappy 14 (14%) 4 (4%) 4 (4%) 5 (6%)
Fairly unhappy 0 0 0 1 (1%)
Very unhappy 0 0 2 (2%) 1 (1%)
Percentages are given as a percentage of women asked.
aIncluding those who had had a device expelled or removed, and reinserted.
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enable women to achieve healthy inter-pregnancy inter-
vals. We would propose that this option is routinely
offered to women as part of good maternity care (27).
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Abstract
Introduction Pharmacists have extended opening hours and are located in
communities. Many offer sexual and reproductive health services such as emer-
gency contraception. The opportunity to receive injectable contraception from
community pharmacists would improve availability of this method and might
increase uptake and continuation. A self-administered survey of women attend-
ing a large urban sexual and reproductive health clinic was undertaken to
determine the acceptability of receiving contraceptive injections from a com-
munity pharmacist.
Methods Women aged 16–50 years attending an NHS walk-in sexual and
reproductive health clinic were invited to complete questionnaires while they
were waiting to attend an appointment with a clinician. Questionnaires asked
women if they were current, previous or never users of the progestogen only
injectable, their method of contraception and whether availability of the inject-
able from a local pharmacist would influence their decision to use this
method.
Results Two hundred and forty questionnaires were distributed and 220 com-
pleted (92%). A total of 9% of respondents were past users of the injectable
(n = 21), 4% were current users (n = 8) and the remaining 87% were never
users. Of those 191 current non-users, 33% (n = 64) indicated that they would
consider using this method if it was available at the pharmacy. The main per-
ceived advantages of attending the pharmacy were quicker appointments (52%)
and easier access (47%).
Conclusion Provision of the injectable contraceptive from a pharmacist might
make this method attractive to almost one in three women who are not cur-
rently using it. This could be a strategy to improve uptake and continuation of
this method.
Key Points
● Almost one in three women surveyed who was not
using the contraceptive injection would consider using
it if they could get injections from their community
pharmacy.
● Women felt that pharmacies would offer quicker
appointments, easier access and better opening hours.
● This approach has the potential to improve uptake and
continuation rates of this effective method of contra-
ception.
Introduction
The contraceptive injection depot medroxyprogesterone
acetate (DMPA) is given every 12 weeks, but discontinua-
tion rates of this contraceptive method have been noted
to be particularly high.[1–3] Although not the only factor,
remembering to return to clinic every 3 months, as well
as the inconvenience of having to do so has been cited by
users as a contributory factor to discontinuation.[1] A
subcutaneous formulation of injectable contraception
(Sayana Press, Pfizer Inc.) is now available in the UK.
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This preparation is a lower dose (104 mg), but is similar
in other aspects including efficacy, injection interval,
return to fertility and bleeding pattern.[4] The subcuta-
neous preparation comes packaged in a simple delivery
system known as uniject, consisting of a polyethylene
reservoir pre-filled with DMPA and an integral fine sub-
cutaneous needle. This may facilitate administration of
injectable contraception and so expand the range of
health professionals who can administer it, including
community pharmacists. Self-administration of subcuta-
neous DMPA has been shown to be feasible in several tri-
als,[5–7] and Sayana Press has recently been licensed in
the UK for this purpose.[8]
There is growing recognition of the potential that com-
munity pharmacists could play in delivering sexual health
services within the UK. Pharmacies are located directly in
communities, and have extended evening and weekend
hours. Examples of sexual health services delivered suc-
cessfully by community pharmacists include provision of
emergency contraception (EC),[9,10] and treatment of
partners of individuals with uncomplicated Chlamydia
infection.[11] In addition, there have been pilot projects of
provision of the combined oral contraceptive pill from
the pharmacy,[12] and pharmacists providing ‘bridging
contraception’ (a 1 month supply of a progestogen-only
pill) alongside oral EC.[13] A pharmacist in the UK has
also been trained to fit contraceptive implants and give
the DMPA-IM injection.[14] Community pharmacists in
the UK currently administer other subcutaneous injec-
tions and are essential for delivery of national flu vaccina-
tion programmes.[15–17] Pharmacists administer these
medications under a Patient Group Directive, a legal
framework that allows certain registered health profes-
sionals to administer specified medicines to a pre-defined
group of patients without the necessity of seeing a doctor.
Patient Group Directives were first introduced through
legislation in 2000, and are currently covered under The
Human Medicines Regulation 2012.[18] This questionnaire
was administered in Scotland, where sexual health services
differ somewhat at an administrative level from other
parts of the UK. However, the same ‘no cost’ services to
the public are provided (through the National Health Ser-
vice) including contraceptive methods.
For women who are already established users of the
contraceptive injection, receiving repeat injections from
their community pharmacy may be an attractive option.
Administration of subcutaneous DMPA by community
pharmacists (using a more complicated system of syringe
and needle) has already been shown to be feasible in pilot
studies conducted in the United States.[19,20]
We wanted to establish whether the option of receiving
the injectable contraceptive from a community pharma-
cist was acceptable to women, particularly in the case of
those who are using less effective methods.
Methods
From 3 February to 11 July 2014, an anonymous, self-
administered questionnaire was offered to women attend-
ing a single-site walk-in clinic at an integrated sexual and
reproductive health (SRH) service located in the centre of
Edinburgh, UK. The site was selected as it sees a high vol-
ume of patients and, as research is often conducted from
this centre, reception staff are used to handing out
research materials to patients. Women attend this walk-in
clinic largely for contraception and sexually transmitted
infection screening. Clinic reception staff were asked to
hand out a questionnaire to all women of reproductive
age (16–50 years) attending the clinic, to complete while
they were waiting to be called to see the doctor or nurse.
Women attending the termination of pregnancy service or
the menopause clinic were not invited to participate.
Women were asked to place completed questionnaires in
a closed collection box.
Questionnaires were piloted with five service users and
consisted of a brief written introduction that outlined the
injectable method of contraception and introduced the
idea that it might be possible to receive injections at a
community pharmacy in the future. It was explained to
women that the injection would be subcutaneous (‘under
the skin rather than into the muscle’). Questions required
simple tick-box responses, with a space to expand upon
responses if wished. Questionnaires asked women if they
were current, previous or never users of the injectable,
which method of contraception they were currently using,
and whether availability of the injectable from a local
pharmacist would influence their decision to use this
method. They were also asked to select perceived advan-
tages or disadvantages of receiving their contraception
from the community pharmacy from a predefined list of
options.
Data analysis
All data was entered into Microsoft Excel for analysis. All
questionnaire responses were entered including those
where not all questions had been answered. Responses to
questions were expressed as numbers and percentages,
with percentages rounded to the nearest integer. Ques-
tions were analysed separately, i.e. if a questionnaire was
not fully answered, analysis was performed on the ques-
tions that were answered.
The local Quality Improvement Team for SRH
approved the project. The scientific officer of the local
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ethics committee reviewed the project proposal and con-
firmed that ethical approval was not required.
Results
Two hundred and forty questionnaires were distributed
and 220 were returned (91%). One hundred and sixty-
three were fully completed (74%) and the remaining 57
were partially completed. Three only had information
completed about the contraception being used by the par-
ticipant, and 54 had answers completed stating whether
they would attend the pharmacist for the contraceptive
injection, but no reasons completed why/why not. During
the study period, 1605 women attended appointments at
the walk-in clinic. The number of women attending is
likely to be smaller as some women may have attended
more than once.
The main contraceptive methods being used by respon-
dents are outlined in Table 1. As a percentage of 220
returned questionnaires, there were eight current users of
the injectable in the women surveyed (4%), 23 previous
users (10%) and 187 who had never used it (85%). Of
those who had never used it, 33 (18%) had considered
using it in the past but decided against it.
Of 23 previous users, the most common reason for
having stopped the injectable was irregular bleeding, cited
by 10 women (44%). Six respondents (26%) indicated
that having to see a doctor or nurse every 3 months was
a reason for stopping this contraceptive method. Other
reasons are cited in Table 2. Of the 33 women who had
considered using the contraceptive injection but decided
against it, 24 (73%) cited having to see a doctor or nurse
every 3 months as one of the reasons they had decided
not to use it. Other reasons are further detailed in
Table 2.
Out of 212 current non-users, 65 (31%) said they
would consider using the contraceptive injection if they
could get this from their local pharmacy. A total of 58%
of them (n = 37) were using less effective methods or no
methods. The methods that all 65 were using are in
Table 1. In response to why this would be a good option
for them, most respondents ticked more than one option
from a list. The main reasons were quicker appointments
(52%) and easier access (47%) Further reasons are
detailed in Table 3. Just one current contraceptive injec-
tion user said that they would be interested in getting
future contraceptive injections from a community phar-
macy.
One hundred and forty-three respondents (65%) said
that they would not consider using the contraceptive
injection even if it could be given by a community phar-
macist. The reasons largely related to the method itself
Table 1 Contraceptive methods currently being used by respondents
(for respondents using more than one method, most effective method
being used)












60 (27%) 15 (25%)
Condoms 43 (20%) 12 (28%)
Not using any contraception 34 (16%) 8 (24%)




27 (12%) 11 (41%)
Progestogen only pill 9 (4%) 2 (22%)
Current depo users 8 (4%) 1 (13%)




Trying for a pregnancy 1 (0.5%) 0
Diaphragm 1 (0.5%) 0




Table 2 Reasons for stopping the contraceptive injection, or decid-
ing not to use it
Reason
n (no. of times ticked)
(%) (percentage of
respondents selecting it*)
Reasons for stopping (completed
by 23 ex-users of this method)
Irregular bleeding 10 (44%)
Weight gain 6 (26%)
Acne 6 (26%)
Having to see a nurse or
doctor every 12 weeks
6 (26%)
Reasons for deciding not to use the method (completed by 33
women who had considered using the contraceptive injection
but decided not to)
Worry about weight gain 28 (85%)
Having to see a doctor or nurse
every 3 months
24 (73%)
Don’t want a method where
your period stops
22 (67%)
Delay in return to fertility 15 (45%)
Worry about bone health 14 (42%)
Prefer something more long acting 14 (42%)
Other people put me off 9 (27%)
Not familiar with this method 8 (24%)
*Percentages add up to >100 as most respondents selected more
than one option.
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rather than the place of delivery. Fifty-three (37%) said
that they did not wish to use this method at all, and 32
respondents (22%) ticked ‘other’ and stated that they
wanted a hormone free method. Only 11 (8%) stated that
they would prefer to see a nurse or doctor. Reasons are
further outlined in Table 3. We did not include cost as a
factor because in the United Kingdom; all contraception
is free to users, as is seeking advice from a pharmacist,
doctor or nurse. Obtaining contraception from a pharma-
cist would therefore represent no financial advantage or
disadvantage to patients.
Discussion
Our survey suggests that almost one in three women who
is not currently a user of the contraceptive injection
would consider using this method if they could receive
injections from their local pharmacy. Quicker appoint-
ments, better opening hours and the pharmacy being
easier to get to were all stated as reasons why women
thought this would be a good option for them.
Questions examined only what people said they might
do in theory, so it is possible that this may not truly
reflect the proportion of women who would choose to go
to the pharmacist for contraceptive injections if this were
a current option. We also captured only a small number
of current users. This may be an indication that regular
users of DMPA are choosing to attend their General Prac-
titioner (GP) or practice nurse, rather than a SRH clinic.
It may also reflect the local service policy of actively
encouraging women who need a repeat injection to attend
their local GP practice for this, so that SRH consultations
can be prioritised for individuals with more complex sex-
ual health needs. It does mean, however, that the survey
findings cannot estimate what proportion of total current
users would switch to go a pharmacy if this option was
available. It would be worthwhile repeating this survey in
a primary care setting to see if results differ. Since we
relied on reception staff handing out questionnaires to
women, only a small proportion of women that were eli-
gible were handed questionnaires. We did not capture
information on demographics of respondents. Due to
busy clinics and a high workload reception, staff were
unable to keep track of how many eligible women were
not offered questionnaires. The list of possible advantages
and disadvantages of receiving contraception at the phar-
macy were created based on what we anticipated women’s
views would be and not on qualitative research with
users.
Interestingly, a quarter of ex-users stated that having to
visit a doctor or nurse every 3 months had been a reason
that led to them stopping this method of contraception,
suggesting that some women might continue using the con-
traceptive injection if they did not have to make a regular
appointment with a doctor or nurse. In keeping with the
existing literature, the main reason cited for stopping was
problematic bleeding.[1–3] Among the women who had
given consideration to using the contraceptive injection in
the past, but elected not to use it, almost three quarters of
respondents stated that the fact that you had to see a doctor
or nurse regularly had been a factor in them deciding not
to use it. This gives a strong indication that removing this
aspect of the contraceptive injection might make it a more
attractive option to women who are considering using this
as their method of contraception.
Although almost one in three women indicated that
they would be interested in the contraceptive injection if
the option to receive it from pharmacies was available,
this may be an overestimation of the proportion of
women choosing this if available. When asked about the
Table 3 Perceived benefits and disadvantages of receiving contra-
ceptive injections from a pharmacist in the community
Perceived disadvantages (completed by 143 respondents who would
not choose this option)
Perceived disadvantages
n (no. of times ticked)
(%) (percentage of
respondents selecting it*)
Would not consider using this
method ever
53 (37%)
Other: ‘want hormone free method’ 32 (22%)
Other reasons given† 25 (17%)
Prefer to see a nurse or doctor
every 12 weeks
11 (8%)
Prefer coming to this clinic 7 (5%)
Prefer an injection into the muscle
to under the skin
4 (3%)
Do not trust a pharmacist to give it 0 (0%)
Did not answer 47 (33%)
Perceived benefits (completed by 65 respondents who indicated inter-
est in this service)
Perceived benefits
n (no of times ticked)
(%) (percentage of
respondents selecting it*)
Better opening hours 25 (38%)
Easier to get to 31 (47%)
Closer to my home 20 (30%)
Quicker appointment 34 (52%)
Prefer an injection under the skin 14 (21%)
Did not answer 17 (26%)
*Percentages add up to >100 as most respondents selected more
than one option. †Other reasons given included ‘scared of jags’, ‘out
at sea for work so will not be able to get injection’, ‘Mirena is better
option for me’ and concerns about bone health and a delay in return
to fertility. These all represented reasons why the method would not
be considered, regardless of location of delivery.
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reason they had decided not to use, or stopped using, the
contraceptive injection, respondents mainly cited many
reasons unrelated to delivery of the contraception, notably
irregular bleeding and weight gain. As with all contracep-
tion, women’s decision to use a method is likely to be
influenced by a number of factors, and perceived disad-
vantages may be more or less relevant when weighed up
against perceived advantages. Our survey does seem to
suggest that availability at a pharmacy would be a per-
ceived advantage to a fair proportion of women who are
using less effective methods. Very few women stated that
they preferred to see a doctor or nurse or attend a clinic.
This research captures patients’ opinions on a novel
potential option for delivering contraceptive injections in
the community and demonstrates that a significant propor-
tion of women would welcome the possibility of receiving
this method from a community pharmacy. The availability
of contraception injections from a local pharmacy would
increase access for women and might make this longer act-
ing method more attractive to a greater number of women,
notably to women who are put off by the necessity of regu-
lar appointments with a doctor or nurse, who may opt
instead for less effective methods. It may also mean that
women might be less likely to discontinue the method once
they start using it and this could potentially prevent more
unintended pregnancies. Although a pilot study of pharma-
cists administering the contraceptive injectable in the US
did not observe any difference in continuation rates of the
method compared to standard practice, the study was a
pilot of just 50 women randomised to clinic or phar-
macy.[19] The study did confirm that women found the
pharmacy convenient, that pharmacists were respectful and
overall women were very satisfied with receiving the inject-
able from this setting.
Studies indicate that both providers and women prefer
a subcutaneous injection of DMPA delivered via Sayana
Press’s uniject system to an intramuscular injection
DMPA.[21,22] While self-administration of the subcuta-
neous DMPA remains highly acceptable to women,[5–7]
the option of receiving injections from pharmacists never-
theless expands the options for increasing access to this
method and may be particularly attractive to women who
do not want to self-administer injections.
Our survey did not specify whether injections from the
community pharmacy would be repeat or first injections
of this method. It would make sense for a pilot project to
explore continuation injections from the pharmacy, fol-
lowing method initiation from a clinician.
Conclusions
Our survey indicates that for a significant proportion of
women who are not using the contraceptive injection, the
ability to receive repeat injections at a local pharmacy would
be an attractive prospect. This could be a simple strategy that
might increase uptake and continuation rates of injectable
contraception, and reduce unplanned pregnancies.
Further research piloting pharmacists as providers of
this method of contraception is therefore warranted. Our
survey did not specify whether injections from the com-
munity pharmacy would be repeat or first injections of
this method. It would make sense for a pilot project to
explore continuation injections from the pharmacy, fol-
lowing method initiation from a clinician.
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Background Women in the postpartum period
need effective contraception. Unintended
pregnancies soon after childbirth may lead to
abortion or short inter-pregnancy intervals
associated with adverse outcomes. Using databases
for a 6-month period (September 2013–February
2014) we examined the proportion of women
attending for abortion in Edinburgh, Scotland who
had given birth in the preceding 12 months, and
the proportion of women giving birth in this region
after an inter-pregnancy interval of 12 months or
less. We also surveyed 250 women prior to
discharge from the same maternity service about
their contraceptive intentions.
Results Some 75/1175 (6.4%) attending for
abortion had given birth within the preceding
12 months and 332/4713 (7.0%) postpartum
women gave birth following an inter-pregnancy
interval of 12 months or less. When considering
parous women, percentages were 13.3% and
13.9%, respectively. The majority (n=237, 96.7%)
of postpartum women were not planning another
pregnancy within the year but only a minority
(n=32, 12.8%) were planning on using long-
acting reversible contraception (LARC), namely the
implant or intrauterine device. However, 42.8%
(n=107) indicated that if the implant or
intrauterine contraception could be inserted before
they left hospital then they would choose these
methods (p<0.0001).
Discussion Almost one in thirteen women in our
population presenting for abortion or giving birth
has conceived within 1 year of giving birth.
Provision of LARC immediately postpartum appears
to be an attractive option to mothers, and could be
an important strategy to prevent unintended
pregnancy and short inter-pregnancy intervals.
INTRODUCTION
The World Health Organization (WHO)
recommends that birth to pregnancy
intervals be at least 2 years in order to
optimise maternal and infant outcomes
across both resource-poor and
resource-rich countries.1 Data from the
UK have shown that women with inter-
vals between births of less than
12 months are at increased risk of obstet-
ric complications, premature birth and
neonatal death, even after the potentially
confounding effect of maternal obstetric
history has been taken into account.2 It is
therefore essential that in the postpartum
period there are as few barriers as pos-
sible to accessing effective contraception,
particularly long-acting reversible contra-
ceptive (LARC) methods such as intra-
uterine contraception and the
contraceptive implant, since these are the
most effective at preventing pregnancy.3 4
Guidelines from the National Institute
for Health and Care Excellence (NICE)
state that method and timing of contra-
ception should be discussed in the first
week postpartum, although they provide
no guidance about the content of this
Key message points
▸ One in thirteen women presenting for
abortion or giving birth has conceived
within 1 year of giving birth.
▸ More than one in eight parous women
presenting for abortion or giving birth
have conceived within a year of giving
birth.
▸ Just under half of women say that they
would be likely to choose an intrauter-
ine method or implant if these
methods were available in the immedi-
ate postpartum period.
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discussion.5 The Faculty of Sexual & Reproductive
Healthcare guidelines advise that time should be
found in both the antenatal and postnatal period to
discuss all forms of contraception.6 However, a large
internet survey of UK mothers found widespread dis-
satisfaction with the timing and quality of contracep-
tive advice received postnatally.7 8 Although
traditionally contraception is discussed at the 6 week
general practitioner visit, fertility may have returned
by this time for women who are not exclusively
breastfeeding.9 There is evidence that 35–57% of
mothers resume intercourse within 6 weeks post-
partum,10 11 and that attendance for additional visits
required to insert an intrauterine method or implant
is poor at this time.12 Caring for a young baby, as well
as fatigue and adapting to a period of change, may
make attendance particularly challenging. At delivery,
however, the mother is already in a healthcare setting
with access to trained health professionals. Provision
of implants and intrauterine contraception from the
maternity service after childbirth could be convenient
for women as they are already in a healthcare setting
with skilled providers available. Although some mater-
nity services in the UK currently provide contraceptive
implants for some women before they are discharged
home,13 14 this is not universal across UK maternity
services.
The Royal Infirmary of Edinburgh (RIE) is the main
delivery unit for women in NHS Lothian (Edinburgh
and the surrounding region), a district that had more
than 9000 births in the year ending 31 March 2013.15
In NHS Lothian in 2013, there were 2314 induced
abortions.16 The RIE and the Chalmers Centre for
Sexual and Reproductive Healthcare are the main provi-
ders of abortion in NHS Lothian. The aim of this study
was to determine what proportion of women attending
the abortion service had given birth in the preceding
12 months, and what proportion of women giving birth
in NHS Lothian had given birth following a birth to
pregnancy interval of 12 months or less. We also wished
to determine views of postpartum mothers on future
contraception and in particular on the theoretical
acceptability of provision of intrauterine contraception
and implants in the immediate postpartum period.
METHODS
We examined the computerised database for women
presenting for abortion at RIE and Chalmers Centre,
Edinburgh between 1 September 2013 and 28
February 2014 to determine if women had given birth
in the preceding year. All women attending the abor-
tion service have a routine ultrasound for gestational
dating, and so we calculated the inter-pregnancy inter-
val from the date of last childbirth to the estimated
date of conception of the index pregnancy (abortion
request). The date of conception was assumed to be
2 weeks after the last menstrual period (using the
ultrasound gestational age).
We used the regional maternity computer database
(Trak) to identify women who gave birth during the
same study period in the region. We then gathered
further data on anyone with an inter-pregnancy interval
of 12 months or less, namely a previous birth within
21 months (we assumed a gestation of 9 months for the
index pregnancy and added 12 months for an inter-birth
interval to give 21 months). This method may underesti-
mate the number of inter-pregnancy intervals less than
12 months, as it does not take account of shorter gesta-
tions associated with preterm birth. [For reference pur-
poses, in 2012/2013 the percentage of babies born
under 37 weeks was 5.3% (476/9050 births)].15
Demographic data collected on women from abor-
tion and maternity cohorts included age, parity and
deprivation scores based upon postcode area of resi-
dence. Due to the different ways that the services
managed data, women presenting for abortion were
assigned deprivation scores (DEPCAT) based on 2001
census data about their postcode at the time of pres-
entation,17 18 but for maternity patients the depriv-
ation measure assigned was the Scottish Index of
Multiple Deprivation (SIMD) spread into population-
weighted categories of roughly equal quintiles.19 20
An anonymous self-administered survey asking
women their views on postnatal contraception and
contraceptive intentions was conducted between 3
October 2013 and 31 January 2014 on postnatal
wards and the Lothian Birth Centre (low risk delivery
unit) in the RIE. Specifically, women were asked
whether they would be likely to use a contraceptive
implant or intrauterine contraception, if these
methods were available in the immediate postpartum
period, before discharge from the maternity service.
Questionnaires were distributed by a research
midwife. Women who spoke little English and who
were without an interpreter or who had had poor
pregnancy outcomes (e.g. stillbirth) were not given a
questionnaire. The questionnaire consisted mainly of a
series of simple tick box answers or a Likert scale
(very likely to very unlikely) to indicate level of agree-
ment with a range of statements on contraception.
The questionnaire also provided free space for any
comments women wished to make. Women were
asked to place placed completed questionnaires in a
closed box on the ward.
The local Quality Improvement Team for obstetrics
and gynaecology approved both projects. The scien-
tific officer of the local ethics committee reviewed the
project proposal and confirmed that ethical approval
was not required.
Statistics
The questionnaires were coded and the data were
entered into Microsoft Excel. Statistical analysis was
conducted using IBM Statistical Package for Social
Sciences (SPSS) software V.18 (SPSS Inc., Chicago, IL,
USA). Descriptive statistics were performed for
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demographics and groups were compared by
Chi-squared (χ2) test of significance. Statistical signifi-
cance was taken as p<0.05.
RESULTS
Women presenting for abortion within 1 year of childbirth
Over the study period, 1179 women attended request-
ing abortion. Of these, 75 (6.4%) had given birth
within the year preceding conception of this index
pregnancy. Considering only the parous women
(n=563) who attended the clinic, 13.3% of women
had given birth within the year preceding the index
conception. The average gestation at the time of pres-
entation for abortion was 52 days. The average
number of days between childbirth and the start of
the index pregnancy as determined by ultrasound was
193 ( just over 6 months), with a minimum of 51 days
( just over 7 weeks). The average age of women who
had given birth in the previous year was 26 (17–37)
years. Some 29.3% of women (n=22) who attended
for abortion within 1 year of giving birth were aged
30 years or older. Table 1 demonstrates their demo-
graphics and compares them to the demographics of
all women presenting to the same abortion service
during this period. Women who had given birth
within 12 months were more likely to be deprived
(p=0.016) and to be aged 20–34 (p=0.021).
Women giving birth who previously delivered within
1 year of pregnancy
A total of 4713 women gave birth in the region over
the time period. Three hundred and thirty-two
women had given birth within the preceding
21 months (representing a birth to pregnancy interval
of less than a year), representing 7.0% of the total
births. When considering only the 2393 parous
women, the percentage was 13.9%. The average time
between births of this cohort was 17 months, with the
shortest period being 9.5 months between births (in
this case the index birth was significantly preterm).
One hundred and eight women (4.5% of parous
women) had a birth to birth interval of 15 months or
less, representing conception within 6 months of
childbirth.
The average age of the women with a birth to preg-
nancy interval of 12 months or less was 29 years (see
Table 2). 53.6% (n=178) were aged 30 years or older.
Table 2 demonstrates the deprivation and ages of
women in both categories. There was a statistically sig-
nificant difference in the characteristics of women
with a short birth to pregnancy interval and the
general population of women giving birth .Women
who had given birth within 12 months of their previ-
ous birth were more likely to come from areas of
deprivation (p=0.002) and tended to be younger
(p=0.020).
Questionnaires
A total of 300 questionnaires were handed out to 318
postpartum women, present in the maternity wards
over the study period, representing a distribution rate
of 95%. The completion rate was 83% (250 com-
pleted). The reasons why 18 women did not receive a
questionnaire included inability to speak English and
poor pregnancy outcome. These judgments were
made through discussion with the midwives looking
after the women on the ward. Women may have also
Table 1 Demographics of women attending for abortion who
had given birth within 12 months of conception of index
pregnancy compared with demographics of all women attending












1–2 (affluent) 14 (18.7) 193 (16.4)
3–5 (intermediate) 44 (58.7) 820 (69.6)
6–7 (most deprived) 17 (22.7) 146 (12.6)
Unknown 0 20 (1.7)
Age (years) (p=0.021)
<20 8 (10.6) 221 (18.7)
20–24 24 (32.0) 362 (30.7)
25–29 21 (28.0) 266 (22.6)
30–34 17 (22.7) 161 (13.7)
35–39 5 (6.7) 106 (9.0)
40+ 0 61 (5.2)
Unknown 0 2 (0.2)
*See McLoone and Boddy.18
Table 2 Demographics of women giving birth who had given
birth within the preceding 21 months compared with
demographics of all women giving birth within same time period
(September 2013–February 2014)
Demographics









4–5 (affluent) 107 (32.2) 1927 (40.9)
3 (intermediate) 79 (23.8) 912 (19.4)
1–2 (deprived) 137 (41.3) 1715 (36.4)
Unknown 9 (2.7) 159 (3.4)
Age (years) (p=0.020)
<20 10 (3.0) 190 (4.0)
20–24 61 (18.4) 633 (13.4)
25–29 83 (25.0) 1165 (24.7)
30–34 105 (31.6) 1554 (33.0)
35–39 64 (19.3) 927 (19.7)
40+ 9 (2.7) 244 (5.2)
*The Scottish Government.19
SIMD, Scottish Index of Multiple Deprivation.
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been absent from the ward when researchers were dis-
tributing questionnaires.
Of those completing the questionnaires, 49%
(n=121) had given birth before. The average age was
30 (16–47) years. Twenty percent of women were
from DEPCAT Categories 1–2 (affluent), 65.6% were
from Categories 3–5 (moderate deprivation) and 8%
were from Categories 6–7 (severely deprived). Some
(6.4%) did not provide their postcode. Of the 242
(97%) women who answered the question about
whether or not they could recall ever having a discus-
sion antenatally with a health care provider about
future contraception, 73 (30%) women indicated that
they had discussed contraception during the preg-
nancy. Of this group, 56 women (77%) had found the
discussion helpful.
The majority of the women (237/245, 96.7%)
stated that they were not planning a baby in the next
year. Table 3 shows which methods of contraception
women intended using.
Only 32 (12.8%) women were planning on using
the contraceptive implant or intrauterine contracep-
tion and 27 (10.8%) were planning male or female
sterilisation; 88 (35.2%) women indicated that they
did not know what contraception they would be using
postnatally. Four percent (n=10) of women indicated
that contraception was not necessary for them. The
most popular method that women were planning to
use was condoms (see Table 3).
Of 239 women who answered the question about
whether they would choose an intrauterine method if
it could be inserted prior to leaving the hospital, 78
(32.6%) described themselves as ‘very likely’ or ‘quite
likely’ to choose this method. Of 241 women answer-
ing the same question about the likelihood of choos-
ing the contraceptive implant if it could be fitted
before leaving the hospital, 74 (30.7%) said they
would be ‘very likely’ or ‘quite likely’ to choose this.
Combining the numbers of women likely to choose
either intrauterine methods or implants gives a total
of 107 (42.8%) respondents who stated they would
opt for one of these methods if insertion were avail-
able before leaving hospital. The difference in
planned use of implant and intrauterine method and
‘theoretical’ use of the method if it was immediately
available was statistically significantly (p<0.0001).
Only 12 (4.8%) women who completed question-
naires were aged 20 years or under and six (50%)
indicated that they would be very likely or quite likely
to choose a contraceptive implant if available before
discharge home.
DISCUSSION
Almost one in thirteen women in our population pre-
senting for abortion or giving birth have conceived
within 1 year of giving birth. Of women who already
have children, over one in eight requesting an abor-
tion or giving birth conceived again within 1 year of
their previous birth. Yet the survey suggests that the
vast majority of postnatal women do not plan on
having another pregnancy within the next year. Does
this suggest that we are failing to meet the contracep-
tive need of women postpartum? It may well do.
Most women had not discussed ongoing contracep-
tion during the pregnancy with a health professional
and most were unsure about what method they would
use. Although one in ten women were considering
intrauterine contraception or implants, almost one in
two women indicated that they would ‘in theory’
choose these methods if they could be provided
before they left hospital. This interesting finding may
reflect the convenience of this option, or the removal
of important barriers that would otherwise deter
them from choosing this method. Immediate post-
partum provision of these methods could therefore be
an important strategy to prevent unintended pregnan-
cies for women, in the same way that immediate
uptake of LARC post-abortion reduces a woman’s risk
of having another abortion in the next 2 years.21
There is also evidence that uptake of contraceptive
implants in the early postpartum period reduces the
risk of another pregnancy in young women in the
next 12 months.22 23 Although there has been some
concern about the impact of early initiation of proges-
togen on breastfeeding, the available evidence is con-
sistently reassuring and shows no adverse effects on
lactation or infant growth.24
Women who attended for an abortion within 1 year
of giving birth were more likely to be from areas of
deprivation, as were women who gave birth to a baby
that had been conceived within 1 year of childbirth.
Nevertheless, both women who gave birth after a
short inter-pregnancy interval and those attending for
an abortion were from a wide age range and all socio-
economic groups, suggesting that all women, not only
Table 3 Intentions for contraceptive use (n=250)
Intentions [n (%)]*
Don’t know 88 (35.2)
Condoms 71 (28.4)
Progestogen-only pill 28 (11.2)
Combined oral contraceptive pill 24 (9.6)
Progestogen-only implant 16 (6.4)
Intrauterine contraception† 16 (6.4)
Progestogen-only injectable 13 (5.2)
Male sterilisation 14 (5.6)
Contraception not necessary 10 (4)
Female sterilisation 10 (4)
Lactational amenorrhoea 7 (2.8)
Combined contraceptive patch or ring 2 (0.8)
Question not answered 5 (2)
*Numbers add up to more than 100% as some respondents ticked more
than one answer.†Intrauterine contraception includes both the copper
intrauterine device and the levonorgestrel-releasing intrauterine system.
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those from vulnerable groups (who are often the
focus of targeted, contraceptive interventions),23 25–28
could benefit from immediate access to implants and
intrauterine contraception postpartum.
Although a significant proportion of women
expressed a desire for immediate intrauterine contra-
ception, this service is not usually available in the UK,
with insertion usually taking place after 4 weeks post-
partum.29 There is, however, reasonable evidence
from low- and middle-income countries that post-
placental insertion of intrauterine contraception
(within 10 minutes of placental expulsion) is safe and
effective,30–33 although expulsion rates of between
7% and 25% have been reported.30–32 34 Insertion
immediately postpartum may also be easier since the
cervix is dilated. Small studies also show that insertion
at elective caesarean section may be a particularly
beneficial option, with low expulsion rates of 0–
4%.33 35 36
A major limitation of our study is that the survey
asked women about what contraceptive method they
would theoretically choose: that is, they are open to
the idea in theory, but this is not the same as evidence
of acceptability. Addressing the question of whether
women would choose LARC immediately post-
partum and whether this would result in fewer unin-
tended pregnancies and fewer short inter-pregnancy
intervals will need further research. In addition, this
study is unable to determine what proportion of the
pregnancies following a short inter-pregnancy interval
was intentional. Any intervention to improve uptake
of LARC postpartum would ideally therefore contain
an educative component which makes clear the risks
of short inter-pregnancy intervals, as well as providing
the means to prevent them. Finally, although our
research was conducted in one of the largest maternity
services and abortion services in the UK, our findings
cannot be assumed to reflect others throughout the
UK.
CONCLUSIONS
This study shows that short inter-pregnancy intervals
are not uncommon, However, our survey data suggest
that a significant proportion of women might be open
to choosing one of the most effective methods of
contraception (intrauterine contraception or the
implant) in the immediate postpartum period, if this
option was available. Provision and uptake of these
methods at this time could in theory prevent more
unintended pregnancies that currently end in abor-
tion, miscarriage, ectopic pregnancies or short inter-
pregnancy intervals. This would have important
health benefits for women, their children and their
future opportunities. Research is therefore necessary
to progress strategies to provide LARC in the immedi-
ate postpartum period and to evaluate the acceptabil-
ity and effectiveness of such strategies. This will
necessitate both training of healthcare providers in
maternity services to counsel and provide LARC to
women postpartum, and funding to provide this
service.
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